Immunogenic fusion protein compositions and methods of use thereof

An immunogenic fusion protein targeting conserved pneumococcal proteins addresses the limitations of current vaccines by enhancing protection against Streptococcus pneumoniae across serotypes, preventing colonization and invasion, and improving vaccine efficacy in diverse age groups.

JP2024541094AInactive Publication Date: 2024-11-06マトリバックスインコーポレイティド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529734
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-18
Filing Date
2022-11-18
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2024541094000001_ABST
    Figure 2024541094000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to immunogenic fusion protein compositions and methods of use thereof for preventing or treating pneumococcal infection. The present disclosure relates to methods for producing and purifying the immunogenic fusion proteins. The present disclosure further relates to compositions and formulations comprising the immunogenic fusion proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to, and the benefit of, U.S. Provisional Patent Application No. 63 / 280,908, filed November 18, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] The present invention relates to the field of vaccines for preventing or treating pneumococcal infections.

[0003] INCORPORATION BY REFERENCE TO SEQUENCE LISTING The Sequence Listing XML associated with this application has been provided electronically in XML file format and is hereby incorporated by reference herein. The XML file containing the Sequence Listing XML is named "MTRV-001_001WO_Seq_Listing_ST26.xml". The XML file is 65,890 bytes in size and was created on November 18, 2022. [Background technology]

[0004] Streptococcus pneumoniae is a Gram-positive bacterium that is a major cause of diseases such as septicemia, meningitis, otitis media, and lobular pneumonia (Tuomanen et al. NEJM 322:1280-1284, 1995). Infection with S. pneumoniae remains a significant health threat worldwide. Pneumococci bind tightly to cells of the upper and lower respiratory tract, as well as to endothelial cells present in blood vessels. Like most bacteria, attachment of pneumococci to human cells is achieved by the presentation of bacterial surface factors that bind to eukaryotic cell surface proteins (Cundell, D. & Tuomanen, E. (1994) Microb Pathog 17:361-374). For example, bacteria translocate across cells of the upper respiratory tract and nasopharynx via the polymeric immunoglobulin receptor (pIgR) (Zhang et al. (2000) Cell 102:827-837). Alternatively, when the bacteria are in the bloodstream, pneumococci bind to endothelial cells and the bacteria cross the vascular endothelium and enter tissues by binding to and transcytosing platelet-activating factor (PAF) receptors (Cundell et al. (1995) Nature, 377:435-438).

[0005] Current vaccines against S. pneumoniae use purified capsular saccharides of up to the 23 most common serotypes of this bacterium found in disease, however, non-conjugated polysaccharide vaccines are only 50% protective against pneumonia (Shapiro et al. NJEM 325:1453, 1991) and are not immunogenic in children under 2 years of age. Conjugate vaccines against S. pneumoniae involve the covalent linkage of pneumococcal capsular polysaccharides to proteins, such as diphtheria toxoid or tetanus toxoid, to elicit a higher immune response and provide protection in children under 2 years of age. However, the protection provided by these vaccines against pneumococcal disease, including pneumonia, septicemia, or meningitis, is limited, however, to the serotypes present in the formulation, thereby leaving patients unprotected against the majority of the more than 100 S. pneumoniae serotypes. Additionally, there is a need in the art for a vaccine that can prevent nasopharyngeal colonization, tissue invasion, and disease symptoms of S. pneumoniae regardless of serotype. Thus, the compositions and methods provided herein fulfill these needs by providing pharmaceutical compositions (e.g., vaccines) for the prevention and treatment of a broad range of serotypes of pneumococcal infection across all age groups. Summary of the Invention

[0006] The present disclosure provides an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO: 43. The present disclosure provides a polynucleotide encoding any one of the immunogenic fusion proteins of the present disclosure. The present disclosure provides a host cell comprising any one of the polynucleotides of the present disclosure.

[0007] The present disclosure provides a composition comprising any one of the immunogenic fusion proteins of the present disclosure and a pharma- ceutically acceptable carrier.

[0008] In some embodiments, the immunogenic fusion protein is glycosylated. In some embodiments, the immunogenic fusion protein is non-glycosylated.

[0009] In some embodiments, the composition further comprises at least one adjuvant. In some embodiments, the adjuvant comprises aluminum hydroxide, aluminum phosphate, or aluminum sulfate. In some embodiments, the adjuvant comprises aluminum hydroxide. In some embodiments, the aluminum hydroxide comprises Alhydrogel®.

[0010] The disclosure provides: i) a population of purified immunogenic fusion proteins, wherein at least about 90% of the purified immunogenic fusion proteins are full-length purified immunogenic fusion proteins comprising the amino acid sequence of SEQ ID NO:43; ii) less than 80,000 ng of host cell protein per mg of purified immunogenic fusion protein; and / or iii) less than 17 EU of endotoxin per mg of purified immunogenic fusion protein.

[0011] In some embodiments, the composition comprises: i) a population of purified immunogenic fusion proteins, wherein about 95%, about 96%, about 97%, about 98%, or about 99% of the purified immunogenic fusion proteins are full-length purified immunogenic fusion proteins comprising the amino acid sequence of SEQ ID NO:43; ii) less than 50 ng of host cell protein per mg of purified immunogenic fusion protein; and / or iii) less than 2 EU of endotoxin per mg of purified immunogenic fusion protein.

[0012] The present disclosure provides a method for producing an immunogenic fusion protein, comprising the steps of: a) culturing a population of host cells expressing an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO: 43 under conditions suitable for the population of host cells to produce the immunogenic fusion protein; b) disrupting the cell membrane of the host cells; c) recovering a sample comprising the immunogenic fusion protein and one or more impurities; d) contacting the sample comprising the immunogenic fusion protein with a hydrophobic interaction chromatography resin and eluting the immunogenic fusion protein from the hydrophobic interaction chromatography resin under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein; e) subjecting the eluate comprising the immunogenic fusion protein of step d) to a flow-through anion exchange resin, thereby obtaining an eluate comprising the immunogenic fusion protein; and f) contacting the eluate comprising the immunogenic fusion protein of step e) with a multimodal chromatography resin and eluting the immunogenic fusion protein from the multimodal chromatography resin under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein. In some embodiments, the host cell is an E. coli cell.

[0013] In some embodiments, the method further comprises the steps of: g) contacting the eluate comprising the immunogenic fusion protein of step f) with a flow-through anion exchange membrane, thereby obtaining an eluate comprising the immunogenic fusion protein. In some embodiments, the method further comprises the steps of: h) contacting the eluate comprising the immunogenic fusion protein of step g) with an UF / DF membrane, and i) washing the immunogenic fusion protein from the UF / DF membrane under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein. In some embodiments, the method further comprises the steps of: j) contacting the eluate comprising the immunogenic fusion protein of step i) with a 0.2 μm filter.

[0014] The present disclosure provides a composition comprising a purified immunogenic fusion protein produced by any one of the methods of the present disclosure.

[0015] The disclosure provides a formulation comprising: i) an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO: 43; ii) a detergent; iii) a buffer; and iv) a salt. In some embodiments, the detergent is at a concentration of about 175 μg / mL to about 375 μg / mL.

[0016] In some embodiments, i) the immunogenic fusion protein is at a concentration of about 0.5 mg / mL to about 1.5 mg / mL; ii) the surfactant is at a concentration of about 175 μg / mL to about 375 μg / mL; iii) the buffer is at a concentration of about 5 mM to about 20 mM; iv) the salt is at a concentration of about 50 mM to about 200 mM; and wherein the pH level of the formulation is between pH 6 and pH 9.

[0017] In some embodiments, i) the immunogenic fusion protein is at a concentration of about 0.8 mg / mL to about 1.2 mg / mL; ii) the surfactant is at a concentration of about 275 μg / mL; iii) the buffer is at a concentration of about 10 mM; iv) the salt is at a concentration of about 154 mM; and wherein the pH level of the formulation is about 7.4.

[0018] In some embodiments, the buffer comprises sodium phosphate, the salt comprises sodium chloride (NaCl), and / or the surfactant comprises polysorbate 20.

[0019] In some embodiments, the formulation further comprises an adjuvant. In some embodiments, the adjuvant is at a concentration of about 0.5 mg / mL to about 2 mg / mL. In some embodiments, the adjuvant is at a concentration of about 1 mg / mL. In some embodiments, the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, and aluminum sulfate. In some embodiments, the adjuvant is aluminum hydroxide. In some embodiments, the aluminum hydroxide is Alhydrogel®.

[0020] The disclosure provides a formulation comprising: about 1.0 mg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 10 mM sodium phosphate, and about 154 mM sodium chloride, wherein the pH level of the formulation is about 7.4.

[0021] The disclosure provides a formulation comprising: about 20 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.4.

[0022] The disclosure provides a formulation comprising: about 60 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.4.

[0023] The disclosure provides a formulation comprising: about 120 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.4.

[0024] The disclosure provides a formulation comprising: about 180 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.4.

[0025] The present disclosure provides a method of inducing a protective immune response in a subject comprising administering to the subject any one of the compositions or any one of the formulations of the present disclosure.

[0026] The present disclosure provides a method of immunizing a subject against infection caused by Streptococcus pneumoniae, the method comprising administering to the subject any one of the compositions or formulations of the present disclosure.

[0027] The present disclosure provides methods for treating, prophylactically preventing, or reducing the occurrence of a condition, disease, or infection caused by Streptococcus pneumoniae in a subject in need thereof, comprising administering to the subject any one of the compositions or any one of the formulations of the present disclosure.

[0028] In some embodiments, the subject is administered at least one dose of the immunogenic fusion protein. In some embodiments, the subject is administered no more than two doses of the immunogenic fusion protein. In some embodiments, the dose further comprises about 1 mg / mL aluminum hydroxide.

[0029] In some embodiments, the dose comprises about 1 μg to about 150 μg of immunogenic fusion protein. In some embodiments, the dose comprises about 10 μg of immunogenic fusion protein. In some embodiments, the dose comprises about 30 μg of immunogenic fusion protein. In some embodiments, the dose comprises about 60 μg of immunogenic fusion protein. In some embodiments, the dose comprises about 90 μg of immunogenic fusion protein.

[0030] In some embodiments, the amount of time between each dose is about four weeks to about a year. In some embodiments, the amount of time between each dose is about one week, about two weeks, about three weeks, or about four weeks. In some embodiments, the amount of time between each dose is about four weeks.

[0031] In some embodiments, the composition or formulation is administered parenterally, hi some embodiments, parenteral administration is by intramuscular injection.

[0032] In some embodiments, the subject is between 0 and 80 years old. In some embodiments, the subject is between 0 and 2 years old. In some embodiments, the subject is between 18 and 50 years old. In some embodiments, the subject is between 60 and 75 years old. [Brief description of the drawings]

[0033] [Figure 1] Figures 1A-1B are schematics depicting the structure and assembly of MTRV001. Figure 1A is a schematic depicting the structure of MTRV001, which contains PLY with two amino acid substitutions (G293S and L460D) and an adjacent CbpA fragment. CbpA: choline binding protein A; PLY: pneumolysin. Figure 1B depicts the assembly of MTRV001. CbpA: choline binding protein A; PLY: pneumolysin; PLY-DM: double mutant pneumolysin; PLY-SM: single mutant pneumolysin; YLN: PLY-SM with adjacent CbpA peptide.

[0034] [Diagram 2] 2A-2B are schematics depicting the construction of the CbpA peptide used in MTRV001. FIG. 2A is a schematic representation of the R2 domain of CbpA (left panel). Boxes identify two non-helical loop regions and amino acid motifs. Amino acid numbers in the R2 domain are indicated. Percentage of sequence conservation in each motif from 30 clinical isolates is as indicated (right panel). FIG. 2B is a schematic depicting the regions of expressed R2. Amino acid numbers in the R2 domain are indicated.

[0035] [Diagram 3] Figures 3A-3B are two survival curves depicting the survival of MXV01 and PLY-DM immunized BALB / c mice following intranasal (IN) challenge with two dose levels of the serotype 19F S. pneumoniae strain. Figure 3A shows 1x challenge dose (6.81x107 CFU per dose). Figure 3B shows 0.5x challenge dose (3.69x107 CFU per dose). CFU; colony forming unit.

[0036] [Figure 4] Figures 4A-4B are two survival curves depicting the survival of MXV01 and PLY-DM immunized BALB / c mice following intranasal (IN) challenge with two dose levels of a serotype 6B S. pneumoniae strain. Figure 4A shows 1x challenge dose (1.45x108 CFU per dose). Figure 4B shows 0.5x challenge dose (4.45x107 CFU per dose). CFU; colony forming unit.

[0037] [Diagram 5] Figures 5A-5B are two survival curves depicting the survival of MXV01 and PLY-DM immunized BALB / c mice after intranasal (IN) challenge with two dose levels of the serotype 22F S. pneumoniae strain. Figure 5A shows 1x challenge dose (1.19x108 CFU per dose). Figure 5B shows 0.5x challenge dose (9.27x107 CFU per dose). CFU; colony forming unit.

[0038] [Figure 6] Figures 6A-6B are two graphs depicting anti-PLY and anti-CbpA IgG titers from mice immunized with MTRV001, PLY-DM, or vehicle control. Antibody titers were determined by ELISA on day 42 (14 days after the third immunization). Figure 6A shows anti-PLY IgG titers. Figure 6B shows anti-CbpA IgG titers. CbpA: choline binding protein A; GMT: geometric mean titer; IgG: immunoglobulin G; PBS: phosphate buffered saline; PLY-DM: pneumolysin double mutant.

[0039] [Figure 7] 7 is a survival curve depicting the survival of mice immunized with MTRV001, PLY-DM, and vehicle control following intratracheal (IT) infection with a pathogenic serotype 4 S. pneumoniae strain. PLY-DM: pneumolysin double mutant.

[0040] [Figure 8] Figures 8A-8C are a series of microscopy images depicting lung histopathology of mice immunized with MTRV001, PLY-DM, and solvent control 72 hours after intratracheal (IT) challenge with a pathogenic serotype 4 S. pneumoniae strain. Figure 8A shows treatment with MTRV001. Figure 8B shows PLY-DM treatment. Figure 8C shows solvent control (PBS) treatment. PBS: phosphate buffered saline; PLY-DM: pneumolysin double mutant. All images are at original magnification 20x with hematoxylin and eosin staining.

[0041] [Figure 9] FIG. 9 depicts the overall study scheme of a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study of tolerability, safety, and immunogenicity of MTRV001.

[0042] [Figure 10-1] FIG. 10 depicts the study intervention dosing scheme for a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study of the tolerability, safety, and immunogenicity of MTRV001. [Figure 10-2] Same as above. [Figure 10-3] Same as above.

[0043] [Figure 11] FIG. 11 depicts the timeline of participants in a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study of tolerability, safety, and immunogenicity of MTRV001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] The present invention will now be described more fully with reference to the accompanying drawings, in which some, but not all, embodiments of the invention are shown. Indeed, the present invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout.

[0045] Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. It is to be understood, therefore, that the invention is not limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

[0046] Streptococcus pneumoniae (S. pneumoniae) is responsible for significant morbidity and mortality in children, elderly, and immunocompromised populations worldwide, despite the availability of effective vaccines and antibiotics. It is one of the most common human bacterial pathogens, causing severe infections such as pneumonia, meningitis, and bacteremia, as well as common, but less severe, infections such as acute otitis media and sinusitis. S. pneumoniae is the leading cause of morbidity and mortality from lower respiratory tract infections worldwide, accounting for more deaths from pneumonia than all other causes, viral and bacterial, combined (GBD, 2018). Pneumococcal infections caused 740,000 deaths worldwide in children <5 years of age in 2019 (WHO, 2021), while S. pneumoniae is responsible for approximately 30% of all adult pneumonia cases in developed countries with a corresponding mortality rate of 11%-40% (Daniels, 2016). S. pneumoniae remains a leading cause of morbidity and mortality in older adults, with people >65 years of age experiencing up to five times higher incidence of deaths due to community-acquired pneumonia compared to those <65 years of age (Adler, 2017). Due to emerging antibiotic resistance, the inadequate protection of currently available polysaccharide-based vaccines, and limited vaccine access in low- and lower-middle-income countries, there remains a significant need to generate a broadly protective vaccine to prevent pneumococcal infections.

[0047] The S. pneumoniae polysaccharide capsule is an essential virulence factor that protects the pathogen from the host immune response, specifically complement-mediated opsonophagocytosis (Goldblatt, 2008). Importantly, a robust antibody response to a particular capsular serotype confers significant protection against infection with S. pneumoniae expressing that particular capsular serotype.

[0048] Currently, >100 serotypes of S. pneumoniae have been identified, varying in their monosaccharide composition and glycosidic linkages (Donati, 2010; Weinberger, 2011; Geno, 2015; Geno, 2017; GPSC, 2022). This remarkable diversity of S. pneumoniae capsular serotypes is due, in part, to the genetic structure of the capsule locus and the bacteria's natural ability for genetic transformation, which enhances the generation of novel capsular types due to immune selection pressures.

[0049] The essential nature of the capsule for pneumococcal virulence, coupled with its surface localization and accessibility to antibodies, is the basis for serotype specificity (Daniels, 2016). Furthermore, these characteristics target vaccine efforts to focus on the polysaccharide capsule. There are two general categories of commercially available pneumococcal vaccines to prevent S. pneumoniae infection. Both categories are polysaccharide in nature, but one type is based on polysaccharide alone (Pneumococcal polysaccharide vaccine or PPV [e.g., PNEUMOVAX® 23]) and the other is based on polysaccharides conjugated to a protein carrier for enhanced immunogenicity (PCV or polysaccharide conjugate vaccine [e.g., Prevnar 20®]). Unlike PPV, PCV induces high titer, anamnestic responses and IgA in the nasopharynx, which reduces nasopharyngeal carriage and transmission of vaccine serotypes as well as confers high levels of efficacy (Orami, 2020).

[0050] PPV is a T-helper cell-independent antigen and consists of a mixture of unconjugated polysaccharides that do not induce robust or anamnestic immune responses (Daniels, 2016), thereby preventing its use in children <2 years of age. PPV is also poorly immunogenic in older adults due to immunosenescence (Adler 2017). In contrast, PCV mobilizes T-helper cell immune responses, thereby being highly immunogenic and generating protective anamnestic immune responses in younger and older age groups (Bonten, 2015; Farmaki, 2018; van den Biggelaar, 2019). PCVs have been progressively developed to include new serotypes to increase the breadth of protection against emerging serotypes across the world.

[0051] However, commercially available PCVs currently only provide protection against vaccine-containing polysaccharide serotypes, which at best are only 20 of the >100 S. pneumoniae serotypes (Weinberger, 2011; GPSC, 2022). Furthermore, implementation of PCVs is associated with an increased prevalence of non-vaccine S. pneumoniae serotypes in carriage and disease (commonly referred to as serotype replacement) (Weinberger, 2011; Lee, 2014; Galanis, 2015; Balsells, 2017; Vadlamudi, 2018).

[0052] To overcome the serotype limitations of polysaccharide-based vaccines, novel vaccine technologies have been applied to overcome the limitations of traditional chemically conjugated vaccine candidates. The present disclosure provides a serotype-independent protein-based pneumococcal vaccine candidate designed to overcome the serotype restrictions of polysaccharide-based vaccines. This approach involves identifying highly conserved S. pneumoniae protein antigens that target critical virulence factors for infection and disease. Several highly conserved pneumococcal proteins with broad serotype coverage have been extensively tested preclinically as vaccine candidates, including genetically detoxified forms of cholesterol-dependent cytolysin, PLY, and CbpA, relevant surface proteins involved in bacterial adhesion, host tissue invasion, and complement evasion (Mann, 2014; Chen, 2015).

[0053] The present disclosure provides an immunogenic fusion protein comprising genetically detoxified PLY with two conserved peptide fragments of CbpA fused to a toxoid at the N- and C-termini. The immunogenic fusion protein may be adjuvanted with aluminum hydroxide to form a formulation. The inclusion of both PLY and CbpA epitopes in the immunogenic fusion protein is designed to inhibit S. pneumoniae colonization and invasion of host tissues, as well as elicit antibodies that neutralize PLY, which is a major cause of tissue damage, inflammation, and disease symptoms, which is advantageous for therapeutic purposes. The serotype-independent approach of the immunogenic fusion protein of the present invention enhances the protection provided by PCV and confers protection well beyond the serotypes contained in the commercially available PCV vaccine. Furthermore, given the minimal / no selective pressure for polysaccharide immune escape, the immunogenic fusion protein of the present invention has the potential to reduce serotype substitution, thereby reducing the need for increased valency of PCV. The use of a single immunogenic fusion protein (e.g., MTRV001) offers significant commercial and manufacturing advantages for use as a vaccine or therapeutic compared to PCVs known in the art that require the production of more than twenty antigens (e.g., PREVNAR 20™).

[0054] definition

[0055] Before describing the invention in detail, it is to be understood that the invention is not limited to particular compositions or process steps, as such may vary. It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "an" include plural referents unless the context clearly dictates otherwise.

[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0057] The fusion proteins disclosed herein are immunogenic. As used herein, an "immunogen" is a substance that induces an immune response. The term "immunogenicity" refers to the ability of a substance to induce an immune response when administered to an animal. A substance, such as a polypeptide, exhibits "increased immunogenicity" when administration of the first polypeptide to an animal results in a greater immune response than that observed with administration of the other polypeptide, compared to another polypeptide. An increase in immunogenicity can also refer to a greater response in terms of the production of more antibodies or T cells, but also the production of more protective antibodies or T cells. Thus, in certain embodiments, an increase in immunogenicity refers to any statistically significant increase in the level of antibodies or T cells or antibody or T cell production, or any statistically significant increase in a protective antibody response. Such an increase can include a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more increase in the level of antibodies or in a protective antibody response. The immunogenicity of a polypeptide can be assayed by measuring the level of antibodies or T cells produced against the polypeptide. Assays for measuring the level of antibodies are known, for example, see Harlow and Lane (1988) Antibodies, A Laboratory Manual (Cold Spring Harbor Publications, New York) for a standard description of specific antibody production, immunoassay formats, and conditions that can be used to determine specific immune reactivity. Assays for T cells specific for a polypeptide are known, for example, Rudraraju et al. (2011) Virology 410:429-36, incorporated herein by reference. In another example, increased immunogenicity can be detected as improved clinical outcomes, as discussed elsewhere herein.

[0058] As used herein, the terms "bind and elute mode", "bind and elute process", "bind and elute means", and "bind and elute" refer to a separation technique in which at least one immunogenic fusion protein contained in a sample is bound to a suitable resin or medium (e.g., affinity chromatography medium or cation exchange chromatography medium) and then eluted.

[0059] The terms "flow-through process," "flow-through mode," and "flow-through operation" are used interchangeably herein and refer to a separation technique in which at least one immunogenic fusion protein contained in a biopharmaceutical preparation along with one or more impurities flows through a material that normally binds the one or more impurities (e.g., a flow-through anion exchange membrane), and where the immunogenic fusion protein does not normally bind (i.e., flows through).

[0060] The term "chromatography" refers to any type of technique that separates an analyte of interest (e.g., an immunogenic fusion protein) from other molecules present in a mixture through differential adsorption onto a medium. Typically, the immunogenic fusion protein is separated from other molecules as a result of differences in the rate at which individual molecules of the mixture move through a stationary medium under the influence of a mobile phase or in a binding and elution process.

[0061] The term "matrix" or "means" as used herein refers to any type of particulate adsorbent, bead, resin, or other solid phase (e.g., membrane, nonwoven, monolith, etc.). The matrix with ligands or functional groups attached thereto is referred to as the "medium" that acts in a separation process as an adsorbent to separate a target molecule (e.g., an immunogenic fusion protein) from other molecules (e.g., one or more impurities) present in a mixture, or alternatively as a sieve to separate molecules based on size (e.g., a 0.2 μm filter membrane).

[0062] The terms "ion exchange" and "ion exchange chromatography," as used herein, refer to a chromatographic process in which a solute or analyte of interest in a mixture (e.g., a target molecule being purified) interacts with a charged compound linked (e.g., by covalent attachment, etc.) to a solid-phase ion exchange material, and the solute or analyte of interest interacts nonspecifically with the charged compound to a greater or lesser extent than solute impurities or contaminants in the mixture. The contaminant solutes in the mixture elute faster or slower from a column of ion exchange material than the solute of interest, or are bound to or excluded from the resin relative to the solute of interest.

[0063] The term "ion exchange chromatography" specifically includes cation exchange, anion exchange, and mixed-mode ion exchange chromatography. For example, cation exchange chromatography can bind the target molecule (e.g., an immunogenic fusion protein) followed by elution (e.g., using cation exchange binding and elution chromatography or "CEX"), or can primarily bind impurities while the target molecule "flows through" the column (cation exchange flow-through chromatography FT-CEX). Anion exchange chromatography can bind the target molecule (e.g., an immunogenic fusion peptide of SEQ ID NO: 43) followed by elution, or can primarily bind impurities while the target molecule flows through the column, also referred to as negative chromatography. In some embodiments, the anion exchange chromatography step is performed in flow-through mode, as demonstrated in the examples presented herein.

[0064] The term "ion exchange medium" refers to a medium that is negatively charged (i.e., a cation exchange medium) or positively charged (i.e., an anion exchange medium). The charge can be provided by attaching one or more charged ligands to the matrix, e.g., by covalent linkage. Alternatively, or in addition, the charge can be an inherent property of the matrix (e.g., as is the case for silica, which has an overall negative charge).

[0065] The term "anion exchange medium" is used herein to refer to a medium that is positively charged, e.g., has one or more positively charged ligands, such as quaternary amino groups, attached to a matrix. Commercially available anion exchange media include DEAE cellulose, QAE SEPHADEX™, and FAST Q SEPHAROSE™ (GE Healthcare). Other exemplary materials that may be used in the processes and systems described herein are Fractogel® EMD TMAE, Fractogel® EMD TMAE highcap, Eshmuno® Q, and Fractogel® EMD DEAE (EMD Millipore).

[0066] The term "cation exchange medium" refers to a medium that is negatively charged and has free cations for exchange with cations in an aqueous solution in contact with the solid phase of the medium. The negatively charged ligand attached to the solid phase to form the cation exchange medium may be, for example, a carboxylate or a sulfonate. Commercially available cation exchange media include carboxy-methylcellulose, sulfopropyl (SP) immobilized on agarose (e.g., SP-SEPHAROSE FAST FLOW™ or SP-SEPHAROSE High Performance™ from GE Healthcare), and sulfonyl (e.g., S-SEPHAROSE FAST FLOW™ from GE Healthcare) immobilized on agarose. Preferred are Fractogel® EMD SO3, Fractogel® EMD SE Highcap, Eshmuno® S, and Fractogel® EMD COO (EMD Millipore).

[0067] The term "mixed-mode chromatography" or "multimodal chromatography" as used herein refers to a process using a chromatographic stationary phase that carries at least two different types of functional groups, each capable of interacting with a molecule of interest. Mixed-mode chromatography generally uses ligands with two or more modes of interaction with the target protein and / or impurities. The ligand typically contains at least two distinct, but cooperative, sites that interact with the substance to be bound. For example, one of these sites may have a charge-charge type interaction with the substance of interest, while the other site may have an electron acceptor-donor type interaction and / or a hydrophobic and / or hydrophilic interaction with the substance of interest. Electron donor-acceptor interaction types include hydrogen bonding, π-π, cation-π, charge transfer, dipole-dipole, and induced dipole interactions. Generally, based on the difference in the total interactions, the target protein and one or more impurities may be separated under a range of conditions.

[0068] The term "mixed mode ion exchange media" or "mixed mode media" refers to media that are covalently modified with cationic and / or anionic moieties and hydrophobic moieties. A commercially available mixed mode ion exchange media is BAKERBMS ABX™ (JT Baker, Phillipsburg, NJ), which contains weak cation exchange groups, a low concentration of anion exchange groups, and hydrophobic ligands attached to a silica gel solid support matrix. Mixed mode cation exchange materials typically have cation exchange and hydrophobic moieties. Suitable mixed mode cation exchange materials are hydroxyapatite (HA), Capto® MMC (GE Healthcare), and Eshmuno® HCX (EMD Millipore).

[0069] Mixed-mode anion exchange materials typically have an anion exchange portion and a hydrophobic portion. A suitable mixed-mode anion exchange material is Capto® Adhere (GE Healthcare).

[0070] The term "hydrophobic interaction chromatography" or "HIC" as used herein refers to a process for separating molecules based on their hydrophobicity, i.e., their ability to adsorb to hydrophobic surfaces from aqueous solutions. HIC is usually distinguished from reversed-phase (RP) chromatography by specially designed HIC resins, which typically have lower hydrophobicity or density of hydrophobic ligands compared to RP resins. HIC chromatography typically relies on differences in hydrophobic groups on the surface of solute molecules. These hydrophobic groups tend to bind to hydrophobic groups on the surface of an insoluble matrix. Because HIC uses a more polar and less denaturing environment than reversed-phase liquid chromatography, it has become increasingly popular for protein purification, often in combination with ion exchange or gel filtration chromatography.

[0071] The term "impurity" or "contaminant" as used herein refers to any foreign or unwanted molecule, including biological macromolecules such as DNA, RNA, one or more host cell proteins, endotoxins, lipids, and one or more additives that may be present in a sample containing a target molecule that is being separated from one or more foreign or unwanted molecules using the process of the present invention. In addition, such impurities may include any reagents used in steps that may occur prior to the method of the present invention. Impurities may be soluble or insoluble in nature.

[0072] The term "insoluble impurities," as used herein, refers to any undesirable or unwanted entity present in a sample containing a target molecule, where the entity is a suspended particle or solid. Exemplary insoluble impurities include whole cells, cell fragments, and cell debris.

[0073] The term "soluble impurities," as used herein, refers to any undesirable or unwanted entity present in a sample containing a target molecule, where the entity is not an insoluble impurity. Exemplary soluble impurities include host cell proteins (HCPs), DNA, RNA, viruses, endotoxins, cell culture media components, lipids, and the like.

[0074] The terms "purifying," "purification," "separate," "separating," "separation," "isolate," "isolating," or "isolation," as used herein, refer to increasing the degree of purity of a target molecule from a sample that contains the target molecule and one or more impurities. Typically, the degree of purity of the target molecule is increased by removing (completely or partially) at least one impurity from the sample.

[0075] A "buffer" is a solution that resists changes in pH by the action of its acid-base conjugate components. For example, various buffers that can be used depending on the desired pH of the buffer are described in: Buffers. A Guide for the Preparation and Use of Buffers in Biological Systems, Gueffroy, D., ed. Calbiochem Corporation (1975). Non-limiting examples of buffers include MES, MOPS, MOPSO, Tris, HEPES, phosphate, acetate, citrate, succinate, and ammonium buffers, or any combination thereof.

[0076] When loading the sample onto a device or column or separation unit containing a suitable medium, a buffer solution is used to load the sample containing the target molecule and one or more impurities onto the device or column or separation unit. In the bind and elute mode, the buffer solution has a conductivity and / or pH such that the target molecule is bound to the medium, while ideally not all impurities are bound and flow through the column. On the other hand, in the flow-through mode, a buffer solution is used to load the sample containing the target molecule and one or more impurities onto the column or device or separation unit, where the buffer solution has a conductivity and / or pH such that the target molecule is not bound to the medium and flows through, while ideally all or most of the impurities are bound to the medium.

[0077] The term "wash" or "washing" a chromatographic medium refers to passing a suitable liquid, e.g., a buffer, through or over the medium. Typically, washing is used to remove weakly bound contaminants from the medium prior to eluting the target molecules and / or to remove unbound or weakly bound target molecules after loading. In some embodiments, the wash buffer is different from the loading buffer. In other embodiments, the wash buffer and the loading buffer are the same. In certain embodiments, a wash step is eliminated or the number of wash steps is reduced in the purification process by altering the sample loading conditions.

[0078] The terms "elute" or "eluting" or "elution" refer to the removal of a molecule (e.g., a polypeptide of interest or an impurity) from a chromatography medium by using or changing certain solution conditions whereby a buffer (referred to as an "elution buffer") competes with the molecule of interest for ligand sites on the chromatography resin. A non-limiting example is eluting a molecule from an ion exchange resin by changing the ionic strength of the buffer surrounding the ion exchange material such that the buffer competes with the molecule for charged sites on the ion exchange material.

[0079] I. Composition The compositions disclosed herein provide fusion proteins comprising a first polypeptide operably linked to a second polypeptide. As used herein, "fusion protein" refers to the in-frame genetic linkage of at least two heterologous polypeptides. Upon transcription / translation, a single protein is created. In this manner, multiple proteins, or fragments thereof, can be incorporated into a single polypeptide. "Operably linked" is intended to mean a functional linkage between two or more elements. For example, an operably linkage between two polypeptides fuses both polypeptides together in frame to produce a single polypeptide fusion protein. In certain embodiments, the fusion protein further comprises a third polypeptide. Several forms of immunogenic fusion proteins are disclosed herein and discussed in detail below.

[0080] A. A fusion protein containing the immunogenic region of choline binding protein A (CbpA). i.CbpA Compositions and methods are provided that include immunogenic fusion proteins that include immunogenic regions of choline-binding protein A (CbpA). CbpA is also known as PspC, SpsA, and PbcA. As used herein, a "CbpA fusion protein" may include the entire CbpA polypeptide or an active variant or fragment thereof, or any immunogenic fragment of CbpA, as discussed in more detail elsewhere herein. CbpA is a 75 kD surface-exposed choline-binding protein of Streptococcus pneumoniae. CbpA binds to several ligands in the host, including pIgR, C3, factor H, and laminin receptors. The N-terminus of CbpA (the region without the terminal choline-binding domain) contains multiple repeats of leucine motifs that are clustered into five domains, termed the A, B, R1, R2, and C domains (Figure 1). The R2 domain of CbpA (amino acid residues approximately 329-443) contains three antiparallel alpha helices (Figure 2). This three alpha-helical structure is similarly predicted for the R1 domain (Jordan et al. (2006) J. Am. Chem. Soc. 128(28):9119-9128). Notably, the R domain from the TIGR4 strain of S. pneumoniae is highly conserved among CbpA sequences from other pneumoniae strains.

[0081] While any immunogenic fragment or domain of CbpA can be used in the fusion proteins disclosed herein, in one embodiment, the fusion protein comprises at least one R2 domain or an active variant or fragment of the R2 domain. The R2 domain of CpbA comprises two regions, R21 and R22, which have been shown to form loop conformations in each of the two turns of the antiparallel alpha helix in the three-dimensional structure of the R2 domain (FIG. 1). As discussed in U.S. Patent No. 8,722,055 and PCT Application No. PCT / US2012 / 030241, each of which is incorporated herein by reference in its entirety, the loop conformation of the R21 and R22 regions increases the immunogenicity of the R2 region. Thus, the fusion proteins disclosed herein can include at least one immunogenic fragment or variant of the R2 domain of CbpA, such as at least 1, 2, 3, 4, 41, or 42 copies or more of the R2 domain, the R21 region, and / or the R22 region or active variants and fragments thereof.

[0082] The R21 and R22 regions of CbpA have defined functions in disease. The R21 region contains the pIgR binding site. Binding of the R21 region of CbpA to pIgR allows pneumococci to migrate across nasopharyngeal epithelial cells into the bloodstream using an endocytic mechanism. This binding to pIgR contributes to bacterial colonization of the nasopharynx and entry of bacteria into the bloodstream.

[0083] The R21 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or an active variant or fragment thereof. In some embodiments, immunogenic fusion proteins comprising at least one copy of the R21 region or active variants and fragments thereof can generate an immunogenic response that targets bacterial pIgR binding and colonization of the nasopharynx and entry into the blood.

[0084] The R22 region of CbpA contains a laminin receptor binding site. When the R2 region of CbpA binds to the laminin receptor, it facilitates delivery of the bacteria to the platelet activating factor (PAF) receptor, which carries the bacteria into endothelial cells, across the blood vessel wall, and out of the bloodstream into tissues. Binding to the laminin receptor is a critical step for the bacteria to cross the blood-brain barrier and cause meningitis. The R22 polypeptide comprises the amino acid sequence shown in SEQ ID NO:2 or an active variant or fragment thereof. In some embodiments, immunogenic fusion proteins comprising the R22 region of CbpA or active variants and fragments thereof can generate an immunogenic response targeting laminin receptor binding and thus the ability of the bacteria to cross the blood-brain barrier and cause meningitis.

[0085] In view of the different activities of the R21 and R22 regions of CbpA, the immunogenic fusion proteins described herein can comprise one or more copies of the R2 region or active variants or fragments thereof, one or more copies of either the R21 region or the R22 region or active variants and fragments thereof, or a combination of both the R21 and R22 regions or active variants and fragments thereof. In view of the different functional aspects of the R21 and R2 regions, fusion proteins can thereby be designed with immunogenic activity.

[0086] In certain embodiments, the R21 and / or R22 polypeptides or active variants and fragments thereof used in the immunogenic fusion proteins comprise a loop conformation similar to that present in the native protein. By "loop conformation" is intended a three-dimensional protein structure stabilized in a loop structure by a synthetic linkage in the polypeptide. As used herein, "synthetic linkage" includes any covalent or non-covalent interaction created in the polypeptide that does not occur in the native protein. Any form of synthetic linkage that can form a covalent or non-covalent bond between amino acids in the native or variant polypeptide can be used. Such synthetic linkages can include synthetic peptide bonds that have been engineered to occur between amino acids present in either the native polypeptide or its variants. The R21 and R22 polypeptides or active variants and fragments thereof can comprise any form of synthetic linkage that can result in the formation of a covalent bond between amino acids in the native CbpA protein or its variants. Synthetic linkages further include any non-covalent interaction that does not occur in the native polypeptide. For example, a loop polypeptide comprising the R21 and / or R22 regions can be engineered to have cysteine ​​residues that are not present in the native CbpA protein and that allow for the formation of disulfide bridges that stabilize the polypeptide in a loop conformation. A variety of methods for forming such loop conformations in polypeptides are known in the art. See, for example, Chhabra et al. (1998) Tetrahedron Lett. 39:1603-1606; Rohwedder et al. (1998) Tetrahedron Lett. 39:1175-1178; Wittmann & Seeberger (2000) Angew. Chem. Int. Ed. Engl. 39:4348-4352; and Chan et al. (1995) J. Chem. Soc., Chem. Commun. 21:2209-2210, all of which are incorporated herein by reference in their entirety.Non-limiting examples of R21 or R22 polypeptides with loop conformations are discussed, for example, in U.S. Pat. No. 8,722,055 and PCT Application No. PCT / US2012 / 030241, each of which is incorporated by reference herein in its entirety.

[0087] In one embodiment, the loop conformation of the R21 and R22 polypeptides is generated by at least a first cysteine ​​residue and a second cysteine ​​residue, where the first and second cysteine ​​residues form a disulfide bond such that the polypeptides are stabilized in a loop conformation. In some particular embodiments, the cysteine ​​residues can be added to the N-terminus and C-terminus of the R21 and R22 polypeptides, or the cysteine ​​residues can be added internally by substituting an amino acid in the polypeptide sequence with a cysteine ​​residue such that the R21 and R22 polypeptides form a loop conformation. Without intending to be limited to a particular mechanism, it is believed that stabilization of the R21 and R22 polypeptides in a loop conformation more closely mimics the native conformation of these polypeptides in the CbpA protein. The R21 and R22 loop polypeptides thereby have increased protective immunogenicity compared to polypeptides that are not stabilized in a loop conformation (e.g., linear versions of these polypeptides).

[0088] In one non-limiting embodiment, the loop-type R21 and R22 polypeptides or active variants or fragments thereof used in the immunogenic fusion proteins have a cysteine ​​substitution as shown in SEQ ID NO: 3 or SEQ ID NO: 4, or an active variant or fragment thereof. SEQ ID NO: 3 (AKA YPT) comprises amino acid residues 329-391 of the CbpA protein, in which the valine at position 333 and the lysine at position 386 are each substituted with a cysteine ​​residue. SEQ ID NO: 4 (AKA NEEK) comprises amino acid residues 361-443 of the CbpA protein, in which the lysine at position 364 and the valine at position 439 are each substituted with a cysteine ​​residue.

[0089] Active variants and fragments of the full-length CbpA polypeptide (SEQ ID NO:12), the CbpA polypeptide without the choline binding domain (R1R2, SEQ ID NO:13), the R2 domain (SEQ ID NO:14), the R21 region (SEQ ID NO:1 or 3), and / or the R22 region (SEQ ID NO:2 or 4) of the CbpA polypeptide can be used in the various fusion proteins disclosed herein. Such active variants can comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO:1, 2, 3, 4, 12, 13, 14, 41 or 42, wherein the active variant retains biological activity and is therefore immunogenic. Non-limiting examples of R21 and R22 polypeptide variants are disclosed, for example, in U.S. Patent No. 8,722,055 and PCT Application No. PCT / US2012 / 030241, each of which is incorporated herein by reference. An active fragment can comprise an amino acid sequence having at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 100, 150, or more consecutive amino acids of any one of SEQ ID NOs: 1, 2, 3, 4, 12, 13, 14, 41, or 42, where the active fragment retains biological activity and is therefore immunogenic.

[0090] ii. Other components of the CbpA fusion protein. The immunogenicity of the fusion proteins disclosed herein can be increased through the addition of a heterologous T cell epitope (TCE). Thus, the fusion proteins disclosed herein further comprise at least one heterologous TCE fused in frame to a bacterial polypeptide or a variant or fragment thereof (i.e., a CbpA polypeptide or an active variant or fragment thereof). Thus, for example, an amino acid sequence for a TCE can be linked to a CbpA polypeptide or an active variant or fragment thereof to increase the immunogenicity of the polypeptide compared to that of the same polypeptide lacking the TCE sequence.

[0091] As used herein, "TCE" refers to a polypeptide sequence recognized by T cells. See, e.g., El Kasmi et al. (2000) J. Gen. Virol. 81:729-735 and Obeid et al. (1995) J. Virol. 69:1420-1428; El Kasmi et al. (1999) Vaccine 17:2436-2445; El Kasmi et al. (1998) Mol. Immunol. 35:905-918; El Kasmi et al. (2000) J. Gen. Virol. 81:729-735; Obeid et al. (1995) J. Virol. 69:1420-1428; and Bouche et al. (2005) Vaccine 23:2074- 2077. Polypeptides containing a TCE sequence are generally between about 10-30, 30-50, or 50-90, or 90-100 amino acids, or up to the full-length protein. While any amino acid sequence having TCE can be used in the fusion proteins disclosed herein, non-limiting examples of TCE sequences are shown in SEQ ID NOs: 15 and 16, or active variants and fragments thereof.

[0092] "Heterologous" in reference to a polypeptide is a polypeptide derived from a different organism. A heterologous TCE sequence can be derived from the same organism as the other polypeptide components of the fusion protein, or the TCE can be from a different organism than the other polypeptide components of the fusion protein.

[0093] In certain embodiments, an immunogenic CbpA fusion protein comprises a first polypeptide having the R21 or R22 region of CbpA, e.g., the amino acid sequence of SEQ ID NO: 1, 2, 3, 4, 41 or 42, or an active variant or fragment thereof, wherein the first polypeptide comprising either the R21 or R22 region of CbpA forms a loop conformation and is immunogenic, and the fusion protein comprises a second polypeptide comprising at least one heterologous TCE fused in frame to the first polypeptide.

[0094] In some embodiments, the heterologous TCE used in the CbpA fusion proteins disclosed herein comprises an immunogenic pneumococcal polypeptide or an active variant or fragment thereof. In such embodiments, in addition to enhancing the immunogenicity of the first polypeptide by providing a TCE, the employment of a second immunogenic pneumococcal polypeptide in the CbpA fusion proteins described herein provides another means to target the pneumococcus and improve immunogenicity against pneumococcal infection. Non-limiting examples of immunogenic pneumococcal proteins that can be used in the CbpA fusion proteins disclosed herein include pneumolysin, pneumococcal surface protein A (PspA), neuraminidase A (nanA), β-N-acetylhexosaminidase (StrH), DnaK, or AliB proteins, or active variants and fragments thereof. Additional immunogenic pneumococcal polypeptides are known in the art and can be found, for example, in U.S. Patent No. 6,042,838, U.S. Patent No. 6,232,116, U.S. Patent Publication No. 2009 / 0170162A1, CC Daniels et al. (2010) Infection and Immunity 78:2163-72, and Zysk et al. (2000) Infection and Immunity 68:3740-3743, each of which is incorporated by reference herein in its entirety.

[0095] In one embodiment, the TCE of the CbpA fusion protein comprises a pneumolysoid polypeptide or a variant or fragment thereof. Pneumolysin is a pore-forming toxin and is the major cytolysin produced by Streptococcus pneumoniae. Pneumolysin oligomerizes to form pores in the cell membrane and promotes the growth of the bacteria in the lungs and entry into the bloodstream due to its hemolytic and complement activating properties. The amino acid sequence of wild-type or native pneumolysin is shown in SEQ ID NO:5. As used herein, "pneumolysoid" refers to modified pneumolysin (pneumolysin toxoid) in which modifications of the protein inactivate or reduce the oligomerization, hemolytic, and / or complement activating properties of the pneumolysoid protein while still retaining immunogenic activity. A reduction in pneumolysin protein toxicity (i.e., reduction in oligomerization, hemolysis, and / or complement activation) includes a statistically significant reduction of at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a suitable control. Various methods for assaying for pneumolysin activity are known in the art. Complement activation can be determined, for example, by a two-dimensional gel electrophoresis assay to detect the conversion of C3. See JC Paton et al. (1984) Infection and Immunity 43:1085-1087. Incorporated herein by reference. Pneumolysin oligomerization can be assessed, for example, by a combination of sucrose density gradient centrifugation and gel electrophoresis, as described in FD Saunders et al. (1989) Infection and Immunity 57:2547-2552. Incorporated herein by reference. Various pneumolysoids that can be used in the various immunogenic fusion proteins provided herein are described, for example, in WO2005 / 108419, WO2005 / 108580, WO90 / 06951, U.S. Patent Application No. 2009 / 0285846A1, and U.S. Patent Application No. 2010 / 0166795, which are incorporated herein by reference.WO2005 / 108419 and WO2005 / 108580 disclose pneumolysoids having mutations (e.g. substitutions or deletions) within the region of amino acids 144-161 of the wild-type pneumolysin protein. These mutants have reduced oligomerization and / or hemolytic activity and are therefore less toxic compared to wild-type pneumolysin. The mutants may have a substitution or deletion of one or more of amino acids 144-161 of the wild-type pneumolysin sequence. Thus, pneumolysoids may have a mutation at one or more of amino acid residues 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161 of wild-type pneumolysin. Also, pneumolysoids having reduced hemolytic activity and having at least one amino acid substitution or deletion in at least one of the regions corresponding to amino acids 257-297, 367-397 or 424-437 of wild-type pneumolysin are described in WO90 / 06951.

[0096] The pneumolysoid shown in SEQ ID NO:7, or an active variant or fragment thereof, comprises a mutation of the lysine at amino acid position 460 to an aspartic acid residue (L460D), which renders the pneumolysoid non-hemolytic. This pneumolysoid is referred to herein as "L460D" pneumolysoid and is disclosed in U.S. Patent Application Publication No. 2009 / 0285846A1, which is incorporated herein by reference in its entirety. An active variant of SEQ ID NO:7 is provided herein and is shown in SEQ ID NO:39. The active variant comprises an amino acid change from lysine to arginine at position 208 when compared to SEQ ID NO:7.

[0097] Pneumolysoid as set forth in SEQ ID NO:40, or an active variant or fragment thereof, comprises a mutation at amino acid position 293 from a glycine to a serine residue (G293S) and a mutation at amino acid position 460 from a lysine to an aspartic acid residue (L460D), which renders it substantially non-toxic (or substantially non-toxic compared to native PLY protein), substantially non-hemolytic, substantially more stable than PLY protein, reduces the cytolytic activity of pneumolysoid, and / or reduces the ability of pneumolysoid to substantially bind to cell membranes. This pneumolysoid is referred to herein as "G293S / L460D" or "PLY-DM" pneumolysoid, and is disclosed in WO / 2016 / 081839, which is incorporated by reference in its entirety.

[0098] Pneumolysoid, or an active variant or fragment thereof, as set forth in SEQ ID NO:8, contains a substitution of asparagine for aspartic acid at amino acid position 385, and a deletion of alanine 146 and arginine 147 of the wild-type pneumolysin sequence (Δ6Ν385 pneumolysoid), which is defective in both hemolysis and complement activation and is disclosed in U.S. Patent Application Publication No. 2010 / 0166795 and TJ Mitchell et al. (1991) Molecular Microbiology 5:1883-1888, which are incorporated herein by reference in their entireties.

[0099] The pneumolysoid set forth in SEQ ID NO: 17, or an active variant or fragment thereof, comprises an amino acid substitution of phenylalanine for tryptophan at amino acid position 433 of the wild-type pneumolysin sequence (PdB). This PdB pneumolysoid is defective in hemolysis and is disclosed in U.S. Patent No. 6,716,432, which is incorporated herein by reference in its entirety.

[0100] Various active variants or fragments of pneumolysoids are provided herein. Such active variants may comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with SEQ ID NO: 40, 5, 7, 8, 17, or 39. Active variants retain immunogenic activity. Active variants of pneumolysin are well known in the art and find use as pneumolysoids. See, for example, US 2010 / 0166795 and US 2009 / 0285846A1, as well as WO / 2016 / 081839, each of which is incorporated herein by reference in its entirety. The art provides substantial guidance for the preparation of such variants, as described elsewhere herein. Thus, in one embodiment, an immunogenic CbpA fusion protein can comprise a pneumolysoid as set forth in SEQ ID NO: 40, 7, 8, 17, or 39, or an active variant thereof having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to the amino acid sequence of SEQ ID NO: 40, 7, 8, 17, or 39, wherein the active variant is immunogenic. iii. Non-limiting examples of CbpA / TCE fusion proteins.

[0101] The immunogenic polypeptides disclosed herein can be operatively linked in a variety of ways to produce immunogenic fusion proteins. When a single CbpA polypeptide or an active variant or fragment thereof is used, the TCE can be fused to the N-terminus or C-terminus of the CbpA polypeptide or an active variant or fragment thereof. The fusion protein can include other protein components, such as a linker peptide between the polypeptides of the fusion protein, or a peptide tag (e.g., at the N- or C-terminus) for affinity purification.

[0102] In other embodiments, the CbpA immunogenic fusion protein may comprise at least one, two, three, four, five or more of the R21 or R22 regions, or active variants or fragments thereof, operably linked to a heterologous TCE. In one embodiment, the immunogenic fusion protein may comprise a third polypeptide fused in frame to the first polypeptide, or a second polypeptide comprising TCE, where the third polypeptide is from a bacterium and is immunogenic. When multiple CbpA polypeptides or variants and fragments thereof are used in a fusion protein, the TCE may be found at either the N-terminus or C-terminus of the fusion protein, or alternatively, it may be positioned internally in the fusion protein such that it is flanked by CbpA polypeptide sequences. By using multiple regions of the same protein in a fusion protein in combination with TCE, the immunogenicity to the protein may be increased by inducing an antibody response to multiple regions of the protein.

[0103] In one embodiment, the immunogenic fusion protein comprises an R21 or R22 polypeptide (i.e., SEQ ID NO: 1, 2, 3, 4, 41 or 42) or an active variant or fragment thereof in a loop conformation, fused in frame to a heterologous TCE (i.e., a pneumococcal or pneumolysoid polypeptide, such as those in SEQ ID NO: 40, 5, 7, 8, 17 or 39) or an active variant or fragment thereof, and fused in frame to a second R21 or R22 polypeptide (i.e., SEQ ID NO: 1, 2, 3, 4, 41 or 42) or an active variant or fragment thereof in a loop conformation. Table 1 provides a non-limiting list of various structures encompassed by the CbpA fusion proteins disclosed herein.

[0104] In certain embodiments, the immunogenic CbpA fusion protein comprises an R21 polypeptide comprising SEQ ID NO: 1 or 3 or an active variant or fragment thereof in a loop conformation, an L460D pneumolysoid of SEQ ID NO: 7 or 39 or an active variant or fragment thereof, and an R22 polypeptide comprising SEQ ID NO: 2 or 4 or an active variant or fragment thereof in a loop conformation. In certain embodiments, the immunogenic fusion protein comprises the amino acid sequence shown in SEQ ID NO: 9 or an active variant or fragment thereof.

[0105] In one embodiment, an immunogenic CbpA fusion protein comprises an R21 polypeptide comprising SEQ ID NO: 1 or 3 or an active variant or fragment thereof in a loop conformation, an L460D pneumolysoid of SEQ ID NO: 7 or 39 or an active variant or fragment thereof, and an R22 polypeptide comprising SEQ ID NO: 2 or 4 or an active variant or fragment thereof in a loop conformation. In a particular embodiment, the immunogenic fusion protein comprises the amino acid sequence shown in SEQ ID NO: 9 or an active variant or fragment thereof.

[0106] In other non-limiting embodiments, the immunogenic fusion protein comprises an R21 polypeptide comprising SEQ ID NO: 1 or 3 or an active variant or fragment thereof in a loop conformation, a Δ6N385 pneumolysoid of SEQ ID NO: 8 or an active variant or fragment thereof, and an R22 polypeptide comprising SEQ ID NO: 2 or 4 or an active variant or fragment thereof in a loop conformation. In a specific embodiment, the immunogenic fusion protein comprises the amino acid sequence shown in SEQ ID NO: 11 or an active variant or fragment thereof.

[0107] In some embodiments, an immunogenic CbpA fusion protein comprises an R21 polypeptide comprising SEQ ID NO:1, 3, or 41 or an active variant or fragment thereof in a loop conformation, a G293S / L460D pneumolysoid of SEQ ID NO:40 or an active variant or fragment thereof, and an R22 polypeptide comprising SEQ ID NO:2, 4, or 42 or an active variant or fragment thereof in a loop conformation. In certain embodiments, the immunogenic fusion protein comprises the amino acid sequence of SEQ ID NO:43 or an active variant or fragment thereof.

[0108] Exemplary immunogenic fusion proteins of the invention.

[0109] [ka]

[0110] [ka]

[0111] [ka]

[0112] [ka]

[0113] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

[0114] B. A fusion protein containing cytolysoid. As discussed above, the various CbpA fusion proteins provided herein can include a pneumolysoid polypeptide or an active variant or fragment thereof to increase immunogenicity against pneumococcal infection. While CbpA is from Streptococcus pneumoniae, it is recognized that polypeptides from other types of bacteria can be used to generate immunogenic fusion proteins capable of producing protective antibodies against other forms of bacteria, for example, bacteria from the genera Clostridium, Streptococcus, Listeria, Bacillus, and Arcanobacterium.

[0115] In one embodiment, the immunogenic fusion protein may comprise a cytolysoid polypeptide or an active variant or fragment thereof. As used herein, a "cytolysoid fusion protein" may comprise a full-length cytolysoid polypeptide or an active variant or fragment thereof, or any immunogenic fragment of cytolysoid, as discussed in more detail elsewhere herein. Cytolysins are a family of pore-forming toxins produced by more than 20 species from the genera Clostridium, Streptococcus, Listeria, Bacillus, and Alkanobacterium. Each cytolysin is produced as a monomer, and upon encountering a eukaryotic cell, the monomer is converted to an oligomeric structure to form a pore complex. Cytolysins are known as hemolytic proteins. As used herein, "cytolysoid" refers to modified cytolysins, where the modification of the protein inactivates or reduces the oligomerization and / or hemolytic properties of the cytolysoid protein while still retaining immunogenic activity. A reduction in toxicity of the cytolysin protein (i.e., reduction in oligomerization and / or hemolysis) includes a statistically significant decrease of at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a suitable control. A variety of methods for assaying for cytolysin activity are known in the art and are similar to those described elsewhere herein for pneumolysin.

[0116] The art provides substantial guidance regarding modifications required to inactivate or reduce the toxic activity (i.e., oligomerization and / or hemolysis) of cytolysins. These modifications may be amino acid substitutions, deletions, and / or additions. Such modifications are well known in the art. Some examples include, but are not limited to, WO2005 / 108419 and WO2005 / 108580, which disclose cytolysoids having mutations (e.g., substitutions or deletions) in the region corresponding to amino acids 144-161 of the wild-type pneumolysin protein. This region of pneumolysin has a consensus sequence shared among cytolysins. These mutant cytolysins have reduced oligomerization and / or hemolytic activity and are therefore less toxic compared to wild-type cytolysin. The mutants may have one or more amino acid substitutions or deletions in the region corresponding to amino acids 144-161 of the wild-type pneumolysin sequence. Thus, cytolysoids can have mutations at one or more of the amino acid residues corresponding to wild-type pneumolysin amino acids 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, or 161. Additional non-limiting examples of cytolysoids in the art are disclosed in U.S. Patent Application Publication No. 2009 / 0285846A1 and U.S. Patent Application Publication No. 2010 / 0166795, which are incorporated herein by reference.

[0117] Any cytolysin can be modified into a cytolysoid and used in the fusion proteins presented herein. Examples include, but are not limited to, pneumolysin from Streptococcus pneumoniae, perfringolysin O from Clostridium perfringens, intermedilysin from Streptococcus intermedius, alveolysin from Bacillus alvei, anthrolysin from Bacillus anthracis, putative cereolysin from Bacillus cereus, ivanolysin O from Listeria ivanovii, pyolysin from Arcanobacterium pyogenes, seeligerilysin O from Listeria seeligeri, streptolysin O from S. pyogenes, suilisin from Streptococcus suis, tetanolysin O from Clostridium tetani, and cytolysin O from Streptococcus tetani. These include listeriolysin O from Listeria monocytogenes, streptolysin O from Streptococcus equisimilis, streptolysin O from S. canis, thuringiolysin O from Bacillus thuringiensis, latersporolysin O from B. laterosporus, botulinolysin from Clostridium botulinum, chauveolysin from C. chauvoei, bifermentolysin from C. bifermentans, sordellisin from C. sordellii, histolyticolysin from Clostridium histioliticum, noviridin from Clostridium novi, and septicolysin O from Clostridium septicum. Other examples of cytolysins and cytolysoids can be found, for example, in S E Gelber et al. (2008) J. Bacteriology 190:3896-3903; and B H Jost et al. (2003) Infection and Immunity 71:2966-2969, which are incorporated by reference herein in their entireties.

[0118] The immunogenic cytolithoid fusion proteins provided herein can include at least one, two, three, four, five or more immunogenic bacterial polypeptides. Bacterial polypeptide sources can include, but are not limited to, the above-listed examples of cytolysins, including bacteria. The immunogenic polypeptides of the cytolithoid fusion proteins disclosed herein can be assembled in various combinations. The cytolithoid can be at either the N-terminus or C-terminus of the fusion protein, or it can be flanked by immunogenic bacterial polypeptides. The immunogenic bacterial polypeptides can be from the same bacteria as the cytolithoid, or they can be from different bacteria.

[0119] In certain embodiments, the cytolysoid fusion protein comprises pneumolysoid (i.e., SEQ ID NO: 40, 7, 8, 17, or 39, or an active variant or fragment thereof) and the immunogenic bacterial polypeptide can include any immunogenic protein from M. pneumoniae.

[0120] Various immunogenic cytolithoid active variants or fragments are provided herein. Such active variants may comprise at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity with the cytolithoid polypeptides provided herein in that they maintain immunogenic activity as described elsewhere herein. Active variants of immunogenic cytolithoids are known in the art. See, for example, U.S. Patent Application No. 2009 / 0285846A1 and U.S. Patent Application No. 2010 / 0166795, which are incorporated herein by reference in their entireties.

[0121] C. Polynucleotides Encoding Immunogenic Fusion Proteins and Methods for Producing Immunogenic Fusion Proteins. The compositions further include isolated polynucleotides encoding the various immunogenic fusion proteins described herein above, as well as variants and fragments thereof. Exemplary polynucleotides comprising nucleotide sequences encoding various polypeptides and various fusion proteins are summarized in Table 2. Variants and fragments of the isolated polynucleotides disclosed herein are also included.

[0122] [Table 2-1] [Table 2-2]

[0123] Further disclosed are vectors and expression cassettes that contain the polynucleotides described herein. Expression cassettes generally include a promoter operably linked to the polynucleotide and transcription and translation termination regions.

[0124] The use of the term "polynucleotide" is not intended to limit the present invention to polynucleotides that contain DNA. Those skilled in the art will recognize that polynucleotides can contain ribonucleotides, as well as combinations of ribonucleotides and deoxyribonucleotides. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues.

[0125] An isolated polynucleotide is substantially or essentially free from components that normally accompany or interact with the polynucleotide found in its natural environment. Thus, an isolated polynucleotide is substantially free of other cellular material or culture medium if produced by recombinant techniques, or substantially free of chemical precursors or other chemicals if chemically synthesized.

[0126] Conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art may be employed herein, such techniques being fully explained in the literature. For example, Sambrook et al., “Molecular Cloning: A Laboratory Manual” (1989); “Current Protocols in Molecular Biology” Volumes I-III [Ausubel, RM, ed. (1994)]; “Cell Biology: A Laboratory Handbook” Volumes I-III [JECelis, ed. (1994))]; “Current Protocols in Immunology” Volumes I-III [Coligan,JE,ed.(1994)];“Oligonucleotide Synthesis”(MJGait ed.1984);“Nucleic Acid Hybridization” [BDHames & SJHiggins eds.(1985)];“Transcription And Translation” [BDHames & SJHiggins,eds.(1984)];“Animal Cell Culture” [RIFreshney,ed.(1986)];“Immobilized Cells And Enzymes” [IRL Press, (1986)]; B. Perbal, “A Practical Guide To Molecular Cloning” (1984).

[0127] The polypeptides and fusion proteins disclosed herein can be modified in a variety of ways, including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants and fragments of CbpA or cytolysoid proteins can be prepared by mutations in DNA. Methods for mutagenesis and polynucleotide modification are well known in the art. See, for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al. (1987) Methods in Enzymol. 154:367-382; U.S. Patent No. 4,873,192; Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York) and references cited therein. In certain embodiments using looped conformations of the R21 and R22 polypeptides, the mutations comprise at least an insertion or substitution of a cysteine ​​residue in the CbpA polypeptide disclosed herein, hi other embodiments, the mutations in the CbpA (R2 domain, R21, or R22 region) pneumolysin or cytolysin comprise at least a deletion, insertion, and / or amino acid substitution.

[0128] Also provided herein is a vector comprising the above polynucleotide operably linked to a promoter. A nucleotide sequence is "operably linked" to an expression control sequence (e.g., a promoter) if the expression control sequence controls and regulates the transcription and translation of that sequence. The term "operably linked" when referring to a nucleotide sequence includes having a suitable initiation signal (e.g., ATG) in front of the nucleotide sequence to be expressed, as well as maintaining the correct reading frame to allow expression of the sequence under the control of the expression control sequence and production of the desired product encoded by the sequence. If a gene desired to be inserted into a recombinant nucleic acid molecule does not contain a suitable initiation signal, such an initiation signal can be inserted in front of the gene. A "vector" is a replicon, such as a plasmid, phage, or cosmid, to which another nucleic acid segment can be attached to effect replication of the attached segment. The promoter may be a bacterial promoter, a yeast promoter, an insect promoter, or a mammalian promoter, or may be the same. Furthermore, the vector may be a plasmid, a cosmid, a yeast artificial chromosome (YAC), a bacteriophage, or eukaryotic viral DNA.

[0129] Numerous other vector backbones known in the art as useful for expressing proteins may be used. Such vectors include, but are not limited to, adenovirus, simian virus 40 (SV40), cytomegalovirus (CMV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, DNA delivery systems, i.e., liposomes, and expression plasmid delivery systems. Additionally, one class of vectors includes DNA elements derived from viruses, such as bovine papilloma virus, polyoma virus, baculovirus, retrovirus, or Semliki Forest virus. Such vectors may be obtained commercially or may be assembled from sequences described by methods well known in the art.

[0130] A host-vector system for the production of polypeptides comprising a vector in a suitable host cell is provided herein. Suitable host cells include, but are not limited to, prokaryotic or eukaryotic cells, such as bacterial cells (including gram-positive cells), yeast cells, fungal cells, insect cells, and animal cells. Many mammalian cells can be used as hosts, including, but not limited to, mouse fibroblasts NIH 3T3, CHO cells, HeLa cells, Ltk- cells, and the like. Additional animal cells, such as R1.1, BW, and LM cells, African green monkey kidney cells (e.g., COS1, COS7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture can also be used.

[0131] A wide variety of host / expression vector combinations can be used in expressing the polynucleotide sequences presented herein. Useful expression vectors can consist of, for example, segments of chromosomal, non-chromosomal, and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, such as E. coli plasmids col El, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4, phage DNAs, such as many derivatives of phage 2, such as NM989, and other phage DNAs, such as M13 and filamentous single-stranded phage DNA, yeast plasmids, such as the 2μ plasmid or its derivatives, vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells, vectors derived from combinations of plasmids and phage DNA, such as plasmids modified to use phage DNA or other expression control sequences, and the like.

[0132] Any of a wide variety of expression control sequences (sequences that control the expression of a nucleotide sequence operatively linked thereto) can be used in these vectors to express the polynucleotide sequences provided herein. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the lac system, the trp system, the TAC system, the TRC system, the LTR system, the major operator and promoter regions of phage lambda, the control region of the fd coat protein, promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoter of acid phosphatase (e.g., Pho5), the promoter of yeast alpha mating factor, and other sequences known to control the expression of genes in prokaryotic or eukaryotic cells or viruses thereof, as well as various combinations thereof.

[0133] It will be understood that not all vectors, expression control sequences, and hosts function equally well to express the polynucleotide sequences provided herein. Not all hosts also function equally well in the same expression system. Those skilled in the art will be able to select appropriate vectors, expression control sequences, and hosts without undue experimentation to achieve the desired expression without departing from the scope of the invention. In selecting a vector, the host must be considered, since the vector must function within it. The copy number of the vector, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

[0134] In selecting an expression control sequence, a variety of factors are usually considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular nucleotide sequence or gene to be expressed, especially with respect to potential secondary structures. Suitable unicellular hosts are selected by considering, for example, their compatibility with the selected vector, their secretion characteristics, their ability to correctly fold proteins, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the expressed nucleotide sequence, and the ease of purification of the expressed product.

[0135] In preparing an expression cassette, various polynucleotides may be manipulated to provide the polynucleotide sequences in the proper orientation and, where appropriate, in the proper reading frame. To this end, adaptors or linkers may be used to join the polynucleotides, or other manipulations may be included to provide convenient restriction sites, removal of superfluid DNA, removal of restriction sites, or the like. For example, a linker, such as two glycines, may be added between the polypeptides. A methionine residue encoded by the atg nucleotide sequence may be added to allow initiation of gene transcription. To this end, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, such as transitions and translocations, may be included.

[0136] Further provided is a method of producing a polypeptide comprising expressing a polynucleotide encoding a fusion protein disclosed herein in a host cell under suitable conditions allowing production of the polypeptide, and recovering the polypeptide so produced.

[0137] D. Variants and fragments of the disclosed polynucleotides and polypeptides. Active variants and fragments of the disclosed polynucleotides and polypeptides are also used in the immunogenic fusion proteins described herein. "Variant" refers to a substantially similar sequence. As used herein, "variant polypeptide" is intended to mean a polypeptide derived from a native protein by the deletion (so-called truncation) of one or more amino acids at the N-terminus and / or C-terminus of the native protein; the deletion and / or addition of one or more amino acids at one or more internal sites in the native protein; or the substitution of one or more amino acids at one or more sites in the native protein. Variant polypeptides retain the desired biological activity of the native polypeptide, i.e., they are immunogenic. Variants of the polypeptide or polynucleotide sequences disclosed herein (i.e., SEQ ID NOs: 1-25 or 39, 40) typically have at least about 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the reference sequence.

[0138] The term "fragment" refers to a portion of an amino acid or nucleotide sequence that contains a specified number of consecutive amino acids or nucleotide residues. In certain embodiments, fragments of the polypeptides disclosed herein retain the biological activity of the full-length polypeptide and may therefore be immunogenic. Fragments of polynucleotides may encode protein fragments that retain the biological activity of the protein and are therefore immunogenic. Alternatively, fragments of polynucleotides that are useful as PCR primers generally do not retain biological activity. Thus, fragments of the nucleotide sequences disclosed herein (i.e., SEQ ID NO: 6 or 10) can range from at least about 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 175, 200, 225, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 consecutive nucleotides or up to the full-length polynucleotide. Fragments of the polypeptide sequences disclosed herein (i.e., SEQ ID NOs: 1-5, 7-9, 11, 12-14, 17-25, or 39) can contain at least 10, 15, 25, 30, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 400, 425, 450, 475, or 500 consecutive amino acids, or up to the total number of amino acids present in the full-length protein.

[0139] Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent sequence identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (1988) CABIOS 4:11-17; the local alignment algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the global alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453; the local alignment search method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, as modified in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

[0140] Computer implementations of these mathematical algorithms can be used to compare sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC / Gene program (available from Intelligenetics, Mountain View, Calif.); ALIGN program (version 2.0) in the GCG Wisconsin Genetics Software Package, version 10, as well as GAP, BESTFIT, BLAST, FASTA, and TFASTA (available from Accelrys Inc., 9685 Scranton Road, San Diego, Calif., USA). Alignments using these programs can be performed using default parameters. The CLUSTAL program is more fully described by Higgins et al. (1988) Gene 73:237-244 (1988); Higgins et al. (1989) CABIOS 5:151-153; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) CABIOS 8:155-65; and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331. The BLAST program of Altschul et al. (1990) J. Mol. Biol. 215:403 is based on the algorithm of Karlin and Altschul (1990), supra. BLAST nucleotide searches are performed using the BLASTN program, score=100, wordlength=12, to obtain nucleotide sequences homologous to the nucleotide sequences provided herein. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra.When utilizing BLAST, Gapped BLAST, or PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for proteins) can be used. See www.ncbi.nlm.nih.gov. Alignments may also be performed manually by inspection.

[0141] Unless otherwise stated, sequence identity / similarity values ​​provided herein refer to values ​​obtained using GAP version 10 with the following parameters: % identity and % similarity for nucleotide sequences using GAP weight 50 and length weight 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for amino acid sequences using GAP weight 8 and length weight 2, and the BLOSUM62 scoring matrix. By "equivalent program" is intended any sequence comparison program that produces alignments that have identical nucleotide or amino acid residue matches and identical percent sequence identity for any two sequences in question when compared to the corresponding alignment produced by GAP version 10.

[0142] Units, prefixes, and symbols may be denoted in their SI accepted format. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. Numeric ranges are inclusive of the numbers defining the range. Amino acids may be referred to herein by their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted single-letter codes. The terms defined above are more fully defined by reference to the specification as a whole.

[0143] II. Pharmaceutical Compositions and Formulations Compositions further include immunogenic compositions and vaccines comprising the immunogenic fusion proteins disclosed herein. The immunogenic compositions provided herein comprise at least one immunogenic fusion protein described herein in combination with a pharma- ceutically acceptable carrier. In some embodiments, the immunogenic fusion protein is present in an amount effective to induce antibody production when administered to an animal. Methods for detecting antibody production in animals are well known in the art.

[0144] Vaccines for treating or preventing bacterial infections are provided, comprising at least one fusion protein provided herein in combination with a pharma- ceutically acceptable carrier, wherein the fusion protein is present in an amount effective to treat or prevent bacterial infection. In certain embodiments, the vaccine induces the production of protective antibodies against the bacteria when administered to an animal. In certain embodiments, the vaccine comprises an immunogenic fusion protein comprising a cytolithoid. In other embodiments, the vaccine comprises an immunogenic fusion protein comprising a cytolithoid and one or more immunogenic polypeptides from the same bacterial source as the cytolithoid or from a different bacterial source.

[0145] Vaccines for treating or preventing pneumococcal infection are also provided, comprising at least one fusion protein provided herein in combination with a pharma- ceutically acceptable carrier, wherein the fusion protein is present in an amount effective to treat or prevent pneumococcal infection. In certain embodiments, the vaccine induces the production of protective antibodies against Streptococcus pneumoniae when administered to an animal. In certain embodiments, the vaccine comprises an immunogenic fusion protein comprising a CbpA polypeptide (i.e., such as a fusion protein presented in Table 1).

[0146] Also provided is a composition comprising an immunogenic fusion protein or a biologically active variant or fragment thereof, and an adjuvant in combination with a pharma- ceutically acceptable carrier. The immunogenic fusion protein presented herein can be prepared in admixture with an adjuvant to prepare a vaccine. Pharmaceutically acceptable carriers and adjuvants are well known in the art. Methods for formulating pharmaceutical compositions and vaccines are generally known in the art. A thorough discussion of formulation and selection of pharma-ceutically acceptable carriers, stabilizers, and isomolytes can be found in Remington's Pharmaceutical Sciences (1896), 1999, 1981, 1992, 1999, 1996, 1998, 1999, 1999, 2001, 1999, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 203, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 225, 226, 227, 228, 230, 233, 234, 235, 236, 237, 238, 239, 240, 241, 245, 246, 247, 248, 250 th ed.; Mack Publishing Company, Eaton, Pennsylvania, 1990), incorporated herein by reference. As provided herein, a vaccine can include, for example, at least one of the fusion proteins disclosed in Table 1, or a biologically active variant or fragment thereof.

[0147] As described elsewhere herein, the R21 region of CbpA is believed to be involved in bacterial colonization of the nasopharynx, while both the R21 and R22 regions of CbpA mediate bacterial invasion of host cells. Thus, a vaccine comprising a fusion protein comprising both the R21 and R22 polypeptides can provide protection against both steps involved in pneumococcal infection. In certain embodiments, a vaccine comprising a fusion protein comprising both the R21 and R22 polypeptides, e.g., a fusion protein of SEQ ID NO: 43 or an active variant or fragment thereof, can provide protection against both steps involved in pneumococcal infection.

[0148] The immunogenic compositions and vaccines disclosed herein may comprise a mixture of one or more fusion proteins with one or more polypeptides provided herein. A vaccine may comprise any one of the immunogenic fusion proteins described in Table 1 or active variants or fragments thereof combined as a mixture with one or more of the polypeptides of SEQ ID NO: 1, 2, 3, 4, 5, 7, 8, 12, 13, 14, 17, 39, 40, 41, 42, 43, or active variants or fragments thereof. In some embodiments, the vaccine comprises SEQ ID NO: 43.

[0149] The immunogenic compositions may be formulated in liquid form (i.e., solution or suspension) or in lyophilized form. Liquid formulations may advantageously be administered directly from their packaged form and are thus ideal for injection, without the need for reconstitution in an aqueous medium otherwise required for the lyophilized compositions of the invention.

[0150] Formulation of the immunogenic compositions of the present disclosure can be accomplished using art-recognized methods. For example, individual polysaccharides and / or conjugates can be formulated with a physiologically acceptable solvent to prepare the composition. Examples of such solvents include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and glucose solutions. The present disclosure provides formulations comprising any of the immunogenic compositions disclosed herein in combination with a pharma-ceutically acceptable excipient, carrier, or diluent.

[0151] In another embodiment, the immunogenic compositions of the present invention are administered orally and thus are formulated in a form suitable for oral administration, i.e., as solid or liquid preparations. Solid oral formulations include tablets, capsules, pills, granules, pellets, and the like. Liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils, and the like.

[0152] Pharmaceutically acceptable carriers for liquid formulations are aqueous or non-aqueous solutions, suspensions, emulsions, or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. In one embodiment, the immunogenic composition of the present disclosure is in liquid form, preferably in aqueous liquid form.

[0153] Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Examples of oils are oils of animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, other marine oils, or lipids from milk or eggs.

[0154] In one embodiment, the present disclosure provides a container filled with any of the immunogenic compositions disclosed herein. In one embodiment, the container is selected from the group consisting of a vial, a syringe, a flask, a fermenter, a bioreactor, a bag, a jar, an ampoule, a cartridge, and a disposable pen. In a particular embodiment, the container is siliconized.

[0155] In one embodiment, the container of the present disclosure is made of glass, metal (e.g., steel, stainless steel, aluminum, etc.) and / or polymer (e.g., thermoplastic, elastomer, thermoplastic elastomer). In one embodiment, the container of the present disclosure is made of glass.

[0156] In one embodiment, the present disclosure provides a syringe filled with any of the immunogenic compositions disclosed herein. In certain embodiments, the syringe is siliconized and / or made of glass. The immunogenic compositions of the present invention can be formulated as single-dose vials, multi-dose vials, or as pre-filled glass or plastic syringes.

[0157] The immunogenic composition of the present invention may be isotonic, hypotonic, or hypertonic. However, it is often preferred that compositions for infusion or injection are essentially isotonic when administered. Therefore, for storage, the composition may preferably be isotonic or hypertonic. If the composition is hypertonic for storage, it may be diluted to become an isotonic solution before administration.

[0158] The isotonicity agent may be an ionic isotonicity agent, such as a salt, or a non-ionic isotonicity agent, such as a sugar. Examples of ionic isotonicity agents include, but are not limited to, NaCl, CaCh, KCl, and MgCh. Examples of non-ionic isotonicity agents include, but are not limited to, mannitol, sorbitol, and glycerol.

[0159] It is also preferred that at least one pharma- ceutical acceptable additive is a buffering agent. For some purposes, for example when the pharmaceutical composition is intended for infusion or injection, it is often desirable for the composition to contain a buffer capable of buffering the solution to a pH in the range of 4 to 10, such as 5 to 9, for example 6 to 8.

[0160] In some embodiments, a composition or formulation of the present disclosure has a pH level between pH 6 and pH 9. In some embodiments, a composition or formulation of the present disclosure has a pH level between pH 5.5 and pH 7.5. In some embodiments, a composition or formulation has a pH of about 7.4.

[0161] The composition or formulation of the present disclosure may include at least one buffer. The buffer may be selected from USP compatible buffers for parenteral use, especially when the pharmaceutical formulation is for parenteral use. For example, the buffer may be selected from the group consisting of monobasic acids, such as acetic acid, benzoic acid, gluconic acid, glyceric acid, and lactic acid; dibasic acids, such as aconitic acid, adipic acid, ascorbic acid, carbonic acid, glutamic acid, malic acid, succinic acid, and tartaric acid; polybasic acids, such as citric acid and phosphoric acid; and bases, such as ammonia, diethanolamine, glycine, triethanolamine, and TRIS. Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Examples are sterile liquids such as water and oils, with or without the addition of surfactants and other pharma- ceutically acceptable adjuvants. In general, water, saline, aqueous glucose and related sugar solutions, glycols such as propylene glycol or polyethylene glycol, polysorbate 80 (PS-80), polysorbate 20 (PS-20), and poloxamer 188 (P188) are preferred liquid carriers, especially for injection solutions. Examples of oils are oils of animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, olive oil, sunflower oil, fish liver oil, other marine oils, or lipids from milk or eggs. The buffer may be selected from the group consisting of, for example, TRIS, acetate, glutamate, lactate, malate, tartarate, phosphate, citrate, carbonate, glycine, histidine, glycine, succinate, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MES (2-( / V-morpholino)ethanesulfonic acid) and triethanolamine buffer.

[0162] In some embodiments, the buffer concentration is in the range of about 1 mM to about 100 mM. In some embodiments, the buffer concentration is in the range of about 10 mM to about 80 mM. In some embodiments, the buffer concentration is in the range of about 1 mM to about 50 mM, or about 5 mM to about 50 mM.

[0163] In some embodiments, the buffer is a phosphate buffer. In some embodiments, the buffer is a sodium phosphate buffer. In some embodiments, the composition or formulation comprises a sodium phosphate buffer. In some embodiments, the concentration of the sodium phosphate buffer is between about 1 mM and about 50 mM. In some embodiments, the concentration of the sodium phosphate buffer is about 5 mM to about 50 mM, about 5 mM to about 45 mM, about 5 mM to about 40 mM, about 5 mM to about 35 mM, about 5 mM to about 30 mM, about 5 mM to about 25 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 10 mM to about 50 mM, 10 mM to about 45 mM, about 10 mM to about 40 mM, about 10 mM to about 35 mM, about 10 mM to about 30 mM, about 10 mM to about 25 mM, about 10 mM to about 20 mM, about 10 mM to about 15 mM, about 15 mM to about 50 mM, about 15 mM to about 45 mM, about between about 15 mM to about 40 mM, about 15 mM to about 35 mM, about 15 mM to about 30 mM, about 15 mM to about 25 mM, about 15 mM to about 20 mM, about 20 mM to about 45 mM, about 20 mM to about 40 mM, about 20 mM to about 35 mM, about 20 mM to about 30 mM, about 20 mM to about 25 mM, about 25 mM to about 45 mM, about 25 mM to about 40 mM, about 25 mM to about 35 mM, about 25 mM to about 30 mM, about 30 mM to about 45 mM, about 30 mM to about 40 mM, about 30 mM to about 35 mM, about 35 mM to about 45 mM, about 35 mM to about 40 mM, or about 40 mM to about 45 mM. In some embodiments, the final concentration of the sodium phosphate buffer is about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12 mM, about 13 mM, about 14 mM, or about 15 mM. In some embodiments, the composition or formulation comprises a sodium phosphate buffer at a concentration of about 10 mM. In some embodiments, the final concentration of the sodium phosphate buffer is about 9 mM.

[0164] In one embodiment, the composition or formulation of the present disclosure comprises a salt. In some embodiments, the salt is selected from the group consisting of magnesium chloride, potassium chloride, calcium chloride, sodium chloride, and combinations thereof. In one particular embodiment, the salt is sodium chloride. Non-ionic isotonicity agents, including but not limited to, sucrose, trehalose, mannitol, sorbitol, and glycerol, may be used in place of salt. Suitable salt ranges include, but are not limited to, 20 mM to 500 mM or 40 mM to 170 mM. In one embodiment, the immunogenic composition of the present invention comprises sodium chloride. In a particular embodiment, the sodium chloride is at a final concentration of about 100 mM to about 500 mM, about 100 mM to about 400 mM, about 100 mM to about 300 mM, or about 100 mM to about 200 mM. In a particular embodiment, the buffer is at a final concentration of about 125 mM to about 175 mM sodium chloride. In certain embodiments, the final concentration of sodium chloride is about 130 mM to about 160 mM. In certain embodiments, the final concentration of sodium chloride is about 135 mM, about 136 mM, about 137 mM, about 138 mM, about 139 mM, about 140 mM, about 141 mM, about 142 mM, about 143 mM, about 144 mM, about 145 mM, about 146 mM, about 147 mM, about 148 mM, about 149 mM, about 150 mM, about 151 mM, about 152 mM, about 153 mM, about 154 mM, or about 155 mM. In some embodiments, the final concentration of sodium chloride is about 154 mM. In some embodiments, the final concentration of sodium chloride is about 138.6 mM. In some embodiments, the final concentration of sodium chloride is about 139 mM.

[0165] In one embodiment, the immunogenic composition of the disclosure comprises a surfactant. Surfactants include, but are not limited to, polysorbate 20 (TWEEN™ 20), polysorbate 40 (TWEEN™ 40), polysorbate 60 (TWEEN™ 60), polysorbate 65 (TWEEN™ 65), polysorbate 80 (TWEEN™ 80), polysorbate 85 (TWEEN™ 85), TRITON™ N-101, TRITON™ X-100, oxtoxynol 40, nonoxynol 9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene 660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin, poloxamer, poloxamer 188 (P188; Pluoronic; F68 copolymers of ethylene oxide (EO), propylene oxide (PO), and / or butylene oxide (BO), such as the linear EO / PO block copolymers sold under the trade name DOWFAX™; octoxynol, which may vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, of particular interest is octoxynol 9 (Triton X-100, or t-octylphenoxypolyethoxyethanol); (octylphenoxy)polyethoxyethanol (IGEPAL CA-630 / NP-40); phospholipids, such as phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as the Tergitol™ NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl, and oleyl alcohols (known as Brij surfactants), such as triethylene glycol monolauryl ether (Brij 30), as well as sorbitan esters (commonly known as SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Mixtures of surfactants can be used.

[0166] Preferred amounts of surfactants (% by weight) are: 0.01-1%, especially about 0.01%, of a polyoxyethylene sorbitan ester (such as PS-80); 0.001-0.1%, especially 0.005-0.02%, of an octyl- or nonylphenoxy polyoxyethanol (such as Triton X-100, or other surfactants in the Triton series); 0.1-20%, preferably 0.1-10%, especially 0.1-1% or about 0.5% of a polyoxyethylene ether (such as Laureth 9).

[0167] In some embodiments, the composition or formulation of the present invention comprises a surfactant. In one embodiment, the surfactant is polysorbate 20 (Tween 20). In some embodiments, the Tween 20 is at a final concentration of about 1 μg / mL to about 600 μg / mL. In certain embodiments, the Tween 20 is at a final concentration of about 100 μg / mL to about 200 μg / mL, about 200 μg / mL to about 300 μg / mL, about 300 μg / mL to about 400 μg / mL, about 400 μg / mL to about 500 μg / mL, or about 500 μg / mL to about 600 μg / mL.

[0168] In some embodiments, Tween 20 is from about 100 μg / mL to about 500 μg / mL, from about 100 μg / mL to about 475 μg / mL, from about 100 μg / mL to about 450 μg / mL, from about 100 μg / mL to about 425 μg / mL, from about 100 μg / mL to about 400 μg / mL, from about 100 μg / mL to about 375 μg / mL, from about 100 μg / mL to about 350 μg / mL, from about 100 μg / mL to about 325 μg / mL, from about 100 μg / mL to about 300 μg / mL, from about 100 μg / mL to about 275 μg / mL, from about 100 μg / mL to about 250 μg / mL, from about 100 μg / mL to about 300 μg / mL Approximately 225μg / mL, approximately 100μg / mL to approximately 200μg / mL, approximately 100μg / mL to approximately 175μg / mL, approximately 100μg / mL to approximately 150μg / mL, approximately 100μg / mL to approximately 125μg / mL, approximately 125μg / mL to approximately 500μg / mL, approximately 125μg / mL to approximately 475μ g / mL, approximately 125 μg / mL to approximately 450 μg / mL, approximately 125 μg / mL to approximately 425 μg / mL, approximately 125 μg / mL to approximately 400 μg / mL, approximately 125 μg / mL to approximately 375 μg / mL, approximately 125 μg / mL to approximately 350 μg / mL, approximately 125 μg / mL to approximately 325 μg / mL, Approximately 125μg / mL to approximately 300μg / mL, approximately 125μg / mL to approximately 275μg / mL, approximately 125μg / mL to approximately 250μg / mL, approximately 125μg / mL to approximately 225μg / mL, approximately 125μg / mL to approximately 200μg / mL, approximately 125μg / mL to approximately 175μg / mL, approximately 125μ g / mL~about 150μg / mL, about 175μg / mL~about 500μg / mL, about 175μg / mL~about 475μg / mL, about 175μg / mL~about 450μg / mL, about 175μg / mL~about 425μg / mL, about 175μg / mL~about 400μg / mL, about 175μg / mL~ Approximately 375μg / mL, approximately 175μg / mL to approximately 350μg / mL, approximately 175μg / mL to approximately 325μg / mL, approximately 175μg / mL to approximately 300μg / mL, approximately 175μg / mL to approximately 275μg / mL, approximately 175μg / mL to approximately 250μg / mL, approximately 175μg / mL to approximately 225μ g / mL, approximately 175 μg / mL to approximately 200 μg / mL, approximately 200 μg / mL to approximately 500 μg / mL, approximately 200 μg / mL to approximately 475 μg / mL, approximately 200 μg / mL to approximately 450 μg / mL, approximately 200 μg / mL to approximately 425 μg / mL, approximately 200 μg / mL to approximately 400 μg / mL,From about 200 μg / mL to about 375 μg / mL, from about 200 μg / mL to about 350 μg / mL, from about 200 μg / mL to about 325 μg / mL, from about 200 μg / mL to about 300 μg / mL, from about 200 μg / mL to about 275 μg / mL, from about 200 μg / mL to about 250 μg / mL, from about 200 μg / mL to about 225 μg / mL, from about 225 μg / mL to about 500 μg / mL, from about 225 μg / mL to about 475 μg / mL, from about 225 μg / mL to about 450 μg / mL, from about 225 μg / mL to about 425 μg / mL, from about 225 μg / mL to about 400 μg / mL, from about 225 μg / mL to about 375 μg / mL, from about 225 μg / mL to about 350 μg / mL, from about 225 μg / mL to about 325 μg / mL, from about 225 μg / mL to about 300 μg / mL, from about 225 μg / mL to about 275 μg / mL, from about 225 μg / mL to about 250 μg / mL, from about 250 μg / mL to about 500 μg / mL, from about 250 μg / mL to about 475 μg / mL, from about 250 μg / mL to about 450 μg / mL, from about 250 μg / mL to about 425 μg / mL, from about 250 μg / mL to about 400 μg / mL, from about 250 μg / mL to about 375 μg / mL, from about 250 μg / mL to about 350 μg / mL, from about 250 μg / mL to about 325 μg / mL, from about 250 μg / mL to about 300 μg / mL, from about 275 μg / mL to about 500 μg / mL, from about 275 μg / mL to about 475 μg / mL, from about 275 μg / mL to about 450 μg / mL, from about 275 μg / mL to about 425 μg / mL, from about 275 μg / mL to about 400 μg / mL, from about 275 μg / mL to about 375 μg / mL, from about 275 μg / mL to about 350 μg / mL, from about 275 μg / mL to about 325 μg / mL, from about 275 μg / mL to about 300 μg / mL, from about 300 μg / mL to about 500 μg / mL, from about 300 μg / mL to about 475 μg / mL, from about 300 μg / mL to about 450 μg / mL, from about 300 μg / mL to about 425 μg / mL, from about 300 μg / mL to about 400 μg / mL, from about 300 μg / mL to about 375 μg / mL, from about 300 μg / mL to about 350 μg / mL, from about 300 μg / mL to about 325 μg / mL, from about 325 μg / mL to about 500 μg / mL, from about 325 μg / mL to about 475 μg / mL, from about 325 μg / mL to about 450 μg / mL, from about 325 μg / mL to about 425 μg / mL, from about 325 μg / mL to about 400 μg / mL,Approximately 325μg / mL to approximately 375μg / mL, approximately 325μg / mL to approximately 350μg / mL, approximately 350μg / mL to approximately 500μg / mL, approximately 350μg / mL to approximately 475μg / mL, approximately 350μg / mL to approximately 450μg / mL, approximately 350μg / m L ~ about 425 μg / mL, about 350 μg / mL to about 400 μg / mL, about 350 μg / mL to about 375 μg / mL, about 375 μg / mL to about 500 μg / mL, about 375 μg / mL to about 475 μg / mL, about 375 μg / mL to about 450 μg / mL The final concentration is about 375 μg / mL to about 425 μg / mL, about 375 μg / mL to about 400 μg / mL, about 400 μg / mL to about 500 μg / mL, about 400 μg / mL to about 475 μg / mL, about 400 μg / mL to about 450 μg / mL, about 400 μg / mL to about 425 μg / mL, about 425 μg / mL to about 500 μg / mL, about 425 μg / mL to about 475 μg / mL, about 425 μg / mL to about 450 μg / mL, about 450 μg / mL to about 500 μg / mL, about 450 μg / mL to about 475 μg / mL, or 475 μg / mL to about 500 μg / mL. In some embodiments, Tween 20 is at a final concentration of about 275 μg / mL.

[0169] In another embodiment, Tween 20 is at a final concentration of about 1 μg / mL to about 100 μg / mL. In some embodiments, Tween 20 is at a final concentration of about 4 μg / mL to about 8 μg / mL. In some embodiments, Tween 20 is at a final concentration of about 12 μg / mL to about 24 μg / mL. In some embodiments, Tween 20 is at a final concentration of about 23 μg / mL to about 38 μg / mL. In some embodiments, Tween 20 is at a final concentration of about 35 μg / mL to about 73 μg / mL. In some embodiments, Tween 20 is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 or 80 μg / mL final concentrations.

[0170] In some embodiments, the immunogenic compositions disclosed herein may further comprise at least one, two, or three adjuvants. In some embodiments, the immunogenic compositions disclosed herein may further comprise an adjuvant. The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An antigen may act primarily as a delivery system, primarily as an immunomodulator, or have both strong features. Suitable adjuvants include adjuvants suitable for use in mammals, including humans.

[0171] Exemplary adjuvants for enhancing the effectiveness of the immunogenic compositions disclosed herein include, but are not limited to, the following: (1) oil-in-water emulsion formulations (with or without other specific immunostimulants, such as muramyl peptides (see below), or bacterial cell wall components), such as (a) SAF comprising 10% squalene, 0.4% Tween 80, 5% pluronic block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (b) RIBI™ Adjuvant System (RAS) (Ribi Immunochem, Hamilton, Montana), comprising 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components, such as monophosphorylated lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+ CWS (DETOX™); (2) saponin adjuvants such as QS21, STIMULON™ (Cambridge Bioscience, Worcester, Mass.), ABISCO® (Isconova, Sweden), or ISCOMATRIX® (Commonwealth Serum Laboratories, Australia) may be used or particles generated therefrom, such as ISCOMs (immunostimulating complexes), which ISCOMS may lack added surfactants (e.g., WO 00 / 07621); (3) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (4) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (e.g., WO 99 / 44636), interferons (e.g., gamma interferon), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.;(5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) (see, e.g., GB-2220221, EP 0689454), optionally in the substantial absence of alum when used with pneumococcal saccharides (see, e.g., WO 00 / 56358); (6) 3dMPL in combination with, for example, QS21 and / or an oil-in-water emulsion (see, e.g., EP 0835318, EP 0735898, EP 0761231); (7) polyoxyethylene ether or polyoxyethylene ester (see, e.g., WO 99 / 52549); (8) polyoxyethylene sorbitan ester surfactants in combination with octoxynol (see, e.g., WO 01 / 21207), or polyoxyethylene alkyl ether or ester surfactants in combination with at least one additional non-ionic surfactant, such as octoxynol (see, e.g., WO 01 / 21152); (9) saponin and immunostimulatory oligonucleotides (e.g., CpG oligonucleotides) (e.g., WO 00 / 62800); (10) particles of immunostimulants and metal salts (see, e.g., WO 00 / 23105); (11) saponin and oil-in-water emulsions (e.g., WO 99 / 11241); (12) saponin (e.g., QS21) + 3dMPL + IM2 (optionally + sterol) (e.g., WO 98 / 57659); (13) other substances which act as immunostimulants to enhance the effectiveness of the composition. Muramyl peptides include, but are not limited to, N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetylnormuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamine-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamine MTP-PE;

[0172] In one embodiment, the compositions or formulations disclosed herein include an aluminum salt (alum) as an adjuvant. In some embodiments, the compositions or formulations include aluminum phosphate, aluminum sulfate, or aluminum hydroxide. In some embodiments, the final concentration of the adjuvant is between about 0.01 mg / mL and about 3.0 mg / mL. In some embodiments, the final concentration of the adjuvant is between about 0.01 mg / mL and about 1.0 mg / mL. In some embodiments, the final concentration of the adjuvant is between about 0.5 mg / mL and about 2 mg / mL.

[0173] In some embodiments, the compositions or formulations disclosed herein include aluminum phosphate or aluminum hydroxide as an adjuvant. In some embodiments, the adjuvant is aluminum hydroxide. In some embodiments, the aluminum hydroxide is Alhydrogel®.

[0174] In one embodiment, the adjuvant is at a final concentration of about 0.1 mg / mL to about 2.0 mg / mL. In some embodiments, the adjuvant is at a final concentration of about 0.5 mg / mL to about 1.5 mg / mL, about 0.6 mg / mL to about 1.4 mg / mL, about 0.7 mg / mL to about 1.3 mg / mL, about 0.8 mg / mL to about 1.2 mg / mL, or about 0.9 mg / mL to about 1.1 mg / mL. In some embodiments, the adjuvant is at a final concentration of about 1 mg / mL.

[0175] The compositions or formulations of the present disclosure include an immunogenic fusion protein (e.g., SEQ ID NO: 43). In some embodiments, the immunogenic fusion protein is at a final concentration of about 1 μg / mL to about 100 μg / mL, about 1 μg / mL to about 200 μg / mL, about 1 μg / mL to about 300 μg / mL, about 1 μg / mL to about 400 μg / mL, or about 1 μg / mL to about 500 μg / mL. In some embodiments, the immunogenic fusion protein is at a concentration of about 10 to about 30 μg / mL, about 48 μg / mL to about 72 μg / mL, about 96 μg / mL to about 124 μg / mL, or about 144 μg / mL to about 216 μg / mL. In some embodiments, the immunogenic fusion protein is about 10 μg / mL, about 15 μg / mL, about 20 μg / mL, about 25 μg / mL, about 30 μg / mL, about 35 μg / mL, about 40 μg / mL, about 45 μg / mL, about 50 μg / mL, about 55 μg / mL, about 60 μg / mL, about 65 μg / mL, about 70 μg / mL, about 75 μg / mL, about 80 μg / mL, about 85 μg / mL, about 90 μg / mL, about 95 μg / mL, about 100 μg / mL, about 105 μg / mL, about 110 μg / mL, about 115 μg / mL, about 120 μg / mL, about 125 μg / mL, about 130 μg / mL, about 135 μg / mL, about 140 μg / mL, about 145 μg / mL , about 150μg / mL, about 155μg / mL, about 160μg / mL, about 165μg / mL, about 170μg / mL, about 175μg / mL, about 180μg / mL, Approximately 185μg / mL, approximately 190μg / mL, approximately 195μg / mL, approximately 200μg / mL, approximately 205μg / mL, approximately 210μg / mL, approximately 215μg / mL, approximately The immunogenic fusion protein may be at a final concentration of about 220 μg / mL, about 225 μg / mL, about 230 μg / mL, about 235 μg / mL, about 240 μg / mL, about 245 μg / mL, about 250 μg / mL, about 255 μg / mL, about 260 μg / mL, about 265 μg / mL, about 270 μg / mL, about 275 μg / mL, about 280 μg / mL, about 285 μg / mL, about 290 μg / mL, or about 300 μg / mL, or any concentration therebetween. In some embodiments, the immunogenic fusion protein is at a final concentration of about 20 μg / mL. In some embodiments, the immunogenic fusion protein is at a final concentration of about 60 μg / mL. In some embodiments, the immunogenic fusion protein is at a final concentration of about 120 μg / mL.In some embodiments, the immunogenic fusion protein is at a final concentration of about 180 μg / mL.

[0176] The amount of immunogenic fusion protein in each dose of the composition or formulation is selected as an amount that induces an immune protective response without significant adverse effects. In some embodiments of the present invention, the dose of the immunogenic fusion protein is about 1 μg to about 150 μg, about 1 μg to about 200 μg, about 1 μg to about 250 μg, about 1 μg to about 300 μg, about 1 μg to about 350 μg, about 1 μg to about 400 μg, about 1 μg to about 450 μg, or about 1 μg to about 500 μg. In some embodiments, the dose of the immunogenic fusion protein is about 5 μg to about 15 μg, about 48 μg to about 72 μg, about 96 μg to about 116 μg, or about 144 μg to about 216 μg. In some embodiments, the dose of the immunogenic fusion protein is about 10 μg, about 15 μg, about 20 μg, about 25 μg, about 30 μg, about 35 μg, about 40 μg, about 45 μg, about 50 μg, about 55 μg, about 60 μg, about 65 μg, about 70 μg, about 75 μg, about 80 μg, about 85 μg, about 90 μg, about 95 μg, about 100 μg, about 105 μg, about 110 μg, about 115 μg, about 120 μg, about 125 μg, about 130 μg, about 135 μg, about 140 μg, about 145 μg, about 150 μg, about 160 μg, about 170 μg, about 180 μg, about 190 μg, about 200 μg, about 210 μg, about 220 μg, about 230 μg, about 240 μg, about 250 μg, about 260 μg, about 270 μg, about 280 μg, about 290 μg, about 300 μg, about 310 μg, about 320 μg, about 330 μg, about 340 μg, about 350 μg, about 360 μg, about 370 μg, about 380 μg, about 390 μg, about 400 μg, about 410 μg, about 420 μg, about 430 μg, about 440 μg, about 450 μg, about 460 μg, about 470 μg, about 480 μg, about 490 μg, about 500 μg, about 5 g, about 150 μg, about 155 μg, about 160 μg, about 165 μg, about 170 μg, about 175 μg, about 180 μg, about 185 μg, about 190 μg, about 195 μg, about 200 μg, about 205 μg, about 210 μg, about 215 μg, about 220 μg, about 225 μg, about 230 μg, about 235 μg, about 240 μg, about 245 μg, about 250 μg, about 255 μg, about 260 μg, about 265 μg, about 270 μg, about 275 μg, about 280 μg, about 285 μg, about 290 μg, or about 300 μg, or any amount therebetween. In some embodiments, the dose of the immunogenic fusion protein is about 10 μg. In some embodiments, the dose of the immunogenic fusion protein is about 30 μg. In some embodiments, the dose of the immunogenic fusion protein is about 60 μg. In some embodiments, the dose of the immunogenic fusion protein is about 90 μg.

[0177] The present disclosure provides an injectable formulation comprising an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 0.5 mg / mL to about 1.5 mg / mL, sodium phosphate buffer at a final concentration of about 10 mM, NaCl at a final concentration of about 154 mM, and polysorbate 20 (Tween 20) at a final concentration of about 275 μg / mL, wherein the pH of the injectable formulation is about 7.4.

[0178] The present disclosure provides an injectable formulation comprising an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 0.5 mg / mL to about 1.5 mg / mL, sodium phosphate buffer at a final concentration of about 10 mM, NaCl at a final concentration of about 154 mM, and Tween 20 at a final concentration of about 275 μg / mL, wherein the pH of the injectable formulation is about 7.4.

[0179] Exemplary formulations of the immunogenic compositions of the invention are shown in Tables 3 and 4.

[0180] [Table 3]

[0181] [Table 4]

[0182] In some embodiments, the drug product formulation comprises 180 μg / mL immunogenic fusion protein, 1 mg / mL aluminum (in the form of aluminum hydroxide) in 9 mM sodium phosphate, 139 mM sodium chloride, 275 μg / mL polysorbate 20, pH 7.4.

[0183] The disclosure also provides an injectable formulation in a multiple unit dose vial containing about 1 mL, wherein the injectable formulation comprises an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 20 μg / mL, sodium phosphate buffer at a final concentration of about 9 mM, NaCl at a final concentration of about 139 mM, polysorbate 20 at a final concentration of about 275 μg / mL, and aluminum hydroxide at a final concentration of about 1 mg / mL, wherein the pH of the injectable formulation is about 7.4.

[0184] The disclosure also provides an injectable formulation in a multiple unit dose vial containing about 1 mL, wherein the injectable formulation comprises an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 60 μg / mL, sodium phosphate buffer at a final concentration of about 9 mM, NaCl at a final concentration of about 139 mM, polysorbate 20 at a final concentration of about 275 μg / mL, and aluminum hydroxide at a final concentration of about 1 mg / mL, wherein the pH of the injectable formulation is about 7.4.

[0185] The disclosure also provides an injectable formulation in a multiple unit dose vial containing about 1 mL, wherein the injectable formulation comprises an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 120 μg / mL, sodium phosphate buffer at a final concentration of about 9 mM, NaCl at a final concentration of about 139 mM, polysorbate 20 at a final concentration of about 275 μg / mL, and aluminum hydroxide at a final concentration of about 1 mg / mL, wherein the pH of the injectable formulation is about 7.4.

[0186] The disclosure also provides an injectable formulation in a multiple unit dose vial containing about 1 mL, wherein the injectable formulation comprises an immunogenic fusion protein of SEQ ID NO: 43 at a final concentration of about 180 μg / mL, sodium phosphate buffer at a final concentration of about 9 mM, NaCl at a final concentration of about 139 mM, polysorbate 20 at a final concentration of about 275 μg / mL, and aluminum hydroxide at a final concentration of about 1 mg / mL, wherein the pH of the injectable formulation is about 7.4.

[0187] The optimal amount of components for a particular immunogenic composition can be ascertained by standard tests, including observing suitable immune responses in subjects. For example, in another embodiment, the dosage for human vaccination is determined by extrapolation from animal tests to human data. In another embodiment, the dosage is determined empirically.

[0188] In some embodiments, the pharmaceutical composition is delivered in a controlled release system. For example, the drug can be administered using intravenous infusion, a transdermal patch, liposomes, or other modes of administration. In another embodiment, the polymeric material is used, for example, in a microsphere or in an implant.

[0189] In certain embodiments, the compositions of the present invention are administered to a subject by one or more methods known to those of skill in the art, such as parenterally, mucosally, transdermally, intramuscularly, intravenously, intradermally, intranasally, subcutaneously, intraperitoneally, etc., and formulated accordingly. In one embodiment, the compositions of the present invention are administered via epidermal, intramuscular, intravenous, intraarterial, subcutaneous, or intrarespiratory mucosal injection of a liquid preparation. Liquid formulations for injection include solutions and the like.

[0190] III. Method of Use

[0191] These fusion proteins disclosed herein, which comprise two or more different immunogenic polypeptides, represent a novel, cost-effective way to improve vaccine efficacy. The CbpA cytolysoid fusion proteins provided herein (such as those examples provided in Tables 1 and 2) are immunogenic and, depending on the design of the fusion protein and the selection of the polypeptide components, they find use in the treatment and prevention of a variety of bacterial infections.

[0192] The compositions provided herein find use in methods for preventing and treating bacterial infections. As used herein, "preventing bacterial infection" contemplates administration of a therapeutically effective amount of an immunogenic fusion protein, immunogenic composition, or vaccine provided herein to an animal to protect the animal from developing a bacterial infection or symptoms thereof. In some embodiments, the compositions provided herein are administered to a subject, such as a human, at risk of developing a bacterial infection. By "treating bacterial infection" is intended administration of a therapeutically effective amount of a fusion protein, immunogenic composition, or vaccine provided herein to an animal having or exposed to a bacterial infection, where the purpose is to cure, cure, alleviate, alleviate, alter, treat, ameliorate, improve, or affect the condition or symptoms of the bacterial infection.

[0193] As used herein, a "therapeutically effective amount" refers to an amount that provides a therapeutic effect for a given condition and administration regimen. Thus, the phrase "therapeutically effective amount" is used herein to mean an amount sufficient to cause an improvement in a clinically significant condition in a host. In certain aspects, a "therapeutically effective amount" refers to an amount of an immunogenic fusion protein, immunogenic composition, or vaccine provided herein that, when administered to an animal, results in a positive therapeutic response in terms of preventing or treating the subject for bacterial infection. A positive therapeutic response in terms of preventing bacterial infection includes, for example, the production of antibodies by the subject in an amount sufficient to protect against the development of disease. Similarly, a positive therapeutic response in terms of treating bacterial infection includes curing or ameliorating symptoms of disease. In the present context, a defect in the host's response can be evidenced by the continued or spread of the bacterial infection. An improvement in a clinically significant condition in a host includes a reduction in bacterial load, clearance of bacteria from colonized host cells, a reduction in fever or inflammation associated with the infection, or a reduction in any symptom associated with the bacterial infection.

[0194] In certain aspects, a method for preventing pneumococcal infection in an animal comprises administering to the animal a therapeutically effective amount of an immunogenic fusion protein disclosed herein, an immunogenic composition comprising an immunogenic fusion protein disclosed herein, in combination with a pharma- ceutically acceptable carrier, or a vaccine disclosed herein, thereby preventing pneumococcal infection. When treating or preventing pneumococcal infection, at least one of a variety of immunogenic fusion proteins comprising at least one polypeptide from pneumococcus is used (e.g., a CbpA fusion protein, a fusion peptide from any other immunogenic pneumococcal protein, or a pneumolysoid fusion protein, as discussed elsewhere herein). In other embodiments, a method for treating pneumococcal infection in an animal infected or exposed to pneumococcus comprises administering to the animal a therapeutically effective amount of a fusion protein, an immunogenic composition comprising a fusion protein, in combination with a pharma- ceutically acceptable carrier, or a vaccine disclosed herein, thereby treating the animal. For example, in individuals already infected with pneumococcus, the immunogenic fusion proteins provided herein may be used as a defense against the spread of infection from the blood to the brain.

[0195] Further provided is a method of inducing an immune response in a subject exposed to or infected with pneumococcus, comprising administering to the subject a therapeutically effective amount of an immunogenic fusion protein provided herein (i.e., such as a fusion protein listed in Tables 1 or 2), or a biologically active variant or fragment thereof, immunogenic composition, or vaccine disclosed herein, thereby inducing an immune response.

[0196] Pneumococcal infection involves bacterial colonization of nasopharyngeal epithelial cells and subsequent bacterial invasion into the bloodstream, lungs, and possibly the brain. Without being bound by any theory, CbpA-mediated binding to pIgR and laminin receptors contributes to colonization of the nasopharynx and invasion into the bloodstream and brain. The two binding activities have been localized to specific regions of the R2 domain of CbpA. In particular, the R21 region is involved in binding to pIgR and bacterial colonization in the nasopharynx and invasion via transcytosis, whereas the R22 region is involved in binding to laminin receptors and subsequent bacterial invasion of the brain and other host tissues. This information can be utilized to develop immunogenic compositions and vaccines that are protective against both steps of pneumococcal infection, i.e., colonization of the nasopharynx and invasion into the bloodstream.

[0197] In some embodiments, fusion proteins comprising, but not limited to, CbpA polypeptides, or biologically active variants or fragments thereof, can be used in a variety of ways to reduce pneumococcal colonization of the nasopharynx (i.e., fusion proteins comprising the R21 region of SEQ ID NO: 1 or 3, or an active variant or fragment thereof, in which the R21 region is in a loop conformation), or to reduce bacterial entry into the bloodstream and brain (i.e., fusion proteins comprising the R22 region of SEQ ID NO: 2 or 4, or an active variant or fragment thereof, in which the R22 region is in a loop conformation), or in other embodiments, to reduce bacterial entry into the lungs, into the bloodstream, or across the blood-brain barrier (i.e., fusion proteins comprising both the R21 and R22 sequences, such as, for example, the sequences of (SEQ ID NO: 1, 2, 3, 4, 41 or 42, or active variants or fragments thereof, in which R21 and / or R22 are in a loop conformation). As used herein, "reduction" means at least a 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction compared to a suitable control, or alternatively, to a level sufficient to produce a desired therapeutic effect in an animal. Various methods of measuring bacterial colonization are known in the art. For example, bacteria in blood can be measured by taking a blood sample and spreading the blood on an agar plate containing a suitable medium for bacterial growth. Bacteria in the nasopharynx can be measured by culturing bacteria from a swab or wash of the animal's nasopharynx. Bacteria that have crossed the blood-brain barrier can be measured in a sample of cerebrospinal fluid or by detecting physical characteristics of meningitis in the animal, such as rolling.

[0198] Embodiments of the invention also include one or more of the immunogenic fusion proteins described herein (i) for use in, (ii) for use as a medicament or composition for, or (iii) for use in the preparation of a medicament for: (a) therapy (e.g., of the human body); (b) medicine; (c) inhibiting infection with Streptococcus pneumoniae, (d) inducing an immune response or a protective immune response against S. pneumoniae, (e) (g) reducing the progression, onset or severity of pathological symptoms associated with S. pneumoniae infection, including prevention of associated complications such as brain damage, hearing loss, and seizures, (h) reducing the likelihood of S. pneumoniae infection, or (i) treating, preventing, or delaying the onset, severity, or progression of pneumococcal disease, including, but not limited to, pneumococcal pneumonia, pneumococcal bacteremia, pneumococcal meningitis, otitis media, and sinusitis. In these uses, the immunogenic fusion protein compositions of the invention can optionally be used in combination with one or more adjuvants or without an adjuvant.

[0199] Thus, the invention provides methods for the prophylactic treatment of (i.e., protection against) S. pneumoniae infection or pneumococcal disease comprising administering to a patient in need of treatment one or more of the immunogenic fusion protein compositions of the invention.

[0200] The compositions and formulations of the invention can be used to protect against or treat humans susceptible to infection, e.g., pneumococcal infection, by administering such compositions or formulations via a systemic or mucosal route.

[0201] In one embodiment, the invention provides a method of inducing an immune response against S. pneumoniae, comprising administering to a patient an immunoeffective amount of an immunogenic fusion protein of the invention. In another embodiment, the invention provides a method of vaccinating a human against pneumococcal infection, comprising administering to the human an immunoeffective amount of an immunogenic fusion protein composition of the invention.

[0202] Thus, in one aspect, the invention provides a method for (1) inducing an immune response in a human patient, (2) inducing a protective immune response in a human patient, (3) vaccinating a human patient against infection with S. pneumoniae, or (4) reducing the likelihood of S. pneumoniae infection in a human patient, the method comprising administering to the patient an immunogenic fusion protein composition of the invention.

[0203] In one embodiment, the invention provides a method for the prevention of pneumococcal pneumonia and / or invasive pneumococcal disease in infants (under 1 year of age), toddlers (about 12-24 months of age), or children (about 2-5 years of age). In another embodiment, the invention provides a method for the prevention of pneumococcal pneumonia and / or invasive pneumococcal disease in patients 6 months to 17 years of age. In another embodiment, the invention provides a method for the prevention of pneumococcal pneumonia and / or invasive pneumococcal disease in adults 18 years of age and older. In another embodiment, the invention provides a method for the prevention of pneumococcal pneumonia and / or invasive pneumococcal disease in adults 50 years of age and older. In another embodiment, the invention provides a method for the prevention of pneumococcal pneumonia and / or invasive pneumococcal disease in adults 65 years of age and older.

[0204] The invention provides a method of inducing an immune response, vaccinating, or inducing a protective immune response against S. pneumoniae in a patient, comprising administering to the patient an immunogenic fusion protein composition, wherein the patient has previously been vaccinated against S. pneumoniae. In an embodiment of this aspect of the invention, the immunogenic composition can be any of the immunogenic fusion protein compositions described herein.

[0205] In additional embodiments of the above methods, the patient has been previously treated with PREVNAR® 13 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein], Pfizer, Inc., Philadelphia, PA, USA). In further embodiments of the above methods, the patient has been previously treated with PNEUMOVAX® 23 (Pneumococcal vaccine multivalent, Merck & Co., Inc., Kenilworth, NJ, USA), SYNFLORIX™ (Pneumococcal polysaccharide conjugate vaccine (adsorbed), GlaxoSmithKline Biologicals sa, Rixensart, Belgium), PREVNAR 20™ (20-valent conjugate vaccine; Pfizer), VAXNEUVANCE™ (valent; Merck), or any combination thereof.

[0206] In yet another embodiment, the immunogenic fusion proteins provided herein can be used in various methods for treating and preventing Neisseria meningitidis infection. Neisseria meningitidis is another bacterium that crosses the blood-brain barrier and causes meningitis. As disclosed in U.S. Patent Publication No. 2010-0143394-A1, which is incorporated herein by reference, Neisseria meningitidis binds to laminin receptors to cross the blood-brain barrier. This is the same mechanism used by Streptococcus pneumoniae. Disclosed herein are fusion proteins that include, but are not limited to, the R21 or R22 regions of CbpA, where the R21 or R22 regions have a loop conformation or an active variant or fragment thereof, and can cross-protect against Neisseria meningitidis. Thus, the fusion proteins provided herein have use as vaccines for treating and preventing infection with other bacteria that utilize similar infection mechanisms.

[0207] Fusion proteins containing cytolysoids can be used in various methods for treating and preventing bacterial infections. As discussed above, cytolysoid polypeptides (or active variants or fragments thereof) can be modified from any bacterial cytolysin and used to create fusion proteins with one or more immunogenic polypeptides from the same bacterial source as the cytolysoid or from different bacterial sources. In this way, methods for treating and preventing various bacterial infections are encompassed herein. Some examples of bacteria that can cause bacterial infections are disclosed elsewhere herein.

[0208] The immunogenic fusion proteins provided herein can also be used in a variety of methods to treat or prevent multiple bacterial infections in animals. The immunogenic fusion proteins can include a combination of immunogenic polypeptides from two or more bacteria. In certain embodiments, the immunogenic polypeptides of the fusion protein will be derived from bacterial sources that are frequently found simultaneously in a given animal. For example, infections caused by Streptococcus pneumoniae and Haemophilus influenzae, which can simultaneously infect the nasopharynx, can be treated or prevented by a fusion protein that includes immunogenic polypeptides from both bacteria.

[0209] IV. Method of Administration. The immunogenic fusion proteins (e.g., MTRV001), vaccines, compositions, and formulations provided herein can be administered via any parenteral route, including, but not limited to, intravenous, intramuscular, subcutaneous, intraperitoneal, intradermal, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. In some embodiments, the immunogenic fusion proteins are administered intramuscularly. Preferably, since the desired outcome of administration is to elicit an immune response to an antigen and thereby to a pathogenic organism, it is desirable to administer directly to lymphoid tissues, e.g., lymph nodes or spleen, or indirectly by targeting or choosing a viral vector. Because immune cells are continually replicating, they are ideal targets for retroviral vector-based nucleic acid vaccines, since retroviruses require replicating cells.

[0210] It will be understood that the administration of therapeutic entities according to the present invention will be administered with suitable carriers, excipients, and other agents incorporated into the formulation to provide improved transfer, delivery, tolerability, and the like, as described above. Numerous suitable formulations can be found in formularies known to all medicinal chemists: Remington's Pharmaceutical Sciences (15th ed., Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 therein by Blaug, Seymour. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (such as Lipofectin™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be suitable for use in treatments and therapies according to the present invention, provided that the active ingredients in the formulation are not inactivated by the formulation and the formulation is physiologically compatible with the route of administration and is tolerated.See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance" Regul. Toxicol Pharmacol. 32(2):210-8(2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals" Int. J. Pharm. 203(1-2):1-60(2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery- some emerging concepts" J Pharm Sci. 89(8):967-78(2000), Powell et al. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol. 52:238-311(1998) and the references cited therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

[0211] A. Dosing Regimen

[0212] The subject for which the administration of the active ingredient as shown above is an effective treatment regimen for bacterial infection is preferably human, but can be any animal.Thus, as can be easily understood by those skilled in the art, the method and pharmaceutical composition provided herein are particularly suitable for administration to any animal, particularly mammals, including but not limited to domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine and porcine subjects, wild animals (whether in the wild or in zoos), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., i.e. for veterinary use.

[0213] In the therapeutic methods and compositions provided herein, a therapeutically effective dosage of the active ingredient is provided. The therapeutically effective dosage can be determined by a medical practitioner of ordinary skill in the art based on the characteristics of the patient (age, weight, sex, condition, comorbidities, other diseases, etc.), as is well known in the art. Furthermore, as further routine testing is performed, specific information will emerge regarding the appropriate dosage levels for the treatment of various conditions in various patients, and the skilled artisan can ascertain the appropriate dosage, taking into account the recipient's medical situation, age, and general health. In general, for intravenous injection or infusion, the dosage may be lower than intraperitoneal, intramuscular, or other routes of administration. The dosage schedule may vary depending on the circulating half-life and the formulation used. The composition is administered in a manner compatible with the dosage formulation in a therapeutically effective amount. The precise amount of active ingredient required to be administered depends on the physician's judgment and is peculiar to each individual. However, suitable dosages may range from about 0.1 mg / kg to 20 mg / kg, preferably about 0.5 mg / kg to about 10 mg / kg, more preferably 1 to several milligrams of active ingredient per kilogram of body weight of an individual per day, depending on the route of administration. A general range for therapeutically effective dosing of the immunogenic fusion proteins of the invention may be, as a non-limiting example, from about 0.1 mg / kg body weight to about 50 mg / kg body weight. Preferred doses may include 1, 3, 6, 10 mg / kg body weight. Typical dosing frequencies may range, for example, from once a month. Treatment may continue for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more. Suitable regimens for initial administration and booster shots are also variable, but are typically represented by an initial administration, followed by repeated administration at one or more time intervals by subsequent injections or other administrations. Alternatively, continuous injection (eg, subcutaneous or intramuscular) sufficient to maintain a concentration in the blood of 10 nanomolar to 10 micromolar is contemplated.

[0214] The present disclosure provides a method of treating, prophylactically preventing, or reducing the occurrence of a condition, disease, or infection caused by Streptococcus pneumoniae in a subject in need thereof, comprising administering to the subject at least one dose of a composition comprising an immunogenic fusion protein (e.g., MTRV001). In some embodiments, the dose of the immunogenic fusion protein comprises from about 5 μg to about 150 μg. In some embodiments, the dose of the immunogenic fusion protein comprises about 10 μg, about 15 μg, about 20 μg, about 25 μg, about 30 μg, about 35 μg, about 40 μg, about 45 μg, about 50 μg, about 55 μg, about 60 μg, about 65 μg, about 70 μg, about 75 μg, about 80 μg, about 85 μg, about 90 μg, about 95 μg, about 100 μg, about 105 μg, about 110 μg, about 115 μg, about 120 μg, about 125 μg, about 130 μg, about 140 μg, about 145 μg, or about 150 μg. In some embodiments, the dose of the immunogenic fusion protein is about 10 μg. In some embodiments, the dose of the immunogenic fusion protein is about 30 μg. In some embodiments, the dose of the immunogenic fusion protein is about 60 μg. In some embodiments, the dose of the immunogenic fusion protein is about 90 μg.

[0215] In some embodiments, the composition comprising the dose of the immunogenic fusion protein is administered in at least one dose. In some embodiments, the composition comprising the dose of the immunogenic fusion protein is administered in two or less doses, three or less doses, four or less doses, or five or less doses. In some embodiments, the composition comprising the dose of the immunogenic fusion protein is administered in two or less doses. In some embodiments, the composition comprising the dose of the immunogenic fusion protein is administered in two doses.

[0216] In some embodiments, the doses are administered in at least a first dose and a second dose. In some embodiments, the first dose is higher than the second dose. In some embodiments, the second dose is higher than the first dose. In some embodiments, the first dose and the second dose are equal.

[0217] In some embodiments, the amount of time between each dose is about 4 weeks to about a year. In some embodiments, the amount of time between each dose is one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, or eight weeks. In some embodiments, the amount of time between each dose is two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, or fifteen months. In some embodiments, the second dose is administered 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days after the first dose. In some embodiments, the second dose is administered 28 days after the first dose.

[0218] B. Administration with other compounds. For the treatment of bacterial infections, the active ingredients of the present invention may be administered in conjunction with one or more pharmaceutical compositions used to treat bacterial infections, including, but not limited to, (1) antibiotics; (2) soluble sugar inhibitors of bacterial adhesins; (3) other small molecule inhibitors of bacterial adhesins; (4) inhibitors of bacterial metabolism, transport, or transformation; (5) stimulators of bacterial lysis, or (6) antibacterial antibodies or vaccines directed against other bacterial antigens. Other potential active ingredients include anti-inflammatory agents, such as steroids and non-steroidal anti-inflammatory drugs. Administration may be simultaneous (e.g., administration of a mixture of the active ingredients of the present invention and antibiotics) or in a ceriatim.

[0219] V. Method of manufacture.

[0220] For recombinant production of an immunogenic fusion protein of the invention, the nucleic acid encoding it is isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. The DNA encoding the immunogenic fusion protein is readily isolated and sequenced using conventional procedures (e.g., by using an oligonucleotide probe capable of specifically binding to the gene encoding the immunogenic fusion protein). Many vectors are available. The choice of vector will depend in part on the host cell to be used. In general, preferred host cells are of either prokaryotic or eukaryotic origin (generally mammalian, but also including nucleated cells from fungi (e.g., yeast), insects, plants, and other multicellular organisms).

[0221] The method provides a method for purifying an immunogenic fusion protein (e.g., MTRV001) comprising: a) providing a vector comprising a nucleic acid encoding a polypeptide; b) introducing the vector into a population of host cells; c) culturing the population of host cells under conditions allowing for expression of the polypeptide; d) disrupting the cell membrane of the host cells; and e) recovering the polypeptide. The method may further comprise at least one purification step comprising contacting the polypeptide with a separation means and eluting the polypeptide from the separation means under conditions allowing for preferential dissociation of the polypeptide. The method may further comprise a filtration step comprising contacting the eluted polypeptide with a filter.

[0222] A. Production of immunogenic fusion proteins using prokaryotic host cells.

[0223] Polynucleotide sequences encoding the polypeptide components of the immunogenic fusion proteins of the invention can be obtained using standard recombinant techniques. Alternatively, polynucleotides can be synthesized using a nucleotide synthesizer or PCR techniques. Once obtained, the sequences encoding the polypeptides are inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in a prokaryotic host. Many vectors available and known in the art can be used for the purposes of the present invention. The selection of an appropriate vector depends mainly on the size of the nucleic acid to be inserted into the vector and the particular host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification or expression of the heterologous polynucleotide, or both) and its compatibility with the particular host cell in which it resides. The vector components generally include, but are not limited to, the following: origin of replication, selectable marker gene, promoter, ribosome binding site (RBS), signal sequence, heterologous nucleic acid insert, and transcription termination sequence.

[0224] Generally, plasmid vectors containing replicon and control sequences derived from species compatible with the host cell are used in connection with these hosts. The vector usually carries a replication site, as well as marking sequences capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using pBR322, a plasmid derived from an E. coli species. pBR322 contains genes encoding ampicillin (Amp) and tetracycline (Tet) resistance, thus providing a simple means for identifying transformed cells. pBR322, its derivatives, or other microbial plasmids or bacteriophages may contain, or be modified to contain, promoters that can be used by the microorganism for expression of endogenous proteins. Examples of pBR322 derivatives used for expression of certain immunogenic fusion proteins are described in detail in Carter et al., U.S. Patent No. 5,648,237.

[0225] The expression vectors of the invention may contain two or more promoter-cistron pairs, one encoding each of the polypeptide components. A promoter is a non-translated regulatory sequence located upstream (5') of a cistron whose expression it controls.

[0226] Prokaryotic promoters are typically divided into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription of the cistron under their control in response to a change in culture conditions, such as the presence or absence of a nutrient or a change in temperature.

[0227] A large number of promoters recognized by various potential host cells are well known. The selected promoter can be operably linked to the cistron DNA encoding the light or heavy chain by removing the promoter from the source DNA via restriction enzyme digestion and inserting the isolated promoter sequence into the vector of the present invention. Both the native promoter sequence and many heterologous promoters may be used to direct the amplification and / or expression of the target gene. In some embodiments, heterologous promoters are utilized because they generally allow greater transcription and higher yields of the expressed target gene compared to the native target polypeptide promoter.

[0228] Suitable promoters for use with prokaryotic hosts include the T7 promoter, the PhoA promoter, the β-galactosidase and lactose promoter systems, the tryptophan (tip) promoter system, and hybrid promoters such as the tac or trc promoter. However, other promoters that are functional in bacteria are also suitable, such as other known bacterial promoters or phage promoters. Their nucleotide sequences have been published, allowing one skilled in the art to ligate them to the cistrons encoding the target light and heavy chains, using linkers or adapters to provide any required restriction sites (Siebenlist et al., (1980) Cell 20:269).

[0229] Suitable prokaryotic host cells for expression of the immunogenic fusion proteins of the invention include Archaea and Eubacteria, such as Gram-negative or Gram-positive organisms. Examples of useful bacteria include Escherichia (e.g., E. coli), Bacillus (e.g., B. subtilis), Enterobacteriaceae, Pseudomonas species (e.g., P. aeruginosa), Salmonella typhimurium, Serratia marcescans, Klebsiella, Proteus, Shigella, Rhizobium, Vitreosira, or Paracoccus. In one embodiment, a Gram-negative cell is used. In one embodiment, E. coli cells are used as hosts for the present invention. Examples of E. coli strains include strain HMS174(DE3), strain W3110 (Bachmann, Cellular and Molecular Biology, vol. 2 (Washington, DC: American Society for Microbiology, 1987), pp. 1 190-1219; ATCC Deposit No. 27,325) and their derivatives, including strain 33D3 (see U.S. Patent No. 5,639,635) having the genotype W31 10 AfhuA (AtonA) ptr3 lac Iq lacL8 AompTA (nmpc-fepE) degP41 kanR. Other strains and their derivatives, such as E. coli 294 (ATCC 31,446), E. coli B, E. coli λ 1776 (ATCC 31,537), and E. coli RVRV308 (ATCC 31,608), are also suitable. These examples are illustrative rather than limiting. Methods for constructing derivatives of any of the above-mentioned bacteria with defined genotypes are known in the art and are described, for example, in Bass et al., Proteins 8:309-314 (1990). In general, it is necessary to select a suitable bacterium, taking into account the replicability of the replicon in the bacterial cell. For example, E. coli, Serratia, or Salmonella species can be suitably used as hosts when the replicon is provided using well-known plasmids, such as pBR322, pBR325, pACYC177, or pKN410.Typically, the host cell should secrete minimal amounts of proteolytic enzymes or other contaminants, and additional protease inhibitors may desirably be incorporated into the cell culture.

[0230] In some embodiments, the immunogenic fusion protein of the present invention is cloned into an E. coli expression vector. In some embodiments, the E. coli expression vector comprises a T7 promoter. In some embodiments, the E. coli expression vector is pET24a+.

[0231] B. Immunogenic Fusion Protein Production

[0232] Host cells are transformed with the above-described expression vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying genes encoding the desired sequences.

[0233] Transformation means introducing DNA into a prokaryotic host so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is performed using standard techniques appropriate for such cells. The calcium treatment using calcium chloride is commonly used for bacterial cells that contain substantial cell wall barriers. Another method for transformation uses polyethylene glycol / DMSO. Yet another technique used is electroporation.

[0234] The prokaryotic cells used to produce the polypeptide of the present invention are grown in media known in the art and suitable for the culture of the selected host cells. An example of a suitable medium includes Luria Broth (LB) plus necessary nutritional supplements. In some embodiments, the medium also includes a selection agent that is chosen based on the construction of the expression vector, allowing selective growth of prokaryotic cells that contain the expression vector. For example, ampicillin is added to the medium for the growth of cells that express an ampicillin resistance gene.

[0235] Any necessary supplements other than carbon, nitrogen, and inorganic phosphate sources may also be included at suitable concentrations introduced alone or as a mixture with another supplement or medium, such as a complex nitrogen source, etc. Optionally, the culture medium may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate, dithioerythritol, and dithiothreitol.

[0236] Prokaryotic host cells are cultured at an appropriate temperature. For E. coli growth, for example, preferred temperatures range from about 20° C. to about 39° C., more preferably from about 25° C. to about 37° C., and even more preferably about 30° C. The pH of the medium may be any pH ranging from about 5 to about 9, depending primarily on the host organism. For E. coli, the pH is preferably from about 6.8 to about 7.4, and more preferably about 7.0.

[0237] When an inducible promoter is used in the expression vector of the present invention, protein expression is induced under appropriate conditions for the activation of the promoter.In one embodiment of the present invention, IPTG is used to control the expression of the polypeptide.A variety of other inducers can be used according to the vector construct used, as known in the art.

[0238] In one embodiment, the expressed polypeptide of the present invention is secreted into the periplasm of the host cell and recovered therefrom. Protein recovery typically involves disrupting the microorganism by means such as osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris or whole cells can be removed by centrifugation or filtration. The protein may be further purified, for example, by separation means. Alternatively, the protein may be transported into the culture medium and isolated therein. The cells may be removed from the culture and the culture supernatant may be filtered and concentrated for further purification of the produced protein. The expressed polypeptide may be further isolated and characterized using commonly known methods, such as polyacrylamide gel electrophoresis (PAGE) and Western blot assays.

[0239] In some embodiments, the separation means is a resin, a membrane, a magnetic bead, or a particle.

[0240] In some embodiments, the separation means is affinity chromatography. Exemplary affinity chromatography methods include, but are not limited to, hydrophobic interaction chromatography, anion exchange chromatography, cation exchange chromatography, hydroxyapatite (mixed mode) chromatography, gel filtration chromatography, size exclusion chromatography, hydrophilic interaction chromatography, and / or combinations thereof.

[0241] In some embodiments, the separation means is a hydrophobic interaction chromatography resin. In some embodiments, the hydrophobic interaction chromatography resin is a Phenyl Sepharose™ FF resin.

[0242] In some embodiments, the separation means is an anion exchange chromatography resin. In some embodiments, the hydrophobic interaction chromatography resin is Q Sepharose™ HP resin.

[0243] In some embodiments, the separation means is a combination of at least two separation means. In some embodiments, the separation means is a combination of at least two affinity chromatography resins. In some embodiments, the separation means is a combination of at least three separation means. In some embodiments, the separation means is a combination of at least three affinity chromatography resins. In some embodiments, the separation means is a combination of three or more affinity chromatography resins, for example, three or more, four or more, and / or five or more affinity chromatography resins.

[0244] In some embodiments, the separation means comprises the use of an anion exchange chromatography resin followed by the use of a hydrophobic interaction chromatography resin, hi some embodiments, the separation means comprises the use of a Q Sepharose™ HP resin followed by the use of a Phenyl Sepharose™ FF resin.

[0245] In some embodiments, the separation means comprises the use of a hydrophobic interaction chromatography resin followed by the use of an anion exchange chromatography resin, hi some embodiments, the separation means comprises the use of a Phenyl Sepharose™ FF resin followed by the use of a Q Sepharose™ HP resin.

[0246] In some embodiments, the separation means involves the use of a hydrophobic interaction chromatography resin, followed by a flow-through anion exchange resin, followed by a multimodal (hydroxyapatite) chromatography resin.

[0247] In some embodiments, the binding and / or elution conditions include step variations in pH level and / or step variations in conductivity corresponding to salt concentration variations. In some embodiments, the binding and / or elution conditions include step variations in inorganic salt concentration, such as sodium chloride (NaCl) concentration, or other inorganic salt concentration, such as combinations of inorganic salts from the Hofmeister series of ions, such as sulfate, as non-limiting and non-exhaustive examples. In some embodiments, the method includes varying the concentration of ammonium sulfate for binding and / or elution. In some embodiments, the method does not include varying the concentration of ammonium sulfate for binding and / or elution.

[0248] The present disclosure provides a method for producing an immunogenic fusion protein, comprising the steps of: a) culturing a population of host cells expressing an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO: 43 under conditions suitable for the population of host cells to produce the immunogenic fusion protein; b) disrupting the cell membrane of the host cells; c) recovering a sample comprising the immunogenic fusion protein and one or more impurities; d) contacting the sample comprising the immunogenic fusion protein with a hydrophobic interaction chromatography resin and eluting the immunogenic fusion protein from the hydrophobic interaction chromatography resin under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein; e) subjecting the eluate comprising the immunogenic fusion protein of step d) to a flow-through anion exchange resin, thereby obtaining an eluate comprising the immunogenic fusion protein; and f) contacting the eluate comprising the immunogenic fusion protein of step e) with a multimodal chromatography resin and eluting the immunogenic fusion protein from the multimodal chromatography resin under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein.

[0249] Generally, the sample contains various impurities in addition to the target molecule (e.g., immunogenic fusion protein). Such impurities include media components, cells, cell debris, nucleic acids, host cell proteins (HCPs), viruses, endotoxins, etc. Other impurities include non-monomeric forms of the target molecule (e.g., immunogenic fusion protein) or non-full-length forms of the target molecule (e.g., N-terminal truncations of immunogenic fusion protein or C-terminal truncations of immunogenic fusion protein). All such target molecule-related impurities can reduce immunogenicity and affect the quality of the immune response in therapeutic applications. The methods herein provide a specific sequence of purification steps to produce compositions with high purity immunogenic fusion protein (e.g., full-length, monomeric form) and low levels of impurities (e.g., HCPs, endotoxins, DNA), suitable for therapeutic applications, that were not previously achievable through means known in the art.

[0250] In a preferred embodiment, the flow-through purification further comprises one or more additional flow-through steps, for example, for aggregate removal and virus filtration. In some embodiments, the sample passes through an adsorptive depth filter, or a charged or modified microporous layer in a normal flow filtration operation mode for aggregate removal. Examples of flow-through steps that can be used for aggregate removal can be found, for example, in U.S. Patent Nos. 7,118,675 and 7,465,397, which are incorporated herein by reference. Thus, in some embodiments, a two-step filtration process for removing protein aggregates and virus particles may be used, in which the sample is first filtered through one or more layers of an adsorptive depth filter, a charged or surface-modified porous membrane, or a small bed of chromatographic media to produce a sample free of protein aggregates. This may be followed by the use of an ultrafiltration membrane for virus filtration, as described in more detail below. The ultrafiltration membranes used for virus filtration are typically referred to as nanofiltration membranes.

[0251] In some embodiments, the method includes the further step of determining the purity of the immunogenic fusion protein in the eluted fraction, which can be accomplished using any of a variety of art-recognized techniques, such as, for example, hydrophobic interaction high performance liquid chromatography (HIC-HPLC), ion exchange high performance liquid chromatography (IEX-HPLC), cation exchange high performance liquid chromatography (CEX-HPLC), or reverse phase high performance liquid chromatography (RP-HPLC), as non-limiting and non-exhaustive examples.

[0252] In some embodiments, the method further comprises the steps of: g) contacting the eluate comprising the immunogenic fusion protein of step f) with a flow-through anion exchange membrane, thereby obtaining an eluate comprising the immunogenic fusion protein. In some embodiments, the method further comprises the steps of: h) contacting the eluate comprising the immunogenic fusion protein of step g) with an UF / DF membrane, and i) washing the immunogenic fusion protein from the UF / DF membrane under conditions allowing preferential detachment of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein. In some embodiments, the method further comprises the steps of: j) contacting the eluate comprising the immunogenic fusion protein of step i) with a 0.2 μm filter.

[0253] The resulting composition contains lower levels of impurities, such as media components, cells, cell debris, nucleic acids, host cell proteins (HCPs), viruses, endotoxins, etc. Other impurities include non-monomeric forms of the target molecule (e.g., immunogenic fusion proteins) or non-full-length forms of the target molecule (e.g., N-terminal truncations of immunogenic fusion proteins).

[0254] In some embodiments, a composition comprising an immunogenic fusion protein (e.g., SEQ ID NO: 43) comprises at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100%, or any percentage therebetween, of the monomeric form of the immunogenic fusion protein. In some embodiments, a composition comprising an immunogenic fusion protein comprises about 98% of the monomeric form of the immunogenic fusion protein. In some embodiments, a composition comprising an immunogenic fusion protein comprises about 99% of the monomeric form of the immunogenic fusion protein. In some embodiments, a composition comprising an immunogenic fusion protein comprises about 100% of the monomeric form of the immunogenic fusion protein.

[0255] In some embodiments, a composition comprising an immunogenic fusion protein (e.g., SEQ ID NO: 43) contains less than 50 EU / mg, less than 45 EU / mg, less than 30 EU / mg, less than 25 EU / mg, less than 20 EU / mg, less than 10 EU / mg, less than 5 EU / mg, less than 4 EU / mg, less than 3 EU / mg, less than 2 EU / mg, less than 1 EU / mg, or less than 0.1 EU / mg endotoxin per mg of immunogenic fusion protein. In some embodiments, the composition comprises less than 2 EU / mg, less than 1.9 EU / mg, less than 1.8 EU / mg, less than 1.7 EU / mg, less than 1.6 EU / mg, less than 1.5 EU / mg, less than 1.4 EU / mg, less than 1.3 EU / mg, less than 1.2 EU / mg, less than 1.1 EU / mg, less than 1.0 EU / mg, less than 0.9 EU / mg, less than 0.8 EU / mg, less than 0.7 EU / mg, less than 0.6 EU / mg, less than 0.5 EU / mg, less than 0.4 EU / mg, less than 0.3 EU / mg, less than 0.2 EU / mg, or less than 0.1 EU / mg endotoxin per mg of immunogenic fusion protein. In some embodiments, the composition comprises about 17 EU / mg endotoxin per mg of immunogenic fusion protein. In some embodiments, the composition comprises less than 10 EU / mg endotoxin per mg of immunogenic fusion protein. In some embodiments, the composition comprises about 1.9 EU / mg endotoxin / mg of immunogenic fusion protein. In some embodiments, the composition comprises less than 0.1 EU / mg endotoxin / mg of immunogenic fusion protein.

[0256] In some embodiments, a composition comprising an immunogenic fusion protein has less than 80,000 ng / mg, less than 75,000 mg / mg, less than 70,000 ng / mg, less than 65,000 ng / mg, less than 60,000 ng / mg, less than 55,000 mg / mg, less than 50,000 ng / mg, less than 45,000 ng / mg, less than 40,000 ng / mg, less than 35,000 mg / mg, less than 30,000 ng / mg, less than 25,000 ng / mg, less than 20,000 ng / mg In some embodiments, the composition comprising the immunogenic fusion protein comprises less than 90 ng / mg, less than 80 ng / mg, less than 70 ng / mg, less than 60 ng / mg, less than 50 ng / mg, less than 40 ng / mg, less than 30 ng / mg, less than 2000 ng / mg, less than 1000 ng / mg, less than 900 ng / mg, less than 800 ng / mg, less than 700 ng / mg, less than 600 ng / mg, less than 500 ng / mg, less than 400 ng / mg, less than 300 ng / mg, less than 200 ng / mg, or less than 100 ng / mg of host cell protein (HCP) per mg of immunogenic fusion protein, or any value therebetween. In some embodiments, a composition comprising an immunogenic fusion protein comprises less than about 200 ng / mg of host cell protein (HCP) per mg of immunogenic fusion protein. In some embodiments, a composition comprising an immunogenic fusion protein comprises about 76,600 ng / mg of host cell protein (HCP) per mg of immunogenic fusion protein. In some embodiments, a composition comprising an immunogenic fusion protein comprises about 30 ng / mg of HCP per mg of immunogenic fusion protein.

[0257] In one aspect of the invention, immunogenic fusion protein production is carried out in large quantities by fermentation processes. A variety of large-scale fed-batch fermentation procedures are available for the production of recombinant proteins. Large-scale fermentations have a volume of at least 1000 liters, preferably about 1,000 to 100,000 liters. These fermenters use stirring impellers to distribute oxygen and nutrients, especially glucose (the preferred carbon / energy source). Small-scale fermentation generally refers to fermentation in a fermenter that is about 100 liters or less in volumetric capacity and can range from about 1 liter to about 100 liters.

[0258] In fermentation processes, induction of protein expression is typically initiated after cells have grown under appropriate conditions to a desired density, e.g., an OD550 of about 180-220, at which stage the cells are in early stationary phase. A variety of inducers are known in the art and may be used according to the vector construct used, as described above. Cells may be grown for a shorter period before induction. Cells are usually induced for about 12-50 hours, although longer or shorter induction times may be used.

[0259] In order to minimize proteolysis of expressed heterologous proteins (especially proteins that are proteolytically sensitive), certain host strains that are deficient for proteolytic enzymes can be used for the present invention. For example, the host cell strain may be modified to carry genetic mutations in genes encoding known bacterial proteases, such as protease HI, OmpT, DegP, Tsp, protease I, protease Mi, protease V, protease VI, and combinations thereof. Some E. coli protease-deficient strains are available and are described, for example, in Joly et al., (1998), Proc. Natl. Acad. Sci. USA 95:2773-2777; U.S. Patent No. 5,264,365 to Georgiou et al.; U.S. Patent No. 5,508,192 to Georgiou et al.; Hara et al., Microbial Drug Resistance, 2:63-72 (1996). In one embodiment, an E. coli strain deficient for a proteolytic enzyme and transformed with a plasmid overexpressing one or more chaperone proteins is used as a host cell in the expression system of the present invention. VI. Working Examples

[0260] The following examples are provided by way of illustration, not by way of limitation. All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0261] Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it will be apparent that certain changes and modifications can be practiced within the scope of the appended claims.

[0262] Example 1: Construction and pharmacodynamics testing of MTRV001.

[0263] overview Disclosed herein is a pneumococcal vaccine candidate for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae. Pharmacodynamic and toxicological details summarize and support the evaluation of MTRV001 in a proposed Phase 1 clinical trial.

[0264] Construction of MTRV001

[0265] As depicted by the schematic diagram in Figures 1A-1B, MTRV001 is a 520 amino acid fusion protein consisting of a genetically detoxified pneumolysin (PLY) component with a conserved peptide sequence derived from choline binding protein A (CbpA) fused to the amino and carboxy termini of the PLY protein.

[0266] The PLY component of MTRV001 (470 amino acids from serotype 4 S. pneumoniae strain TIGR4) contains two highly attenuating amino acid substitutions (G293S and L460D) that abolish the cytolytic activity of native PLY, as depicted in Figure 1A. The G293S mutation locks the protein in a pre-pore confirmation that inhibits oligomerization of PLY molecules, resulting in a soluble monomeric protein (Oloo, 2011). The L460D mutation is intended to prevent cholesterol binding, a key aspect of PLY pore-forming activity (Farrand, 2010).

[0267] The CbpA component of MTRV001 is derived from the R2 domain (second repeat domain) of the S. pneumoniae strain TIGR4 native protein. A schematic diagram of the R2 domain of CbpA is depicted in Figure 2A. The R2 domain is composed of 12 imperfect copies of a leucine motif (Luo, 2005). The highly conserved loops between antiparallel helices 1 and 2, and 2 and 3, are important for binding to the epithelial polymeric immunoglobulin receptor and the laminin-specific integrin receptor, respectively (Mann, 2014). As shown in Figure 2A, the CbpA-Y sequence (31 amino acids) contains the highly conserved RRNYPT from the helix 1-helix 2 loop. The CbpA-N sequence (17 amino acids) contains the highly conserved sequence EPRNEEK from the helix 2-helix 3 loop. Two non-helical loop regions (Figure 2A; box) connect the three antiparallel α-helices. The RRNYPT motif binds to the pIgR receptor on epithelial cells, and the EPRNEEK motif binds to the laminin receptor on endothelial cells. The amino acid numbers of the R2 domain are shown in FIG. 2A. The conservation percentage of the sequence from 30 clinical isolates is listed. As depicted in FIG. 2B, the R2 region was expressed as wild-type (linear: referred to as L-YPT-length, L-NEEK-length: 62 and 82 amino acids, respectively) or as a double Cys-containing (YPT-length or NEEK-length) polypeptide created by replacing the indicated cysteine ​​residues (referred to as "loop-type"). Cysteine ​​residues were engineered into the CbpA sequence to promote disulfide bridge formation and mimic the native structural conformation of the CbpA loop (Mann, 2014).

[0268] General characteristics of MTRV001

[0269] MTRV001 is a fusion protein consisting of detoxified pneumolysin (PLY) with conserved peptide sequences of choline-binding protein A (CbpA) at the amino- and carboxy-termini. Two attenuating mutations in the PLY sequence, G293S and L460D, are intended to abrogate cytolytic activity by locking PLY in a monomeric, prepore confirmation and preventing cholesterol binding, respectively. The prepore structure has been shown to allow for functional antibodies that neutralize PLY toxin cytolytic activity but lack hemolytic activity (Oloo, 2011). The N-terminal CbpA portion (CbpA-Y) is responsible for CbpA-mediated binding to the human epithelial polymeric immunoglobulin receptor, and the C-terminal CbpA portion (CbpA-N) binds to the laminin-specific integrin receptor.

[0270] [Table 5]

[0271] During the initial development of MTRV001, a PLY genetic toxoid containing a unique single amino acid substitution, L460D (PLY-SM), which abolished the ability of PLY to effectively bind cholesterol in membranes and lyse cells (Farrand, 2010), was evaluated in developmental studies. PLY-SM, however, retained residual levels of cytolytic activity, and therefore additional attenuated constructs were developed. As depicted in Figure 1B, a second PLY genetic toxoid ("PLY-DM") was evaluated, which harbors two amino acid substitutions, G293S and L460D, which, respectively, lock the protein in a prepore conformation and prevent cholesterol binding, and together reduce cytolytic activity to undetectable levels (Farrand, 2010; Oloo, 2011; Thanawastien, 2021). In mouse immunogenicity studies, PLY-DM elicited immune responses comparable to those of PLY-SM in terms of anti-PLY IgG titers, functional antibody levels measured in an in vitro hemolytic neutralization assay, and in conferring protection to mice in an intranasal (IN) S. pneumoniae challenge sepsis model. It was subsequently demonstrated that immunization of mice with PLY-DM conferred broad and significant protection against lethal IN challenge with 17 of the 20 S. pneumoniae serotypes, including both the Prevnar 13® serotype as well as emerging serotypes (Thanawastien, 2021). PLY-DM was selected as the PLY toxoid component comprising the final MTRV001 construct because it contained an additional G293S mutation that further attenuated PLY cytolytic activity while still eliciting high titers of functional antibodies.

[0272] PLY-SM is a PLY genetic toxin carrying a single amino acid (aa) attenuating mutation (L460D) (FIG. 1B). PLY-SM was utilized as a template to generate both i) YLN, a recombinant fusion antigen with N- and C-terminal flanking CbpA peptides, and ii) PLY-DM, a highly attenuated PLY toxoid carrying two (2) aa substitutions (G293S and L460D). PLY-DM was subsequently used to generate MTRV001, a fusion construct of PLY-DM with flanking N- and C-terminal CbpA peptides, as depicted in FIG. 1B.

[0273] "YLN" is a protein that varies by one amino acid from MTRV001 and consists of "PLY-SM" as a core antigen and two conserved peptides from the S. pneumoniae cell surface adhesin CbpA fused to its N- and C-termini (Mann, 2014) (Figure 1B). The CbpA-Y and CbpA-N peptide sequences of YLN are derived from the R2 domain (second repeat domain) of the native CbpA protein. The CbpA-Y sequence (31 amino acids) contains the highly conserved RRNYPT from the helix 1-helix 2 loop, and the CbpA-N sequence (17 amino acids) contains the highly conserved sequence EPRNEEK from the helix 2-helix 3 loop. In the native protein, the CbpA-Y sequence is responsible for CbpA-mediated binding to the human epithelial polymeric immunoglobulin receptor, whereas the CbpA-N sequence binds to the laminin-specific integrin receptor. In mouse studies, YLN was highly immunogenic and conferred superior protection compared with PHL-SM in pneumococcal models of infection, including otitis media and meningitis. Furthermore, YLN-immunized mice showed significantly less lung pathology following pneumococcal challenge than PLY-SM-immunized and non-immunized animals.

[0274] Based on published YLN preclinical immunogenicity and efficacy results, MTRV001 was constructed using PLY-DM as a core toxoid component fused to the identical CbpA peptide found in YLN at the N- and C-termini of the toxoid. Preclinical mouse immunogenicity and challenge studies demonstrated that MTRV001 induced anti-PLY immunoglobulin G (IgG) antibody titers and protective efficacy comparable to PLY-DM. Similar to YLN, MTRV001-immunized mice showed no observable lung pathology following virulent pneumococcal challenge, whereas lungs of mice immunized with PLY-DM or administered saline showed active signs of inflammation and pathology. These data clearly demonstrate the additional protection conferred by the CbpA epitope.

[0275] MTRV001 was subsequently evaluated for safety, tolerability, and immunogenicity in a GLP repeat-dose toxicity study in rabbits. In the toxicology study, rabbits were administered three injections of 10, 30, or 90 μg of MTRV001 intramuscularly (IM) every two weeks. MTRV001 was well tolerated and did not demonstrate evidence of toxicity at any of the dose levels evaluated. In addition, MTRV001 was immunogenic in a dose-dependent manner.

[0276] Pharmacology Testing

[0277] Pivotal pharmacology studies were performed to evaluate the immunogenicity and efficacy of MTRV001 and the development construct PLY-DM. Local tolerability was evaluated in a repeated dose toxicity study according to World Health Organization (WHO) guidelines. Non-clinical immunogenicity studies of MTRV001 were performed in both mice and rabbits, whereas efficacy studies were performed in a mouse model of pneumococcal disease. Collectively, these non-clinical studies demonstrate the safety, tolerability, immunogenicity, and protective capacity of MTRV001 for the prevention of pneumonia and invasive disease caused by S. pneumoniae.

[0278] The efficacy of MTRV001 against pathogenic pneumococcal challenge was evaluated in a series of mouse studies. These studies demonstrated that mice immunized with MTRV001 were not only protected from challenge with the three S. pneumoniae serotypes, but also served to bridge the immunogenicity and efficacy data of MTRV001 to the precursor antigen PLY-DM. MTRV001 and PLY-DM elicited highly comparable levels of anti-PLY IgG antibodies and conferred comparable levels of protection against both WT PLY toxin challenge and lethal IN S. pneumoniae challenge. The presence of the CbpA epitope in MTRV001 did not improve protection in this bacterial challenge model, despite eliciting antibodies against CbpA. This apparent lack of additional protection from the MTRV001 CbpA peptide, however, is likely due to the diminished role that CbpA plays in this lethal mouse sepsis model.

[0279] To demonstrate the contribution of the MTRV001 CbpA epitope in reducing S. pneumoniae pathology, a mouse study was performed comparable in design to the one performed in YLN (Mann, 2014). After immunization of groups of mice with either MTRV001, PLY-DM, or sterile saline, the animals were challenged intratracheally (IT) with a pneumococcal serotype 4 strain to ensure bacterial delivery into the lungs. As expected, after immunization, MTRV001 and PLY-DM induced similar levels of anti-PLY IgG antibodies, whereas only MTRV001 induced anti-CbpA IgG antibodies. Mice immunized with MTRV001 and PLY-DM showed similar survival rates after infection, while mice immunized with MTRV001 had significantly improved lung pathology compared to mice immunized with PLY-DM and sterile saline, as shown in Table 6. These data demonstrate a critical role for the CbpA epitope in preventing pneumococcal-induced lung pathology. While the reduced lung pathology in MTRV001-immunized mice did not translate to improved survival, this is likely due to mechanisms of death occurring primarily via bacteremia and sepsis, rather than impaired lung function. Because CbpA functions as an adhesin, it is expected to play a more important role in pneumococcal colonization of the upper respiratory tract and tissue invasion. In addition, the role of CbpA in mouse models of S. pneumoniae disease may be diminished given that CbpA-mediated invasion via polymeric immunoglobulin receptors is specific for human receptors. Thus, the expected contribution of the MTRV001 CbpA epitope in preventing pneumococcal disease will not be realized until human clinical trials (Mann, 2014).

[0280] [Table 6]

[0281] The impact of Alhydrogel® as a MTRV001 adjuvant was evaluated in a non-clinical study comparing no adjuvant with Alhydrogel®. BALB / c mice were immunized three times every two weeks with MTRV001 dose levels of 2 μg and 0.2 μg. Preclinical immunogenicity ELISA data from this study demonstrated that immunization of mice with non-adjuvanted and adjuvanted MTRV001 at 2 μg and 0.2 μg dose levels elicited robust anti-PLY IgG antibody titers. Non-adjuvanted MTRV001, however, required three immunizations to elicit high titer anti-PLY responses and elicited lower anti-PLY titers than adjuvanted MTRV001 after both dose level regimens. For example, the 2 μg dose level of MTRV001 adjuvanted with aluminum hydroxide induced >10-fold higher antibody titers than non-adjuvanted MTRV001 at day 27 (two weeks after the second dose). The difference in non-adjuvanted vs. adjuvanted MTRV001 induced titers was more pronounced at the 0.2 μg dose level, where adjuvanted MTRV001 induced >3 orders of magnitude higher anti-PLY IgG antibody titers than non-adjuvanted MTRV001 at day 27. Anti-CbpA IgG antibody responses were generally low during the early phase of the dosing regimen (days 0-27) before a rapid increase was observed two weeks after the third immunization (day 41). As observed with the PLY antibody response, non-adjuvanted MTRV001 required three immunizations to induce a high titer anti-CbpA antibody response and induced lower anti-CbpA antibody titers than aluminum hydroxide-adjuvanted MTRV001 at both dose levels. Collectively, these data demonstrate that aluminum hydroxide-adjuvanted MTRV001 induces higher titer anti-PLY and anti-CbpA IgG antibody responses than non-adjuvanted MTRV001 after a two-dose regimen at two different dose levels, supporting the use of aluminum hydroxide to adjuvant MTRV001 in clinical trials.

[0282] Pivotal Pharmacodynamics Study of MTRV001

[0283] Mouse preclinical immunogenicity of MTRV001 and PLY-DM followed by intranasal challenge with clinical isolates of S. pneumoniae serotypes 19F, 6B, and 22F, and WT PLY toxin challenge.

[0284] The MTRV001 precursor antigen, PLY-DM, has previously been shown to be broadly protective against 17 of 20 different S. pneumoniae serotypes in a lethal intranasal (IN) mouse challenge model (Thanawastien, 2021). To determine whether MTRV001 immunization conferred protection, three mouse studies (M227, M230, and M231) were performed to compare the immunogenicity and protective capacity of MTRV001 to PLY-DM against challenge with the three S. pneumoniae serotypes.

[0285] In the initial protective efficacy study (M227), 30 female BALB / c mice were immunized intramuscularly (IM) once every two weeks for three injections with either 2 μg MTRV001, 2 μg PLY DM, or phosphate-buffered saline (PBS), each adjuvanted with 50 μg aluminum hydroxide (Alhydrogel®); for the other two studies (M230 and M231), 20 female BALB / c mice were immunized. Two weeks after the third immunization (day 42), all mice in each group were bled, sera were collected and pooled, and anti-PLY and anti-CbpA titers were assessed by enzyme-linked immunosorbent assay (ELISA) (Table 7). In M227, 10 of the 30 mice from each group were used to evaluate protection against a lethal WT PLY toxin challenge, and the remaining 20 mice were used to evaluate protection against serotype 19F Protection against lethal IN challenge with two dose levels (10 mice / dose level) of S. pneumoniae strains was evaluated. For studies M230 and M231, a total of 20 mice were used to evaluate protection against lethal IN challenge with two dose levels of serotype 6B and 22F S. pneumoniae strains.

[0286] As shown in Table 7, mice immunized with MTRV001 and PLY-DM in each of the studies developed high and comparable levels of serum anti-PLY IgG antibodies that inhibited the in vitro hemolytic activity of WT PLY. In the M227 study, anti-PLY responses elicited from both MTRV001 and PLY DM conferred 100% protection (100% survival of mice 2 days after toxin challenge with WT PLY) against a lethal IV dose of WT PLY toxin, indicating that both antigens elicited protective levels of neutralizing anti-PLY antibodies in vivo. Conversely, the group of mice receiving PBS treatment showed 0% survival 2 days after toxin challenge with WT PLY. Anti-hemolytic titers were assayed from sera collected on day 42 from one of the pools of sera from each group.

[0287] As expected, anti-CbpA antibodies were detected in sera from mice immunized with MTRV001, with titers similar in all three studies. For M227, titer data were averaged from three pools of sera (10 mice / pool), while for M230 and M231, data are averages of two pools of sera (10 mice / pool). Surprisingly, anti-CbpA titers were detected in mice immunized with PLY-DM, but at much lower levels (ranging from 24- to 511-fold) compared to MTRV001-immunized mice. The reason for this is unclear, and in subsequent studies comparing MTRV001 and PLY-DM, immunization of mice with PLY-DM did not elicit a detectable anti-CbpA response.

[0288] [Table 7]

[0289] As shown in Figures 3-4, both MTRV001 and PLY-DM conferred statistically significant protection and extended the time to death against serotype 19F (Figures 3A-3B) and 6B (Figures 4A-4B) strains compared to PBS controls. While only PLY-DM conferred significant protection against the 22F strain at high dose levels compared to PBS controls (Figure 5A), both MTRV001 and PLY-DM immunized mice showed extended time to death at lower infectious dose levels (0.5x), which were not statistically different from PBS controls (Figure 5B). Despite MTRV001 and PLY DM inducing similar anti-PLY titers (ELISA and functional), PLY-DM appeared to provide better protection against bacterial challenge than MTRV001. However, because the number of mice challenged with each dose level of S. pneumoniae strains was relatively small (N=10), further studies with a larger number of mice may need to be performed to determine whether the two antigens truly differ in their protective capabilities.

[0290] Overall, MTRV001 induces similar immunogenicity and protective immunity against PLY-DM and WT PLY toxin challenge. Furthermore, MTRV001 also provides significant protection against serotype 19F and 6B S. pneumoniae challenge.

[0291] Evaluation of the efficacy of MTRV001 and PLY-DM following intratracheal infection with serotype 4 S. pneumoniae strains.

[0292] The efficacy contribution of the MTRV001 CbpA epitope was evaluated in an animal model of S. pneumoniae disease. In this study, groups of mice were immunized with either adjuvanted MTRV001, adjuvanted PLY-DM, or a solvent control and then challenged intratracheally (IT) with a lethal dose of a pathogenic serotype 4 S. pneumoniae strain (T4X). In addition to monitoring for survival, histopathology of heart, brain, and lung tissue was performed. A similar study was performed with YLN, which demonstrated that the CbpA epitope significantly reduced lung pathology (Mann, 2014 and Table 6).

[0293] In the MTRV001 study, groups of 27 female BALB / c mice were immunized intraperitoneally (IP) every two weeks with 10 μg MTRV001, 10 μg PLY-DM, or sterile saline (solvent control), each adjuvanted with 130 μg aluminum hydroxide (Alhydrogel®), for a total of three injections. Two weeks after the third immunization, all mice were bled, serum was collected, and anti-PLY and anti-CbpA titers were determined by ELISA. Mice were then infected IT with a lethal dose of the T4X S. pneumoniae strain. At 72 hours post-infection (hpi), 10 mice from each group were sacrificed, lungs were removed and homogenized, and colony forming units (CFU) / mL of S. pneumoniae were determined. An additional 5 mice from each group were sacrificed and the heart, lungs, and brain were removed for histopathological analysis. The remaining mice were monitored for survival.

[0294] Individual mouse antibody ELISA titers at day 42 (14 days after the third immunization), as well as calculated GMT titers, are shown in Figures 6A-6B. In Figure 6A, mice immunized with MTRV001 or PLY-DM developed robust anti-PLY IgG antibody responses compared to mice receiving the solvent control. As expected, only mice immunized with MTRV001 developed anti-CbpA titers, as shown in Figure 6B. Immunization with both MTRV001 and PLY-DM conferred significant levels of protection to mice following challenge with S. pneumoniae strain T4X compared to solvent control challenged mice (**=p-value<0.01; *=p-value<0.1; compared to solvent control). As shown in FIG. 7, MTRV001-immunized mice demonstrated improved survival at early time points post-infection compared to mice immunized with PLY-DM (0-125 hours post-infection), however, by the end of the monitoring period, no significant differences were observed between the two groups of mice.

[0295] As shown in Table 8, assessment of bacterial seeding to the lungs after challenge showed that MTRV001 and PLY-DM immunized mice had fewer T4X colony forming units (CFU) in the lungs at 72 hours post-infection compared to the vehicle control; however, only the CFU in the lungs of PLY DM immunized mice was significantly lower than the saline control group (*p<0.0001 by unpaired Student's T test). PLY-DM = pneumolysin double mutant; CFU = colony forming units; SD = standard deviation.

[0296] [Table 8]

[0297] Histopathology was performed on lung, heart, and brain tissues from immunized and non-immunized mice after T4X challenge. No microscopic abnormalities were observed in the heart or brain of any animals. However, as shown in Figures 8A-8C, lungs from non-immunized and PLY-DM immunized mice showed mixed alveolar and interstitial immune cell inflammation, with pathology in four of five animals per group. In sharp contrast, all five mice administered MTRV001 showed normal lung architecture with no evidence of alveolar or interstitial lung inflammation (Figure 8A).

[0298] Taken together, these studies show that immunization of mice with either MTRV001 or PLY-DM conferred similar levels of protection against mortality, whereas only MTRV001 conferred protection from pulmonary inflammation and pathology, demonstrating the important role of the MTRV001 CbpA epitope in eliciting protective antibodies.

[0299] Dose Immunogenicity Study of Alhydrogel®-Adjuvanted MTRV001

[0300] Next, the effect of Alhydrogel® adjuvant on MTRV001 anti-PLY and anti-CbpA antibody responses as a function of the incidence of antibody induction, the overall antibody response after all immunizations, and the durability of the antibody response was examined.

[0301] Groups of five female BALB / c mice were immunized IM for three injections (days 0, 14, and 28) with 2 μg or 0.2 μg MTRV001, unadjuvanted or adjuvanted with 50 μg Alhydrogel® every two weeks. Sterile saline without adjuvant was administered to a group of mice as a control. Mice were bled on days 0, 6, 13, 27, 41, 70, and 98, serum was collected, and anti-PLY and anti-CbpA titers were determined by ELISA. Individual mouse antibody titers were determined on days 0, 6, 13, and 27, and GMTs were calculated. Collected sera were pooled on days 41, 70, and 98, and group titers were determined.

[0302] At the 2 μg MTRV001 dose level, non-adjuvanted and adjuvanted MTRV001 induced robust anti-PLY IgG antibody responses that were similar in magnitude after three immunizations (day 41) and relatively durable at day 98 (Table 9). However, the adjuvanted 2 μg MTRV001 dose level induced a more rapid rise in anti-PLY responses than the non-adjuvanted 2 μg dose level, with 30-fold higher titers observed two weeks after the second immunization (day 27). At the 0.2 μg MTRV001 dose level, adjuvanted MTRV001 induced both a more rapid induction of anti-PLY responses and a larger magnitude of response by day 41 than non-adjuvanted MTRV001. Both adjuvanted and non-adjuvanted 0.2 μg MTRV001 induced durable anti-PLY responses out to 98 days.

[0303] [Table 9]

[0304] As shown in Table 10, a similar anti-CbpA response profile was elicited by adjuvanted and non-adjuvanted MTRV001 at the 2 μg dose level at day 41 that was durable through day 98. However, similar to the anti-PLY response, higher anti-CbpA titers were observed 27 days after administration of adjuvanted MTRV001 compared to non-adjuvanted MTRV001. Similarly, the adjuvanted 0.2 μg MTRV001 dose level regime elicited higher anti-CbpA titers at early time points compared to the non-adjuvanted dose regime. However, by day 41, similar titers were observed between the adjuvanted and non-adjuvanted 0.2 μg MTRV001 dose levels. Anti-CbpA antibody responses with adjuvanted 0.2 μg MTRV001 increased on days 70 and 98, while a decrease in titers was observed with non-adjuvanted MTRV001, indicating that the presence of adjuvant at this dose level promoted a more sustained anti-CbpA antibody response.

[0305] [Table 10]

[0306] These data demonstrate that the adjuvant does not enhance the magnitude of anti-PLY and anti-CbpA titers after three immunizations with a high dose of MTRV001 (2 μg), but it does result in a more rapid induction of antibody responses. Furthermore, at a 10-fold lower dose level of MTRV001 (0.2 μg), the adjuvant enhanced the magnitude of the anti-PLY antibody response as well as improved the durability of the anti-CbpA antibody response. Overall, the data support the use of aluminum hydroxide as an adjuvant to increase the immunogenicity of MTRV001.

[0307] In vivo immunogenicity of MTRV001 in New Zealand White rabbits

[0308] The immunogenicity, desired efficacy, and potential toxicological impact of the immune response of MTRV001 were evaluated in a GLP repeated dose toxicity study in rabbits.

[0309] Five dose groups with 10 rabbits / sex / group receiving 10 μg, 30 μg, and 90 μg MTRV001 adjuvanted with aluminum hydroxide, 90 μg non-adjuvanted MTRV001, or adjuvanted vehicle control. Rabbits were dosed via intramuscular (IM) injection on days 1, 15, and 29 using a constant dosing volume of 0.5 mL. Blood samples for antibody determination were collected pre-test, pre-dosing on days 15 and 29, and prior to scheduled necropsy on days 31 and 43. Serum anti-PLY IgG and anti-CbpA titers for individual rabbits were determined by PLY-ELISA and CbpA-ELISA, and GMTs were calculated for groups. Individual rabbit antibody responses were compared to baseline sera collected from all rabbits prior to administration of the first dose at each dose level (day -5) to determine seroconversion (defined as an antibody response ≥ 5-fold above pre-immunization levels).

[0310] [Table 11]

[0311] As shown in Table 11, MTRV001 induced a dose-dependent IgG antibody response to PLY. Serum antibody GMTs on days 5 (pre-immunization), 15, and 29 (post-immunization) were assayed from all 20 rabbits per group. GMTs on day 43 were assayed for the remaining 10 rabbits per group designated for recovery necropsy. There was a statistically significant increase in anti-PLY GMTs on days 15, 29, and 43 in rabbits receiving any dose level of adjuvanted MTRV001 (10 μg, 30 μg, and 90 μg) compared to pre-immunization controls. Rabbits immunized with adjuvanted dose levels of MTRV001 developed anti-PLY GMTs in a dose-dependent manner ranging from 2,000- to 4,950-fold above baseline (10 and 90 μg dose levels, respectively). The non-adjuvanted 90 μg MTRV001 dose level induced an approximately 3,500-fold increase in GMT above baseline at day 43 (2 weeks after the third and final immunization). The non-adjuvanted 90 μg MTRV001 dose regimen also induced significantly higher anti-PLY titers over time compared to pre-immune controls. Seroconversion to PLY was observed for 90%-95% of rabbits at all dose levels 14 days after the first immunization (day 15). 14 days after the second vaccination (day 29), 100% of rabbits had seroconverted for all adjuvanted and non-adjuvanted dose levels, and this seroconversion level was maintained until day 43 (end of study). Percent seroconversion is defined as anti-PLY titers ≧10-fold above pre-immune titers. * = p < 0.05, compared with day −5 before immunization, Dunnett. † = p < 0.05 compared with unadjuvanted 90 μg MVX0I on day 29, Tukey's multiple comparisons. # = p < 0.05 compared with solvent control on day 43, Tukey's multiple comparisons. A=p<0.05, compared to 10 and 30 μg MTRV001 and vehicle control at day 43, Tukey's multiple comparison. As shown in Table 12, the CbpA peptide also induced CbpA-specific titers in rabbits immunized with adjuvanted MTRV001. Overall, anti-CbpA titers were much lower than those observed for anti-PLY and were confounded by high background, as evidenced by higher anti-CbpA titers at day 43 in the vehicle control group compared to pre-immunization sera. Three adjuvanted MTRV001 immunizations were required to induce significant levels of anti-CbpA antibodies above pre-immunization titers. Only animals immunized with the 30 μg MTRV001 dose level induced significantly higher anti-CbpA GMTs at day 43 compared to vehicle control. The lower anti-CbpA titers were also reflected in the rate of CbpA-specific seroconversion. A higher background (or more non-specific response) in rabbits to CbpA was reflected in the 30% seroconversion in rabbits immunized with the vehicle control on day 43 (end of study). The percentage of CbpA-specific seroconversion increased after each dose for rabbits immunized with adjuvanted MTRV001 at all dose levels. The highest seroconversion rate (70%) for MTRV001-induced CbpA-specific responses was observed at the 30 μg dose level after the third immunization (day 43).

[0312] [Table 12]

[0313] In conclusion, the MTRV001 vaccine candidate elicited robust anti-PLY and modest anti-CbpA IgG antibody responses in rabbits in a dose-dependent manner following a three-dose immunization regimen.

[0314] PLY-DM Pivotal Pharmacodynamics Study

[0315] PLY-DM is the precursor antigen to MTRV001 in development and lacks the CbpA portion of MTRV001. The PLY-DM genetic toxoid contains two amino acid substitutions (G293S and L460D) that render the antigen atoxic (undetectable levels of cytolytic activity) and is the PLY portion of MTRV001, as depicted in the schematic diagram in FIG. 1B.

[0316] In vivo immunogenicity and efficacy of PLY-DM in naive mice.

[0317] A series of 14 preclinical trials were conducted to evaluate whether mice actively immunized with PLY-DM were protected from lethal IN challenge with various S. pneumoniae strains and serotypes (Thanawastien, 2021). In summary, 28 different S. pneumoniae strains, representing 20 different serotypes from various geographical regions around the world, isolated from different body sites (bacteremia, pneumonia, carriage), and with different degrees of pathogenicity, were evaluated. The 20 serotypes include those covered by Prevnar 13®, as well as selected emerging serotypes.

[0318] In each study, groups of 20 naive BALB / c mice were immunized IM every two weeks for three injections with 2 μg PLY-DM adjuvanted with 50 μg aluminum hydroxide (Alhydrogel®) or PBS control. Two weeks after the third immunization, mice were bled, serum was collected and pooled, and serum anti-PLY antibody levels were determined by ELISA. Mice were then infected IN with two dose levels (10 mice / dose level) of various virulent S. pneumoniae strains. Challenge dose levels were determined from a preliminary 50% lethal dose (LD50) study. The first challenge dose (1×) was the lowest number of bacteria that was 100% lethal in the LD50 study, and the second dose of bacteria (0.5×) was half the lethal dose.

[0319] With nearly all S. pneumoniae strains, except for serotype 23B strains, the 1x dose level resulted in the death of the majority of mice in the non-immunized group. Survival curves of immunized and non-immunized groups were compared using a log-rank Mantel-Cox test. The cumulative results from these studies demonstrate that active immunization of mice with PLY-DM conferred statistically significant protection against 22 of 28 strains tested (79%) and 17 of 20 representative serotypes evaluated (85%) (Table 13 and Thanawastien, 2021). For some of the serotypes, multiple strains were evaluated, and for some, different levels of protection were observed between strains. For serotype 22F, significant protection was observed only for two of the three strains evaluated; however, because PLY-DM induced protective immunity against the majority, it was considered a protective serotype. Conversely, serotype 3 was not considered a protected serotype. This is because only one of the four serotype 3 strains evaluated showed a significant improvement in time to death. Both serotype 1 and 3 strains exhibited high levels of virulence in this model, with infection dose levels 5-100 times lower than those used for the other serotypes, but 100% lethality was observed even at the 0.5x dose level. While it cannot be claimed that immunization with PLY-DM provided significant protection against serotypes 1 and 3 based on the results, it is possible that greater differences in time to survival or death would have been observed at lower challenge dose levels. The serotype 23B strain was not infectious in this mouse model and was not included among the protected serotypes. It is possible that immunization with PLY-DM may be protective against this serotype with the more pathogenic 23B strain.

[0320] Overall, immunization with PLY-DM demonstrated broad, non-serotype-dependent protection of mice from lethal IN S. pneumoniae infection. Furthermore, it was observed that PLY-DM-immunized mice were protected from lethal infection regardless of whether the strains were isolated from different geographic locations, different body locations (i.e., nasopharynx, blood, sputum), or different disease indications (i.e., pneumonia, bacteremia).

[0321] [Table 13-1] [Table 13-2]

[0322] Supportive study of MTRV001-associated antigen YLN

[0323] Data from non-clinical trials conducted with YLN, an MTRV001 precursor antigen that differs in sequence by a single amino acid in the PLY portion, have been previously published (Mann, 2014). Findings from these studies are summarized below.

[0324] Studies evaluating the MTRV001 variant YLN (PLY-SM / CbpA fusion protein) and its components (Mann, 2014)

[0325] YLN is a CbpA / PLY fusion protein consisting of the same conserved CbpA peptide fragment as MTRV001 fused to the N- and C-termini of a PLY gene toxoid carrying the single amino acid substitution L460D (see FIG. 1B, "PLY-SM"). YLN was constructed and evaluated for immunogenicity and efficacy compared to PLY-SM. In this evaluation, YLN and PLY-SM adjuvanted with aluminum hydroxide and administered IP every two weeks for three injections at a 10 μg dose level induced similar anti-PLY titers that inhibited the in vitro hemolytic activity of WT PLY. YLN also induced a robust anti-CbpA antibody response that was greater than that observed with a truncated form of CbpA (CbpA R2). Following immunization, mice were challenged IT with a serotype 4 S. pneumoniae strain and evaluated for survival, presence of bacteria in the cerebrospinal fluid (CSF) (meningitis), and lung pathology. Another group of immunized mice was challenged IN with the serotype 19F strain and assessed for the presence of bacteria in the nasopharynx (colonization) and ears (otitis media).

[0326] No difference in survival was observed between mice immunized with YLN and PLY-SM after IT challenge (Mann, 2014; Figure 5A), but significantly fewer mice immunized with YLN had detectable bacteria in the CSF (Mann, 2014; Figure 5E). Furthermore, mice immunized with YLN exhibited normal lung architecture after infection, whereas non-immunized mice and mice immunized with PLY-SM demonstrated overt signs of pathology including inflammation, immune cell infiltration, and hemorrhage (Mann, 2014; Figure 5D). YLN-immunized mice challenged IN with the 19F strain demonstrated significantly less bacterial load in the ear (Mann, 2014; Figure 5C) and in the nasopharynx (Mann, 2014; Figure 5B) at day 7 post-infection compared to mice immunized with PHL-SM. Taken together, these data demonstrate that the addition of the CbpA peptide to PLY-SM toxoid did not affect the induction of anti-PLY antibody responses and conferred additional protection against bacterial infiltration of the CSF, ear, and lung pathology, as well as showing some reduction in the density of nasopharyngeal colonization.

[0327] MTRV001 in vivo study to develop immunization protocols for PLY and CbpA immunorelease and stability analysis

[0328] Studies were conducted to define optimal immunization regimens and MTRV001 dose levels to assess in vivo PLY and CbpA immunopotency of MTRV001 for routine quality control testing of MTRV001 drug substance and drug product.

[0329] In the main pharmacology study evaluating MTRV001 efficacy, the dosing regimen consisted of three injections administered once every two weeks (days 0, 14, and 28). Given that serum was not collected until 14 days after the final immunization and the time required for ELISA testing of serum, studies were performed to determine whether a suitable immunization protocol could be developed with a shorter in vivo duration to reduce the time to obtain results. For the immunization protocol to support quality control testing, the dosing regimen was changed to once weekly for three injections based on studies demonstrating that MTRV001 dose levels of ≧2 μg elicited high titers of antibodies against both PLY and CbpA. PLY and CbpA titers were lower than those observed with the biweekly dosing regimen, but were deemed sufficient for further optimization to define the immunization protocol for quality control testing. Nonclinical studies conducted to optimize the immunization protocol are described in this section.

[0330] Dose-ranging study of in vivo immunogenicity and efficacy of MTRV001 in naive mice.

[0331] The objectives of this dose ranging study were to evaluate the immunogenicity and efficacy of MTRV001 following weekly administration of two or three injections and to determine whether the immunization schedule could be further shortened from a three-dose weekly regimen.

[0332] In this study, groups of naive BALB / c mice (10 females per group) were immunized IM twice (days 0 and 7) or three times (days 0, 7, and 14) with three different dose levels (0.5, 3, or 5 μg) of MTRV001 adjuvanted prior to dosing (which may be done for drug substance quality control testing), with 3 μg of MTRV001 adjuvanted during manufacture (representative of drug product samples), or with a buffer (PBS) control. All test articles and PBS controls contained 50 μg of aluminum hydroxide (Alhydrogel®) adjuvant. Two weeks after the final immunization, mice were bled, serum was collected, and anti-PLY and anti-CbpA titers were determined by ELISA. For the two-dose regimen (Table 14), serum was pooled and titers were determined for the group; however, for the three-dose regimen (Table 15), titers were determined from individual mice and GMTs were calculated for the group. Serum samples from the 3 dose regimens were also assayed for toxin neutralization, or functional, antibody responses using an in vitro antihemolytic assay. Mice in each group (2 and 3 dose regimens) were challenged IV with a lethal dose (1.5 μg) of WT PLY toxin and monitored for survival to assess protective immune responses from the MTRV001 dose level / regimens.

[0333] Pooled serum anti-PLY IgG titers remained consistent between adjuvanted MTRV001 dose levels (drug substance) prior to dosing, and were consistent with pre-adjuvanted (drug product) MTRV001 (Table 14). Two weeks after the second and final immunization, pooled serum anti-CbpA titers induced by MTRV001 drug substance increased from the 0.5 μg dose to the 3 μg dose, but then decreased slightly with the 5 μg dose. The 3 μg dose of MTRV001 drug product induced similar titers as the equivalent dose of drug substance. Following a two-dose weekly regimen of MTRV001, the percentage of survival of mice immunized with either drug substance or drug product at any dose level ranged between 50% (5 μg drug substance) and 78% (3 μg drug substance), as shown in Table 14. All mice receiving the MTRV001 immunization regimen showed a significant increase in survival and time to death compared to the PBS control group, however survival rates were not statistically significant among MTRV001-immunized mice at any dose level administered in the two-dose weekly regimen.

[0334] [Table 14]

[0335] Following the MTRV001 3-dose immunization regimen, sera from mice administered any of the MTRV001 test articles showed high anti-PLY and anti-CbpA titers, as shown in Table 15. No significant differences were observed in anti-PLY and anti-CbpA titers between drug substance dose levels; however, titers were similar between drug substance and drug product samples at the same dose levels. High anti-PLY IgG titers correlated with the ability of the sera to inhibit the cytolytic activity of WT PLY in an in vitro hemolysis assay (i.e., more functional antibodies). All of the mice immunized with the MTRV001 test articles survived an IV challenge with a lethal dose of WT PLY toxin, indicating that the immune response was sufficient at all dose levels to neutralize toxin activity.

[0336] Given that the 3-dose weekly regimen of MTRV001 conferred superior protection to mice compared to the 2-dose regimen, subsequent immunization studies were performed using the 3-dose weekly regimen. Because the dose range of 0.5-5 μg MTRV001 did not elicit dose-related effects, additional dose-ranging studies were performed evaluating dose levels below 0.5 μg MTRV001.

[0337] [Table 15]

[0338] Further dose ranging study of in vivo immunogenicity and efficacy of MTRV001 in naive mice

[0339] An initial dose ranging study showed that anti-PLY and anti-CbpA titers in mice remained robust and comparable at MTRV001 dose levels between 0.5 and 5 μg administered once weekly over three injections. Effective dose levels were not determined in that study, so this study was conducted using dose levels of MTRV001 below 0.5 μg to determine effective dose levels for the quality control testing immunization procedure.

[0340] Groups of five female BALB / c mice were immunized IM once a week for three injections (days 0, 7, and 14) with 0.01, 0.03, 0.1, 0.3, and 3 μg dose levels of MTRV001 (pre-adjuvanted at time of manufacture) or 1 mg / mL aluminum hydroxide in PBS. MTRV001 doses were prepared from a number of MTRV001 containing 60 μg / mL MTRV001 and 1 mg / mL aluminum hydroxide using sterile saline as the diluent. Thus, as dose levels decreased, the levels of aluminum hydroxide decreased. Fourteen days after the third immunization, mice were bled, serum was collected and pooled, and anti-PLY and anti-CbpA titers were assayed by ELISA. Serum was also analyzed for induced functional anti-PLY titers in an in vitro anti-hemolysis assay that measures the ability of serum to inhibit lysis of red blood cells by WT PLY. Immunized mice were also assessed for protection against IV challenge with a lethal dose of WT PLY toxin.

[0341] Dose-dependent anti-PLY and anti-CbpA titers were observed for mice administered MTRV001 containing test article (Table 16). Anti-PLY IgG antibody titers were high in the serum of mice immunized with MTRV001 dose levels between 0.03 and 3 μg (reciprocal antibody titers between 160,000 and 640,000). However, mice immunized with 0.01 μg MTRV001 developed 32-fold lower anti-PLY titers compared to mice immunized with 0.03, 0.1, and 0.3 μg MTRV001, and 128-fold lower anti-PLY titers compared to mice immunized with 3 μg MTRV001. High anti-PLY titers corresponding to high anti-hemolytic titers showed a direct correlation between ELISA titers and functional antibody titers. Anti-CbpA titers were lower than anti-PLY titers, as was generally observed in all studies, but increased with higher MTRV001 dose levels; at the lowest dose level of MTRV001 administered (0.01 μg), anti-CbpA titers were not different from mice administered PBS.

[0342] A correlation between MTRV001 dose level and protection was clearly evident in this study. Mice immunized with higher dose levels of MTRV001 and subsequently challenged with a lethal dose of WT PLY toxin had increased survival rates and increased geometric mean to death (Table 16). For example, all (100%) of mice administered 3 μg of MTRV001 survived, and 80% of mice administered 0.3, 0.1, and 0.03 μg of MTRV001 survived. Groups administered either 3, 0.3, 0.1, or 0.03 μg of MTRV001 had statistically significant survival compared to the PBS control group. For the group administered the lowest dose level of MTRV001 (0.01 μg), there was no significant difference in survival from WT PLY toxin challenge compared to the PBS control group. None of the mice administered PBS survived the IV challenge.

[0343] [Table 16]

[0344] Based on the results from this study, for anti-PLY immune responses, the lowest MTRV001 dose level that provided statistically significant protection from IV challenge with WT PLY toxin was 0.03 μg MTRV001. This group developed 16,000-fold higher serum anti-PLY titers compared to the PBS control group on day 28 (2 weeks after the third and final immunization). For anti-CbpA antibody responses, titers still increased from 0.3 μg to 3 μg (the highest dose tested in this study). However, anti-CbpA titer results from previous studies demonstrated that a 3 μg MTRV001 dose reached a plateau in the anti-CbpA antibody response. Based on the results from these studies, the effective MTRV001 dose level for assessing the immunogenicity / immunopotency of the CbpA portion of MTRV001 was determined to be between 0.3 and 3 μg MTRV001, while for anti-PLY responses it was determined to be between 0.03 and 0.3 μg MTRV001.

[0345] Stability determination indicating dose levels of MTRV001 for immunopotency assays.

[0346] The objective of this study was to determine whether previously identified effective MTRV001 dose levels for assessing anti-PLY and anti-CbpA antibody / immune responses were capable of detecting changes in MTRV001 that may affect immune efficacy. Therefore, a dose-ranging study was performed to compare the immunogenicity and efficacy of MTRV001 subjected to heat stress conditions versus a non-stressed control.

[0347] To prepare stressed samples of MTRV001, MTRV001 samples (pre-adjuvanted at the time of manufacture) were stored at 37°C ± 4°C for 3 months. Control samples were placed in parallel at long-term storage conditions (5°C ± 3°C). In this study, groups of mice were immunized IM once a week for three injections (days 0, 7, and 14) with 0.005, 0.05, and 0.5 μg of stressed MTRV001, or 0.005 or 0.05 μg of unstressed MTRV001. Two weeks after the final immunization, mice were bled, serum was collected, and anti-PLY and anti-CbpA titers were determined by ELISA on pooled serum from each group. In addition, efficacy was evaluated in a WT PLY toxin mouse challenge model.

[0348] Dose-dependent anti-PLY and anti-CbpA titers were observed in serum from mice immunized with either stressed or unstressed MTRV001; however, exposure to heat stress resulted in a significant decrease in both antibody titers and efficacy (Table 17). For example, at the 0.05 μg dose level, anti-PLY titers were 16-fold lower in serum from animals receiving stressed MTRV001 compared to the corresponding dose of unstressed MTRV001. Similarly, at the 0.005 μg dose level, anti-PLY titers were >8-fold lower in serum from animals receiving stressed MTRV001 compared to the corresponding dose of unstressed MTRV001. When mice were challenged 2 weeks after the third immunization via IV administration of WT PLY toxin, mice immunized with a 0.05 μg dose of stressed MTRV001 had a 60% survival rate compared to the 100% survival rate observed in mice receiving 0.005 μg of unstressed MTRV001. This difference in survival correlated with the observed difference in anti-PLY titers, whereby anti-PLY reciprocal antibody titers of 10,000 and 40,000 were observed for animals immunized with stressed MTRV001 and unstressed MTRV001 (at one-tenth the dose level), respectively.

[0349] [Table 17]

[0350] Based on the results of this study, a MTRV001 dose of 0.05 μg administered once weekly for three injections was selected for the immunization protocol to assess anti-PLY titers for quality control testing of MTRV001.

[0351] In assessing CbpA responses, unstressed MTRV001 at the highest dose tested (0.05 μg) induced an anti-CbpA titer of 3200, while stressed MTRV001 at this dose level induced background level responses. Even at a 10-fold higher dose level of stressed MTRV001 (0.5 μg), an anti-CbpA titer of only 400 was observed. The dose level of stressed MTRV001 of 0.5 μg, corresponding to a CbpA titer of 400, was considered too low for the range of the assay. A two-fold higher dose, the 1 μg dose, administered once weekly over three injections, was selected for the immunization protocol to assess anti-CbpA titers for quality control testing of MTRV001. The 1 μg dose is below the maximum CbpA titer observed at 3 μg with unstressed MTRV001 in previous studies.

[0352] Consideration

[0353] Disclosed herein is a protein-based pneumococcal vaccine candidate, MTRV001, and methods of making and using same. Through screening and selection of highly conserved pneumococcal protein antigens, PLY and CbpA emerged as antigens capable of conferring protection against a broad range of pathogenic pneumococcal strains and serotypes. MTRV001 is designed as a serotype-independent pneumococcal vaccine that confers protection well beyond that of currently commercially available polysaccharide conjugate vaccines.

[0354] MTRV001 is an aluminum hydroxide-adjuvanted recombinant fusion protein consisting of the PLY gene toxoid and conserved CbpA peptide fragments at the N- and C-termini of the toxoid. Inclusion of both the CbpA epitope and the PLY gene toxoid in MTRV001 is designed to elicit antibodies that inhibit the ability of S. pneumoniae to colonize and invade host tissues (anti-CbpA antibodies; upper and lower respiratory tract stages of pathogenesis) and neutralize the PLY toxin, which is the primary cause of tissue damage, inflammation, and disease symptoms (anti-PLY antibodies; lower respiratory tract stage of pathogenesis).

[0355] A series of pharmacodynamic studies were performed to evaluate the in vitro and in vivo pharmacology of MTRV001. To evaluate whether immunization with MTRV001 and its precursor antigen, PLY-DM, could induce protection against S. pneumoniae infection, a murine intranasal S. pneumoniae challenge model that mimics bacterial pneumonia and sepsis was utilized. Immunization with PLY-DM demonstrated broad protective efficacy in this model, providing significant protection against 17 of 20 pneumonia serotypes (85%), including both Prevnar13® serotypes and emerging serotypes. Although the protective efficacy of MTRV001 was only evaluated against challenge with four serotypes (19F, 6B, 22F, and 4), MTRV001 induced similar anti-PLY titers as PLY-DM in these studies, providing approximately equivalent levels of protection from lethal pneumococcal challenge.

[0356] In a separate study, MTRV001 was evaluated for the protective capacity of the CbpA epitope in a S. pneumoniae intratracheal (IT) challenge model of infection. MTRV001-immunized mice showed significantly less lung pathology compared to non-immunized mice or mice immunized with PLY-DM, conclusively demonstrating the additional protective value of the CbpA epitope. In support of these MTRV001 data, immunization of mice with YLN also protected the lungs following challenge with S. pneumoniae.

[0357] The studies described above profiled the immunogenicity and efficacy of MTRV001. Adjuvant studies were performed to determine the immunological impact of adjuvanting MTRV001 with aluminum hydroxide. Data from these studies indicate that adjuvanting MTRV001 with aluminum hydroxide produces a more rapid induction of antibody responses compared to non-adjuvanted MTRV001. Furthermore, at a relatively low MTRV001 dose level (0.2 μg), aluminum hydroxide adjuvant enhanced both the magnitude of the anti-PLY antibody response as well as prolonged the persistence of the anti-CbpA antibody response. Overall, the data support the use of aluminum hydroxide as an adjuvant to increase the immunogenicity of MTRV001.

[0358] Additional pharmacodynamic studies were performed to define optimal immunization regimens and MTRV001 dose levels for evaluating PLY and CbpA immunity. Immunity assays allow monitoring of MTRV001 drug substance and drug product during routine quality control testing. An important aspect of these studies was to determine whether stress-induced changes in MTRV001 could be reflected in immunity assays. Therefore, dose-ranging studies were performed to compare the immunogenicity and efficacy of MTRV001 subjected to heat stress conditions compared to unstressed MTRV001 controls. Based on the cumulative results from these dose-ranging studies, MTRV001 dose levels of 0.05 μg and 1 μg administered weekly over three injections were selected as the immunization protocol to evaluate anti-PLY and anti-CbpA IgG antibody titers, respectively, for immunity-related quality control testing of MTRV001.

[0359] In conclusion, the present application discloses in vitro and in vivo data that demonstrate superior efficacy of MTRV001 as a pneumococcal vaccine candidate over current methods. The MTRV001 non-clinical data package includes pharmacology and toxicology studies of MTRV001 and collectively provides support for the clinical evaluation of MTRV001 in the proposed Phase 1 clinical trial described in Example 4.

[0360] Example 2. Description of manufacturing process and process control.

[0361] overview

[0362] MTRV001 is produced using a recombinant E. coli cell line. The MTRV001 drug substance manufacturing process begins with the thawing and reconstitution of two Master Cell Bank (MCB) vials. These cells are grown in shake flasks to reach a cell density sufficient to inoculate the production fermenter. After reaching the target cell density in the production fermenter, fermentation is induced with isopropyl β-D-1-thioglactopyranoside (IPTG). Cells are harvested by centrifugation, resuspended, and lysed to release soluble MTRV001, then clarified, depth filtered, and membrane filtered. The purification process consists of three chromatography columns (hydrophobic interaction, cation exchange, and hydroxyapatite chromatography), anion exchange membrane filtration, and ultrafiltration / diafiltration (UFDF), followed by final formulation to adjust concentration and add polysorbate 20. The formulated bulk drug substance is 0.2 μm filtered, filled into sterile containers, and stored at ≦−60° C.

[0363] An overview of the MTRV001 drug substance manufacturing process, including the fermentation and purification processes, is provided in Table 18. One batch of MTRV001 drug substance is derived from purification of approximately half of the filtered harvest material from a 270 L production fermentation run.

[0364] [Table 18]

[0365] Fermentation production process explained

[0366] Step 1: MCB vial thawing and cell culture expansion

[0367] After thawing two MCB vials, the inoculum is grown in a shake flask in sterile fermentation medium supplemented with 0.04 g / L sterile kanamycin solution. The shake flask is incubated with agitation at 37.0±2.0° C. to an optical density at 600 nm (OD600) of ≧6.0 AU / cm. The final pool flask material is assessed for host purity.

[0368] Step 2: Fermentation

[0369] The pooled shake flask cultures are used to inoculate a production fermenter containing sterile fermentation medium supplemented with 40 μg / mL sterile kanamycin solution and 0.3 g / L antifoam. The production fermenter has a nominal volume of 300 L and is operated at a working volume of approximately 270 L.

[0370] During fermentation, pH, dissolved oxygen (DO), temperature, agitation rate, and sparge gas flow rate are controlled to meet specified targets and ranges. Fermentation DO is automatically controlled by a combination of agitation and sparge gas composition. Antifoaming agents may be added as needed during the fermentation process to avoid excessive foaming of the culture. Phosphate and ammonium hydroxide solutions are used to maintain a target pH of 7.2±0.2 during fermentation. Fermentation is maintained at 37.0±1.0°C from inoculation through the induction phase. Induction of expression is initiated by the addition of 0.5 mM IPTG after a target OD600 of 16±3 AU / cm is achieved. After a 4-hour induction period, the fermenter is cooled to 8.0°C (range: 5.0°C-15.0°C) with reduced agitation and sparge rates. The cooled fermentation material is assessed for host purity.

[0371] Step 3: Recovery and Clarification

[0372] The cell harvest procedure involves harvesting the cells by centrifugation followed by resuspension and lysis of the cells to release soluble MTRV001, followed by centrifugation followed by depth filtration and clarification by membrane filtration.

[0373] The cooled fermentation material is applied in aliquots to a disc stack centrifuge at 5.0-15.0 °C to collect the cells. The collected cells are resuspended in sodium phosphate / sodium chloride buffer with temperature control at 8.0 ± 3.0 °C and agitation of the resuspended pool. The resuspended pool is applied to a homogenizer to lyse the cells via high pressure, releasing the soluble product. The lysate is passed three times through the homogenizer with a temperature control target of 8 °C and agitation in a collection vessel. The resulting lysate is clarified at 20 ± 5 °C through a disc stack centrifuge to collect the supernatant. The supernatant pool is applied to a series of depth filters flushed with purified water before use and then equilibrated in sodium phosphate / sodium chloride buffer; a buffer chase is used to collect the retained volume. The collection vessel is maintained at 17-23 °C with agitation. The depth filtrate is 0.2 μm filtered and collected at 5 ± 3 °C with agitation. The filters may be replaced as necessary to process the depth filtrate. The filtered recovered material is either held at 5±3° C. for further processing or packed into single-use sterile bags for storage at ≦−60° C. for future use.

[0374] Refining and manufacturing process description

[0375] Purification operations are performed at ambient temperature. The purification process is designed for end-to-end processing from recovered filtrate to drug substance, and hold times during manufacturing are minimized. Limited hold times required for manufacturing are supported by experience gained during process development testing. Water for injection (WFI) is used at or before step 5; earlier steps may utilize purified water.

[0376] Step 4: Hydrophobic interaction chromatography

[0377] Hydrophobic interaction chromatography (HIC) is performed as a capture step and is intended to capture the MTRV001 product from the filtered harvest and reduce process and product related impurities. This step utilizes phenyl-sepharose resin and is operated in bind / elute mode. This step can be performed in multiple cycles based on the resin loading capacity and the amount of material being processed.

[0378] Prior to use, the column is cleaned with NaOH solution followed by high salt Tris / NaCl equilibration buffer. The filtered harvest material is loaded with in-line conditioning using high salt Tris / NaCl buffer and 0.2 μm filtration. After loading, the column was washed with equilibration buffer followed by reducing salt buffer. The product is eluted in a gradient of decreasing salt concentration and absorbance at 280 nm is monitored to guide peak collection. The HIC eluate can be stored at 5±3° C. for ≦12 hours during processing if necessary.

[0379] Step 5: Anion exchange chromatography

[0380] The anion exchange chromatography (AEX) step is performed as a polishing step and is intended to reduce process and product related impurities. This step utilizes a primary amino strong anion exchange resin and is operated in flow-through mode. This step can be performed in multiple cycles based on the resin loading capacity and the amount of material being processed.

[0381] Prior to use, the column is cleaned with NaOH solution, followed by pre-equilibration with high salt sodium phosphate / NaCl buffer and then sodium phosphate equilibration buffer. The HIC eluate is loaded with in-line conditioning using equilibration buffer and 0.2 μm filtration. Loading is followed with equilibration buffer, product is collected in the flow-through and absorbance is monitored at 280 nm to guide peak collection. The AEX eluate may be stored at 5±3° C. for ≦12 hours during processing if necessary.

[0382] Step 6: Hydroxyapatite chromatography

[0383] Hydroxyapatite (HA) chromatography is performed as a polishing step and is intended to reduce process and product related impurities. Mixed mode resins provide molecular separations through a number of mechanisms including electrostatic, adsorption, weak ion exchange, and calcium-based affinity interactions and are operated in bind / elute mode. This step can be performed in multiple cycles based on the resin loading capacity and the amount of material being processed.

[0384] Prior to use, the column is cleaned with NaOH solution, followed by pre-equilibration with sodium phosphate buffer and then sodium phosphate / sodium chloride equilibration buffer. The AEX pool is loaded with in-line conditioning using sodium phosphate buffer and 0.2 μm filtration. After loading, the column was washed with equilibration buffer. The product is eluted in a linear gradient of increasing salt concentration and the absorbance at 280 nm is monitored to guide peak collection. The HA eluate may be stored at 5±3° C. for ≦6 hours during processing if necessary.

[0385] Step 7: Anion exchange membrane filtration

[0386] Anion exchange membrane filtration is performed as a polishing step and is intended to reduce process-related impurities. The filter membrane is based on the AEX principle and is a salt-tolerant interaction chromatographic membrane with primary amine ligands operated in flow-through mode.

[0387] Prior to use, the filters are cleaned with NaOH solution, followed by pre-equilibration with high salt sodium phosphate / sodium chloride buffer and then sodium phosphate equilibration buffer. The HA pool is diluted in equilibration buffer before application and the loading is chased with equilibration buffer. Product collection is based on a fixed volume of pool filtration and chase steps.

[0388] Step 8: UF / DF and final formulation

[0389] Ultrafiltration / diafiltration (UF / DF) is used to concentrate and buffer exchange the AEX membrane filtrate: UF / DF membranes with a 30 kDa cutoff are flushed with WFI, cleaned with NaOH solution, flushed with WFI, and finally equilibrated with diafiltration buffer (10 mM sodium phosphate, 154 mM NaCl, pH 7.4) before use.

[0390] The AEX membrane filtrate is first concentrated to a target of 2.0 mg / mL and then diafiltered with 10.0±1.0 diavolumes of diafiltration buffer. Retentate flow rate and transmembrane pressure are monitored throughout the UF / DF process. Protein concentration is assessed by absorbance at 280 nm throughout the UF / DF and dilution steps. Diafiltration pools are performed up to two times in combination with post-recovery flushes of the system. A final dilution with diafiltration buffer may be performed to adjust the product concentration toward a final drug substance concentration of 1 mg / mL and to allow for the final addition of polysorbate 20 solution.

[0391] Polysorbate 20 stock solution (prepared in diafiltration buffer) is added to the UF / DF pool to a final concentration of 275 μg / mL and then mixed.

[0392] Step 9: Filtration & bulk filling

[0393] The formulated bulk is 0.2 μm filtered (filter is pre-equilibrated with 10 mM sodium phosphate, 154 mM NaCl, 275 μg / mL polysorbate 20, pH 7.4), the initial volume is discarded, and then filled into pre-sterilized PETG bottles in a laminar flow hood. Filter integrity is verified after use. MTRV001 drug substance is stored at ≦-60° C.

[0394] Reprocessing

[0395] Refiltration at step 9 may be performed in the event of unacceptable post-use filter integrity test results or equipment failure. However, filtration is not performed to remove identified microbial contamination or to mitigate other product quality issues. A final refiltered MTRV001 drug substance is required to meet release specifications as previously described.

[0396] Exemplary results of the purification process are shown in Table 21 ("Process (involving 3-column purification)"). In summary, this particular sequence of steps in the manufacturing process resulted in a composition that contained lower levels of impurities, such as media components, cells, cell debris, nucleic acids, host cell proteins (HCPs), viruses, endotoxins, etc., that were not achievable by 2-column purification and that is suitable for therapeutic administration. Furthermore, this process resulted in a high proportion of full-length monomeric forms of the immunogenic fusion protein compared to non-monomeric forms of the target molecule (e.g., immunogenic fusion protein) or non-full-length forms of the target molecule (e.g., N-terminal truncations of the immunogenic fusion protein). This provides a significant advantage for achieving a strong immunogenic response upon administration to human subjects for therapeutic purposes.

[0397] Explanation of in-process control

[0398] In-process control testing for MTRV001 drug substance is performed at the indicated steps, as summarized in Table 19.

[0399] [Table 19]

[0400] Example 3. Manufacturing process development

[0401] Overview of manufacturing process development

[0402] The MTRV001 drug substance manufacturing process was initially developed using a two-column purification process for non-GMP manufacturing. Additional process development was performed to improve clearance of process-related impurities, leading to the current process (three-column purification) described in Example 2 herein.

[0403] Initial Process Development (Process Version 1a)

[0404] Initial process development was performed to establish conditions for fermentation, recovery and downstream purification. The initial process is referred to as Version 1a for contextual clarity.

[0405] The manufacturing process was initiated by thawing a single vial of second generation EC-100 research cell bank (derived from the EC-100 RCB utilized to prepare the master cell bank) and growing in a shake flask with media supplemented with kanamycin to a cell density sufficient to inoculate a 10 L production scale reactor. After reaching the target cell density in the production fermenter, fermentation was induced with isopropyl βD 1 thioglactopyranoside (IPTG). Cells were harvested by centrifugation, frozen, resuspended in sodium phosphate / sodium chloride buffer, and then homogenized via high pressure to release the soluble product. After centrifugation, the supernatant was diluted, sterile filtered, and then applied sequentially to hydrophobic interaction and anion exchange chromatography resins. The purified material was buffer exchanged into final formulation buffer (10 mM sodium phosphate, 154 mM NaCl, pH 7.4) and the drug substance was stored at 5±3°C. Note that for batch MTRV001 ENG01, 275 μg / mL polysorbate 20 was included in the formulation buffer. The polysorbate 20 concentration was selected based on general knowledge of effective polysorbate levels for stabilization of recombinant proteins, as well as levels typically utilized in intramuscularly injected recombinant products and vaccines.

[0406] Non-GMP batch GLPB-002 was utilized to prepare the test article used in GLP toxicology studies and was manufactured via the two-column process described above and analytical equivalence compared to the proposed clinical drug substance batch CB-01. While process improvements were made to the process used for the GLP toxicology batch compared to the initial clinical process, the final product quality of the starting cell bank and materials are similar.

[0407] Process transfer / establishment of the initial process (Process Version 1b)

[0408] The initial process was made to incorporate changes to raw materials / consumables including a transition to MCB and scale with associated necessary adjustments to the process (e.g., larger seed train volume), as well as other modifications required for facility conformance / GMP production. The drug substance was formulated in 10 mM sodium phosphate, 154 mM NaCl, 275 μg / mL polysorbate 20, pH 7.4, as was done with subsequent batches produced via Process 1a previously described.

[0409] After product quality evaluation of the drug substance produced from the process, it was concluded that additional process development was required to achieve a drug substance with a suitable process-related impurity profile suitable for clinical investigational material. The key process-related impurities to be addressed were elevated and inadequate levels of host cell proteins (HCPs). The material produced in this process 1b was therefore designated as non-GMP and was used exclusively for reference standard and developmental testing.

[0410] Process development / establishment of early clinical process (Process Version 2)

[0411] Process development encompassed both the fermentation and purification manufacturing processes with the intent of improving product quality of the drug substance, particularly at the host cell protein level. In addition, changes to raw materials / consumables and other modifications to the process were made as required for facility adaptation.

[0412] Changes to the fermentation process included increasing the seed train scale to accommodate the larger, 300 L production fermentation scale, as well as the development of a new harvest and clarification process. Ammonium sulfate precipitation, acid precipitation, and depth filtration were evaluated for harvest and clarification procedures, but ammonium sulfate and acid precipitation were found to have inadequate product quality and yield, respectively. The final procedure incorporated the use of a disc stack centrifuge in the harvest stage to collect cells from the bulk fermentation product and then capture the soluble product again after homogenization. Depth filtration of the soluble product was also introduced to further remove particulates and improve throughput of membrane filtration prior to chromatography processing. Selected fermentation, harvest, and clarification process parameters from the process development were used in a 30 L pilot run for validation of the process for GMP production.

[0413] The purification process for MTRV001 drug substance was redeveloped and process development included resin screening, chromatography development and optimization for columns 1, 2, and 3, anion exchange membrane filtration step development, and ultrafiltration / diafiltration (UF / DF) development. Throughout the process development, the objective was to optimize for removal of product and process related impurities, especially HCPs. Resin screening included cation and anion exchange resins, heparin affinity resin, hydrophobic interaction resin, and hydroxyapatite resin. Resins were also evaluated with ammonium precipitation, which was then observed to lead to increased product related impurities. After resin screening, chromatographic parameters were developed and optimized, including parameters such as column loading, elution program / buffer system, excipient addition, pooling guidelines, etc. Column sequence was also evaluated and the final scheme selected included hydrophobic interaction chromatography as a capture step followed by anion exchange chromatography and hydroxyapatite polishing chromatography steps. While changes to the chromatography step improved HCP to the target levels, an additional anion exchange membrane filtration step was developed and implemented to further improve HCP levels and provide additional capacity / process redundancy for HCP, endotoxin, and host cell DNA clearance. The membrane selected is a salt-tolerant interaction chromatographic membrane with a primary amine ligand operated in flow-through mode based on the principles of anion exchange chromatography. UF / DF development was performed with the objective of buffer exchange / concentration while maintaining the target product quality and included filter screening as well as packing evaluation. The selected purification operation was used in two 30 L pilot runs for process validation for GMP production. Storage conditions for MTRV001 drug substance were changed from early process to ≦-60°C as is typical for biologic drug substances to support long-term product quality. The selected storage conditions are supported by available drug substance stability data and development studies evaluating freeze / thaw stability.

[0414] The manufacture of non-GMP pilot run batch GLPB-0023 was carried out using the manufacturing process previously described, but with necessary scale and non-GMP facility modifications. Raw materials and consumables, including MCB, cell culture media, purification resins, depth filtration filters, and UF / DF filters, were as similar as possible between lot GLPB-0023 and GMP batch CB-01. Batch analytical results for non-GMP batch GLPB-0023 and GMP batch CB-01 were evaluated.

[0415] Development batch analysis and analytical equivalence

[0416] Analytical results for the drug substance batch used in the GLP toxicology study (batch GLPB-002) and used to manufacture the clinical drug product (batch CB-01) are presented in Table 20. Of note, the target concentration of the drug substance was changed during development and diluted to the target drug concentration during drug product manufacturing. While the results for the percentage of main peak by size exclusion chromatography are 16% less for the clinical drug substance batch compared to the GLP toxicology batch, this is not considered critical to the function or safety of MTRV001. Because the final drug product is adjuvanted, resulting in a high density of MTRV001 on the adjuvant, likely as a higher order species. Within the specified range of high molecular weight species (HMWS), there is no impact on the immunopotency of the final adjuvanted product, and therefore the observed difference in the percentage of main peak is not considered meaningful. The results demonstrate that Batch GLPB-002 was used for GLP toxicology and is comparable to clinical drug substance batch CB-01, supporting the use of Batch CB-01 for the manufacture of clinical drug product.

[0417] [Table 20]

[0418] Batch analysis results for additional development batches are provided in Table 21.

[0419] [Table 21]

[0420] Example 4: Stability Summary and Conclusions.

[0421] Stability Test Overview

[0422] The intended long-term storage conditions for MTRV001 drug substance are ≦-60°C.

[0423] Stability Study Design

[0424] Stability testing of MTRV001 drug substance will be performed in accordance with ICH Q1A and ICH Q6B.

[0425] The stability protocols for batches CB-01 and NB11601p37 are provided in Table 22 and Table 23, respectively. Analytical procedures are the same as previously mentioned. Acceptance criteria for GMP batches at long-term conditions (-75 ± 10°C) are defined by specifications established at the start of the study. For these studies, MTRV001 drug substance was dispensed into 5 mL PETG bottles with HDPE closures, representative of the bulk drug substance container.

[0426] [Table 22]

[0427] [Table 23]

[0428] Stability Data Discussion and Conclusions

[0429] Stability studies for GMP batch CB-01 are ongoing at long-term (-75±10°C) storage conditions and at accelerated storage conditions at 5±3°C. Evaluation at 25±2°C / 60±5% RH accelerated storage conditions has been completed. For the long-term storage conditions, available data for all tests met the acceptance criteria and no significant trends or changes in properties have been observed for any of the tests over the time points examined to date. At the accelerated storage condition at 5±3°C, the percent HMWS trends upward during storage. No other significant trends or changes in properties have been observed over the time points examined to date. A similar, but more significant trend is observed at the accelerated storage condition at 25±2°C / 60±5% RH with HMWS increasing by 14% from initial storage to one month. While increasing HMWS has been observed at both accelerated storage conditions, this trend has not been observed at the long-term storage condition at -75±10°C.

[0430] Stability studies for non-GMP batch NB11601p37 are ongoing at long-term (-75±10°C) storage conditions and at accelerated storage conditions at 5±3°C. Evaluation at accelerated storage conditions at 25±2°C / 60±5% RH has been completed. For long-term storage conditions, no significant trends or changes in properties have been observed for any of the tests over the time points examined thus far. At accelerated storage conditions at 5±3°C, the percent HMWS trends upward during storage. No other significant trends or changes in properties have been observed over the time points examined thus far. A similar, but more significant trend is observed at accelerated storage conditions at 25±2°C / 60±5% RH with HMWS increasing by approximately 15% from initial storage to one month. While increasing HMWS has been observed at both accelerated storage conditions, this trend has not been observed at long-term storage conditions at -75±10°C.

[0431] Available stability data supports long-term storage of MTRV001 drug substance at ≦−60° C. Drug substance stability continues to be monitored according to the stability protocols described herein.

[0432] Example 4. A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Tolerability, Safety, and Immunogenicity of MTRV001, a Pneumococcal Vaccine Candidate, in Healthy Adult Participants.

[0433] 1.1 Overview

[0434] Study Duration: The maximum planned duration is approximately 8.5 months for each participant, including screening (up to 28 days), treatment (two doses administered approximately 1 month apart), and follow-up (assessments extending up to approximately 6.5 months after the second administration of study intervention).

[0435] Population: Healthy male or female adults aged ≥18 to ≤50 years for cohorts 1-4 and ≥60 to ≤75 years for cohort 5.

[0436] Investigational Medicinal Product: The MTRV001 drug product is the recombinant pneumococcal antigen MTRV001 adjuvanted with aluminum hydroxide. The MTRV001 drug product is formulated at 180 μg MTRV001 / mL, 1 mg / mL aluminum (in the form of aluminum hydroxide) in 9 mM sodium phosphate, 139 mM sodium chloride, 275 μg / mL polysorbate 20, pH 7.4.

[0437] Control (Placebo): MTRV001 placebo is formulated at 1 mg / mL aluminum (in the form of aluminum hydroxide) in 9 mM sodium phosphate, 139 mM sodium chloride, pH 7.4.

[0438] Regimen and Dosing by Cohort: Participants will receive two doses of MTRV001 or placebo in one of five cohorts.

[0439] [Table 24]

[0440] [Table 25]

[0441] Study Design: This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the tolerability, safety, and immunogenicity of ascending doses of the pneumococcal vaccine candidate MTRV001. Potential participants will be screened within 28 days prior to Visit 2 (Day 1).

[0442] Approximately 75 participants who meet all inclusion criteria, no exclusion criteria, and provide written informed consent will be enrolled. Participants will receive two doses of MTRV001 or placebo in one of five cohorts.

[0443] Cohort 1:

[0444] Three participants aged ≥18 to ≤50 years will be enrolled to receive MTRV001 in an open-label, staggered fashion.

[0445] The 72-hour safety data for each participant following administration of the first dose of study intervention will be reviewed by the investigator and sponsor prior to administration of the study intervention in the next participant.

[0446] In addition, the Safety Monitoring Committee (SMC) will review the tolerability and safety data for each participant in the cohort through Day 8 (7 days after administration of the first dose of the study intervention), as well as any available immunogenicity data, to determine whether administration of the study intervention in the next cohort can be initiated.

[0447] A second dose of the study intervention will also be administered in an open-label and staggered fashion, and the 72-hour safety data for each participant following administration of the study intervention will be reviewed by the investigator and sponsor prior to administration of the study intervention in the next participant. The tolerability and safety data for each participant within the cohort will be monitored by the investigator for 7 days following administration of the second dose of the study intervention to ensure that no safety concerns are observed.

[0448] Cohorts 2-4:

[0449] In each cohort, 16 participants aged ≥18 to ≤50 years will be enrolled to receive the study intervention (12 participants receiving MTRV001 and 4 participants receiving placebo).

[0450] The first two participants will be enrolled to receive MXV01 in an open-label and staggered fashion (sentinel group). The 72-hour safety data for each participant following administration of the first dose of study intervention will be reviewed by the investigator and sponsor prior to administration of study intervention in the next participant.

[0451] The remainder of the cohorts will be randomized to receive the study intervention in a blinded fashion (10 participants to receive MTRV001 and 4 participants to receive placebo). Within each cohort, the SMC will review each participant's tolerability and safety data through Day 8 (7 days after administration of the first dose of study intervention), as well as any available immunogenicity data, to determine whether study intervention administration in the next cohort can be initiated.

[0452] A second dose of the study intervention will also be administered in an open-label and staggered manner in the first two participants, and the 72-hour safety data for each participant will be reviewed by the investigator and sponsor prior to administration of the study intervention in the next participant. The tolerability and safety data for each participant within the cohort, as well as any available immunogenicity data, will be monitored by the investigator for 7 days following administration of the second dose of the study intervention to ensure that no safety concerns are observed.

[0453] Cohort 5:

[0454] Twenty-four participants aged ≥60 to ≤75 years will be enrolled, along with ≥5 participants aged ≥67 to ≤75 years, to receive the study intervention (20 participants receiving MTRV001 and 4 participants receiving placebo).

[0455] The first two participants will be enrolled to receive MXV01 in an open-label and staggered fashion (sentinel group). The 72-hour safety data for each participant following administration of the first dose of study intervention will be reviewed by the investigator and sponsor prior to administration of study intervention in the next participant.

[0456] The remainder of the cohort will be randomized to receive the study intervention in a blinded fashion (22 participants to receive MTRV001 and 4 participants to receive placebo). Within the cohort, the tolerability and safety data of each participant will be monitored by the investigator until Day 8 (7 days after administration of the first dose of study intervention) to ensure that no safety concerns are observed.

[0457] A second dose of the study intervention will also be administered in an open-label and staggered manner in the first two participants, and the 72-hour safety data for each participant will be reviewed by the investigator and sponsor prior to administration of the study intervention in the next participant. The tolerability and safety data for each participant within the cohort, as well as any available immunogenicity data, will be monitored by the investigator for 7 days following administration of the second dose of the study intervention to ensure that no safety concerns are observed.

[0458] If there is evidence of an unexpected AE, serious AE, or SAE (at least in each case considered possibly related to the study intervention), the full SMC will be convened and asked to review the tolerability and safety data for the participant. In this case, the decision to continue dosing of the study intervention in the remainder of the cohort will be made after consultation with the full SMC.

[0459] Criteria for progressing to the next cohort: The SMC will review all tolerability and safety data through Day 8 (7 days after administration of the first dose of study intervention) for each dose cohort, as well as any available immunogenicity data, prior to the start of administration of study intervention in the next cohort.

[0460] If a particular dose level is determined to be poorly tolerated, an intermediate dose of MTRV001 (i.e., a dose between the dose previously found to be tolerated and the dose found to be poorly tolerated) may be evaluated, pending further review and concurrence by the SMC and IRB.

[0461] A review of safety and tolerability data, as well as any available immunogenicity data, for the first four cohorts will be conducted prior to selecting a dose for Cohort 5. The dose of study intervention for Cohort 5 will be selected as the highest tolerated dose administered in Cohorts 1-4.

[0462] Study Discontinuation Rules: The following study discontinuation rules apply:

[0463] 1. If one participant in any cohort experiences at least a Grade 4 AE or SAE possibly related to the study intervention, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed.

[0464] 2. If ≥ 2 participants in any cohort experience the same Grade 3 AE (not including vital sign AEs [i.e., only heart rate, respiratory rate, and blood pressure]) that cannot be clearly attributable to other causes, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed. If ≥ 3 participants in any cohort experience Grade 3 vital sign AEs that cannot be clearly attributable to other causes, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed.

[0465] The study intervention will be administered by intramuscular (IM) injection in the deltoid muscle of the non-dominant arm (or dominant arm, if participant prefers) at the study site at Visits 2 (Day 1) and 4 (Day 29 [± 2 days]). Participants will be observed by study personnel at the study site for 30 minutes after each administration of study intervention and any AEs will be recorded.

[0466] Using a diary card, each participant will record oral temperature (assessed using a provided thermometer) and local and systemic AEs daily for 7 days following each administration of study intervention. Participants will also be provided with a ruler for injection site assessment. All AEs / SAEs and NOCIs will be recorded from the time of administration of the first dose of study intervention until Visit 6 (Day 57 [± 4 days]). Thereafter, only SAEs and NOCIs will be recorded until Visit 7 (Day 210 [± 14 days]). AEs reported after signing of the ICF and before administration of the first dose of study intervention will be considered medical history.

[0467] Site clinic visits will occur at screening and on days 1, 15 (± 2 days), 29 (± 2 days), 43 (± 4 days), 57 (± 4 days), and 210 (± 14 days). Protocol-specified safety laboratory tests will be performed at screening and on days 1 (pre-dose), 15 (± 2 days), 29 (± 2 days [pre-dose]), and 43 (± 4 days). Blood samples will be collected for immunogenicity assessments on days 1 (pre-dose), 29 (± 2 days; pre-dose), 57 (± 4 days), and 210 (± 14 days).

[0468] Each participant will be contacted by telephone approximately 24 hours, 72 hours, 7 days, and 13 days after each administration of study intervention for safety assessments and diary review. Between Visits 6 (Day 57 [± 4 days]) and 7 (Day 210 [± 14 days]), each participant will be contacted by telephone monthly (Days 90, 120, 150, 180 [± 3 days]) for safety follow-up. A medical professional at the study site, such as a registered nurse, nurse practitioner, or physician assistant, will record study phone calls using a scripted interview questionnaire over the first 7 days after each administration of study intervention. Other phone calls can be conducted and recorded by trained study staff.

[0469] Analyses of safety, tolerability, and immunogenicity data will be performed when data from all cohorts (Cohorts 1-5) through Visit 6 (Day 57 [± 4 days]) are available and monitored. These analyses will constitute the main content of the Clinical Study Report (CSR). All study participants will remain blinded. The Investigator or designee, and a blinded subgroup of study personnel at sites involved in the ongoing conduct of the study (after Visit 6 [Day 57 (± 4 days)]) will remain blinded to the study intervention. The blinded Investigator or designee will assess the relationship of any SAEs or NOCIs reported after Visit 6 (Day 57 [± 4 days]).

[0470] All safety and immunogenicity data after Visit 6 (Day 57 [± 4 days]) will then be summarized and included as an appendix to the CSR.

[0471] Study site personnel will follow the site's COVID-19 guidelines in effect at the time the study is conducted.

[0472] Study population:

[0473] Eligibility Criteria:

[0474] Inclusion:

[0475] To be eligible, participants must meet all of the following criteria:

[0476] 1. Participants must be male or female, aged ≥18–≤50 years for Cohorts 1–4 and ≥60–≤75 years for Cohort 5, at the time of signing the informed consent.

[0477] 2. Range: 18-32kg / m 2 Inclusive body shape index.

[0478] 3. Participant with no clinically significant acute or chronic health conditions in the opinion of the investigator.

[0479] 4. Provided written informed consent prior to the screening procedure.

[0480] 5. Participant's screening laboratory test results must be within normal limits or be deemed not clinically significant by the Investigator.

[0481] 6. Adequate venous access for collection of safety laboratory samples and immunogenicity samples.

[0482] 7. Contraceptive use by men and women should be consistent with local regulations regarding contraceptive methods for participants in clinical trials, and women of childbearing potential must agree to abstain from heterosexual activity for a period of 14 days prior to administration of the study intervention.

[0483] The investigator will evaluate the effectiveness of the contraceptive method in relation to the first dose of the study intervention.

[0484] The investigator will review medical history, menstrual history, and recent sexual activity to reduce the risk for enrollment of women with early undetected pregnancy.

[0485] Exclude:

[0486] Participants will be excluded from the study if any of the following criteria apply to them:

[0487] 1. A positive screening test suggestive of current infection due to human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.

[0488] 2. Suspected or known alcohol and / or illegal drug abuse within the past five years.

[0489] 3. Regular use of tobacco or nicotine-containing products within 6 months prior to screening.

[0490] 4. ECG abnormalities outside the accepted range (with some exceptions) or results considered clinically significant. Exclude participants with QT interval corrected for heart rate according to the Fridericia formula, >450 ms (for men) or >460 ms (for women).

[0491] 5. History of confirmed pneumococcal infection based on participant report of medical history during the past 12 months.

[0492] 6. Use of any investigational (unregistered) medication within 30 days or within 5 half-lives of the investigational drug prior to receiving the first dose of the study intervention. All investigational (unregistered) medications used should be described.

[0493] 7. Use of chronic immunosuppressants or other immune modulating drugs within 6 months prior to receiving the first dose of study intervention. Short-term use (<14 days) of corticosteroids for acute illness is permitted, but the last dose should be ≥28 days prior to administration of the first dose of study intervention. Use of topical, inhaled, and intranasal glucocorticoids is permitted.

[0494] 8. Receipt of immune globulin and / or any blood products within 3 months prior to Day 1, or planned administration of such products during the study and through Visit 6 (Day 57 [± 4 days]).

[0495] 9. Plan to become pregnant between screening and 30 days after the last dose of study intervention.

[0496] 10. History of allergic disease, neurological disease, or adverse reaction likely to be exacerbated by any component of the vaccine and / or known hypersensitivity to any component of the vaccine.

[0497] 11. Any condition that, in the opinion of the Investigator, may pose a health risk to the participant if enrolled, or which may interfere with the evaluation of the study intervention or interpretation of the study results, including neurological or psychiatric conditions deemed likely to impair the quality of safety reporting.

[0498] 12. Known or suspected immune dysfunction.

[0499] 13. History of administration of any vaccine within 30 days of receiving the first dose of study intervention. If a vaccine is administered within the 30-day time frame, enrollment in the study will be at the discretion of the investigator. Vaccines may not be administered until after Visit 6 (Day 57 [± 4 days]).

[0500] 14. Unwilling or unable to donate sperm, eggs, blood, plasma, or platelets between Screening and Visit 6 (Day 57 [± 4 days]).

[0501] 15. Any participant with physical or clinical examination findings or past medical history that, in the opinion of the Investigator, may be suggestive of a good quality of life for the participant, likely to be <24 months old at the time of screening.

[0502] 16. Participant who, in the opinion of the investigator, is unable to comply with all study procedures and visits outlined in the protocol, including follow-up visits.

[0503] 17. A staff member of a clinical research organization or a family member of a staff member.

[0504] Cancellation rules:

[0505] The following exam cancellation rules apply:

[0506] 1. If one participant in any cohort experiences at least a Grade 4 AE or SAE possibly related to the study intervention, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed.

[0507] 2. If ≥ 2 participants in any cohort experience the same grade 3 AE (not including vital sign AEs) that cannot be clearly attributable to other causes, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed. If ≥ 3 participants in any cohort experience grade 3 vital sign AEs that cannot be clearly attributable to other causes, administration of the study intervention will be discontinued for that cohort until a full safety review has been performed.

[0508] Data Analysis:

[0509] At the end of Visit 6 (Day 57 [± 4 days]) for Cohort 5, the database will be locked for analysis if (a) all participant safety data have been entered and all data queries have been resolved; and (b) ELISA-based results from immunogenicity serum samples collected through Visit 6 (Day 57 [± 4 days]) are available.

[0510] All participants and study personnel included in further safety follow-up (through Visit 7 [Day 210 (± 14 days)]) will remain blinded to treatment assignment, and all safety data collected after Visit 6 (Day 57 [± 4 days]), if available, will be reported in the safety appendix attached to the initial CSR.

[0511] After bioanalysis at visit 7 (day 210 [± 14 days]), specimens will be available and the remaining data will be added to the CSR via an appendix.

[0512] The following populations are defined:

[0513] Intention-to-treat population: All participants who are deemed eligible for participation and are enrolled in the study.

[0514] Safety Population: All participants enrolled in the study and receiving ≥ 1 dose of study intervention. Safety analyses will be based on this population.

[0515] Per protocol population: All participants who received both doses of study intervention at Visits 2 (Day 1) and 4 (Day 29 [± 2 days]) and have Visits 2 (Day 1), 4 (Day 29 [± 2 days]), and 6 (Day 57 [± 4 days]) ELISA data. Participants will be analyzed by the actual study intervention they received. All immunogenicity analyses will be based on this population.

[0516] Sample Size: Approximately 75 participants are planned to be enrolled in the study: 3 participants in Cohort 1, 16 participants in each of Cohorts 2-4, and 24 participants in Cohort 5. A formal sample size calculation was not performed. This sample size is expected to provide sufficient data for evaluation of the study objectives.

[0517] Statistical methods:

[0518] All analyses and data presentations are descriptive in nature. All study data are included in the individual participant data listings. All summary tables present descriptive statistics for parameters analyzed by cohort, wherever applicable.

[0519] Data from participants receiving open-label MTRV001 will now be separated from randomized participants. Data for participants assigned to placebo treatment may be pooled. Generally, tabular summaries will present results by cohort and placebo.

[0520] Tolerability and safety will be assessed by tabulating the frequency, duration, and severity of reactogenic events, as well as overall treatment-emergent adverse events (TEAEs), SAEs, AEs leading to discontinuation, NOCIs, changes in clinical laboratory parameters, and vital sign assessments. AEs will be tabulated and characterized with International Medical Dictionary organ system class and preferred term, intensity, and causality to the study intervention. Changes from baseline in clinical laboratory assessments will be summarized narratively. Vital sign assessments will be summarized narratively. Descriptive statistics will be presented for each cohort and summarized across all cohorts.

[0521] Immunogenicity data will be summarized by treatment group according to endpoint. Seroconversion rates, geometric mean titers, and geometric mean fold increase (post / pre) will be tabulated and summarized graphically.

[0522] 1.2 Scheme

[0523] The overall study scheme is presented in FIG. 9, the study intervention administration scheme is presented in FIG. 10, and the participant timeline is presented in FIG.

[0524] Activity Schedule [Table 26-1] [Table 26-2] [Table 27] [Table 28-1] [Table 28-2] [Table 28-3] [Table 29]

[0525] Study intervention administered

[0526] All three participants in Cohort 1 will receive MTRV001 in an open-label fashion. In Cohorts 2-5, the first two participants in each cohort will receive MTRV001 in an open-label fashion prior to administration of the double-blind study intervention (MTRV001 or placebo) in the remainder of the cohort.

[0527] MTRV001 (containing 10, 30, 60, or 90 μg MTRV001 per dose) or placebo will be injected IM into the deltoid muscle of the non-dominant arm (or dominant arm if participant prefers) at Visits 2 (Day 1) and 4 (Day 29 [± 2 days]). Participants must be seated in an armchair during administration of the study intervention.

[0528] The MTRV001 drug product is an aluminum hydroxide adjuvanted recombinant pneumococcal protein antigen. The MTRV001 drug product is formulated at 180 μg MTRV001 / mL, 1 mg / mL aluminum (in the form of aluminum hydroxide) in 9 mM sodium phosphate, 139 mM sodium chloride, 275 μg / mL polysorbate 20, pH 7.4. The MTRV001 drug product is a white to off-white cloudy suspension. Each single dose vial of MTRV001 drug product contains ≧1 mL. The MTRV001 drug product is manufactured via a recombinant bacterial (E. coli) expression system.

[0529] MTRV001 placebo is formulated with 1 mg / mL aluminum (in the form of aluminum hydroxide) in 9 mM sodium phosphate, 139 mM sodium chloride, pH 7.4. MTRV001 placebo is a white to off-white cloudy suspension. Each single dose vial of MTRV001 placebo contains ≧2 mL.

[0530] MTRV001 Drug Product and MTRV001 Placebo vials will be stored at 5°C ± 3°C. Do not freeze.

[0531] MTRV001 Drug Product and MTRV001 Placebo should be mixed thoroughly by inversion prior to syringe / dosing solution preparation.

[0532] Dosing solutions for the 10, 30, and 60 μg dose levels are prepared from the MTRV001 drug product using MTRV001 placebo as a diluent according to the drug manual. For the placebo and 90 μg MTRV001 dose levels, no solution preparation is required and syringes can be prepared directly from the vialed placebo and MTRV001 drug products, respectively. Prepared syringes of MTRV001 or placebo may be stored at ambient conditions according to the drug manual. The dosing volume for all dose levels and placebo is 0.5 mL. Each 0.5 mL dose and placebo contains 0.5 mg of aluminum (in the form of aluminum hydroxide).

[0533] Preparation, handling, storage, and accountability of study interventions

[0534] The Principal Investigator or designee will be responsible for accountability, reconciliation, and record-keeping of the study intervention (i.e., receipt, reconciliation, and final disposition records). Each dose of study intervention dispensed and used by each participant will be documented.

[0535] The pharmacist, investigator, or designee must also meet regulatory requirements for drug accountability. All doses of study intervention will be collated and retained or destroyed in accordance with applicable regulations. Additional guidance and information regarding the final disposition of unused study intervention is provided in the Medication Manual.

[0536] Study supplies (MTRV001 drug product and MTRV001 placebo vials) will be shipped to the study site in insulated containers with temperature trackers to ensure there are no significant deviations (outside of 5°C ± 3°C). Data from the temperature trackers should be downloaded and shared via email to the relevant email list indicated in the drug manual. Upon receipt of study supplies, they must be stored in a secure, environmentally controlled area at 5°C ± 3°C and monitored (manually or automatically) according to the labeled storage conditions with access limited to the Investigator and authorized site staff.

[0537] How to assign participants to treatment groups

[0538] Following a sentinel group of two participants in cohorts 2-5 (each receiving MTRV001 in an open-label fashion), the remaining participants in each cohort will be randomized to receive either MTRV001 or placebo.

[0539] After confirmation of participant eligibility and at the last practical moment before administration of the study intervention, participants in the double-blind part of each cohort (Cohorts 2 to 5) will be centrally assigned to either MTRV001 or placebo using the IWRS according to a computer-generated randomization list.

[0540] The IWRS will be used to assign unique participant numbers and to allocate participants to study intervention arms at the randomization visit and to study interventions at each study intervention visit according to a randomization scheme generated by a biostatistician.

[0541] The IWRS module is linked to the EDC data capture portion of the clinical database. Once a participant is randomized into the trial, all data entry begins automatically.

[0542] Blinding

[0543] After administration of open-label MTRV001 to the sentinel group of two participants in cohorts 2-5, the remaining participants in the cohorts will be randomly assigned to receive either MTRV001 or placebo in a double-blind fashion. In cohorts 2-4, the remaining participants will be randomized (i.e., 10 participants to MTRV001 and 4 participants to placebo). In cohort 5, the remaining participants will be randomized (18 participants to MTRV001 and 4 participants to placebo). Participants and study staff (except for the open-label pharmacist) will be blinded to treatment. The pharmacist will prepare the doses of the blinded study intervention according to the randomization scheme generated by the biostatistician.

[0544] At the study site, only pharmacists will have access to the randomization schedule.

[0545] If unblinding is deemed necessary by the investigator and sponsor, the unblinded pharmacist will be required to disclose the study intervention information to the investigator (and SMC, as appropriate). The decision and process to unblind participants shall be appropriately documented in accordance with the Safety Manual. If unblinding is requested, the sponsor must be notified immediately.

[0546] After database lock for preparation of the CSR, which initially includes data through Visit 6 (Day 57 [± 4 days]), study participants and the subgroup of study personnel responsible for the ongoing conduct of the study (including the investigator or designee) will remain blinded. The blinded investigator or designee will assess the relationship of any SAEs or NOCIs reported after Visit 6 (Day 57 [± 4 days]).

[0547] In the case of a quality assurance audit, auditors will be allowed access to the unblinded study intervention records at the site to verify that randomization / dispensation was performed correctly.

[0548] Adherence to study intervention

[0549] If participants are medicated at the site, they will receive the study intervention directly from the investigator or designee under medical supervision. The date and time of each dose administered at the site will be recorded in the source document and recorded in the eCRF.

[0550] Combination treatment

[0551] Permitted and Restricted Treatments

[0552] Participants who have received chronic treatment with immunosuppressants or other immune-modulating drugs within 6 months prior to receiving the first dose of the study intervention will not be eligible for the study, and these medications will not be allowed during the study. Short-term use (<14 days) of corticosteroids for acute illness is permitted, but the last dose should be ≥28 days prior to administration of the first dose of the study intervention. In addition, the use of topical, inhaled, and intranasal glucocorticoids will be permitted.

[0553] The protocol imposes no restrictions on rescue medication, and the investigator will recommend medication for symptom relief if necessary.

[0554] Participants who have used any investigational drug within 30 days (or 5 half-lives of the investigational drug) prior to receiving the first dose of the study intervention are ineligible, and no other investigational drugs are permitted during the study.

[0555] Participants who have received any vaccine within 60 days of receiving the first dose of the study intervention are not eligible. Administration of pneumococcal vaccine (other than the study intervention) is not permitted until after Visit 7 (Day 210 [± 14 days]). Administration of any other vaccine is not permitted until after Visit 6 (Day 57 [± 4 days]).

[0556] Administration of immune globulin and / or any blood products within the 3 months prior to Day 1, or planned administration of such products during the study and through Visit 6 (Day 57 [± 4 days]), is not permitted.

[0557] Record of concomitant medication

[0558] Participants will be asked about their use of concomitant medications at each study visit. Any medications used within 30 days of administration of the first dose of study intervention through the final study visit (Visit 7 [Day 210 (± 14 days)] will be recorded in the eCRF. This includes all prescription drugs, over-the-counter medicines, herbal or other supplements, vitamins, and minerals. Record the name of each medication along with the date of administration, dose, frequency, and reason for use. Participants will also be asked to record on the diary card any concomitant medications used to treat reactogenic events.

[0559] Possible Drug Interactions

[0560] Immunosuppressants and other immune modifiers, which may impede the immune response to vaccination, should be avoided.

[0561] Dose Modification

[0562] There will be no dose modifications in individual participants. This is a dose escalation study, with the possibility for dose modifications by the investigator and sponsor between cohorts. If a particular dose level of MTRV001 is determined to be poorly tolerated, intermediate doses of MTRV001 (i.e., doses between the doses previously found to be tolerated and those found to be poorly tolerated) may be evaluated, pending further review and concordance by the SMC and IRB.

[0563] Withdrawal of a participant from the study or discontinuation of the study intervention

[0564] Reasons for withdrawal / discontinuation

[0565] Participants are free to withdraw from participation in the study at any time upon request. Participants may withdraw from the study at any time at the discretion of the investigator or at the request of the sponsor.

[0566] Reasons for discontinuation from the study intervention and for withdrawal from the study should be described in the eCRF. Any of the following may apply: Participant withdraws consent. · Non-compliance with protocols. -Serious or intolerable AEs that, in the opinion of the investigator, require discontinuation of the study intervention. ·Laboratory test results revealing a safety concern that, in the opinion of the investigator, requires discontinuation of the study intervention. -Occurrence of illness inconsistent with protocol requirements or justifying withdrawal. Other (e.g. pregnancy, occurrence of contraindications to the use of the study intervention). - Untraceable. · Closure of the trial by the sponsor.

[0567] The investigator will follow up participants who withdraw as a result of an SAE / AE until the event returns to normal or stabilizes, the event is otherwise explained, or the participant is lost to follow-up.

[0568] Handling withdrawals from the study or discontinuation from the study intervention

[0569] If a participant discontinues from the study before Visit 5 (Day 43 [± 4 days]), the site should attempt to complete the assessments listed for the Early Termination visit. If a participant discontinues early after Visit 5 (Day 43 [± 4 days]), the site should attempt to complete the assessments at Visit 7 (Day 210 [± 14 days]). It is particularly important to obtain follow-up data on any ongoing AEs or ongoing SAEs leading to discontinuation.

[0570] Untraceable

[0571] A participant is considered lost to follow-up if he / she does not return for a scheduled visit and cannot be contacted by the study site.

[0572] The following actions will be taken if a participant fails to return to the clinic for a required study visit:

[0573] Sites must contact participants and attempt to reschedule any missed visits as soon as possible, advise participants about the importance of maintaining their assigned visit schedule, and confirm whether the participant wishes to continue in the study.

[0574] Before a participant is considered "lost to follow-up," the investigator or designee will make every effort to re-establish contact with the participant by: 1) making three phone calls (or participant's preferred form) if possible; 2) sending a certified letter (or local equivalent) to the participant's last known mailing address, if necessary; and 3) contacting the participant's general physician or caregiver (if permitted by local regulations) for information, if the participant has given appropriate consent. These contact attempts will be documented in the participant's medical record.

[0575] exchange

[0576] If a participant is withdrawn by the investigator before receiving both doses of study intervention, or withdraws from the study and is lost to follow-up until Day 29 for reasons other than reactogenic AEs, the AE may be replaced. In the event that additional participants are enrolled, the IWRS and associated computer-generated randomization list will ensure that blinding will not occur. Additional participants will receive the same blinded study intervention as the discontinued participant according to the randomization scheme.

[0577] Test Evaluation and Procedures

[0578] Immunogenicity assessment

[0579] Blood samples will be collected for immunogenicity assessment at the visits. At Visits 2 (Day 1) and 4 (Day 29 [± 2 days]), samples will be collected prior to administration of study intervention. Additional instructions for sample collection, storage, and shipping will be provided in the Study Reference Manual. Samples will be analyzed for: Serum IgG for anti-PLY and anti-CbpA. GMTs are measured by ELISA. Samples will also be banked for future exploratory analyses: In vitro PLY neutralization assay. · In vitro inhibition of CbpA-mediated cell adhesion assay.

[0580] The holding time of samples after completion of the study and possible analyses are specified in each ICF.

[0581] References 1.Bologa M,Kamtchoua T,Hopfer R,Sheng vaccine.Vaccine.2012 Dec 14;30(52):7461-8.doi:10.1016 / j.vaccine.2012.10.076.Epub 2012 Nov 2.PMID:23123106. 2.Brooks WA,Chang LJ,Sheng 3.Chen A,Mann B,Gao G,et al.Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes / Fragments of CbpA and / or PspA Elicit Strong and Broad Protection.Clin Vaccine Immunol.2015;22(10):1079-89. 4.Farrand AJ,LaChapelle S,Hotze EM,Johnson AE,Tweten RK.Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface.Proc Natl Acad Sci U S A.2010 Mar 2;107(9):4341-6.doi:10.1073 / pnas.0911581107.Epub 2010 Feb 9.PMID:20145114;PMCID:PMC2840085. 5.Hammitt LL,Campbell JC,Borys D,Weatherholtz RC,Reid R,Goklish N,Moulton LH,Traskine M,Song Y,Swinnen K,Santosham M,O’Brien KL.Efficacy,safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children:A phase IIb randomized study.Vaccine.2019 Dec 3;37(51):7482-7492.doi:10.1016 / j.vaccine.2019.09.076.Epub 2019 Oct 16.PMID:31629570. 6.Kamtchoua T,Bologa M,Hopfer R,et al.Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.Vaccine.2013;31(2):327-33. 7.Leroux-Roels G,Maes C,De Boever F,et al.Safety,reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults:a phase I / II randomized clinical study.Vaccine.2014;32(50):6838-46. 8.Luo R,Mann B,Lewis WS,Rowe A,Heath R,Stewart ML,Hamburger AE,Sivakolundu S,Lacy ER,Bjorkman PJ,Tuomanen E,Kriwacki RW.Solution structure of choline binding protein A,the major adhesin of Streptococcus pneumoniae.EMBO J.2005 Jan 12;24(1):34-43.doi:10.1038 / sj.emboj.7600490.Epub 2004 Dec 16.PMID:15616594;PMCID:PMC544903. 9.Mann B,Thornton J,Heath R,Wade KR,Tweten RK,Gao G,El Kasmi K,Jordan JB,Mitrea DM,Kriwacki R,Maisonneuve J,Alderson M,Tuomanen EI.Broadly protective protein-based pneumococcal vaccine composed of recombinant pneumolysin toxoid-CbpA peptide fusion protein.J Infect Dis.2014 Apr 1;209(7):1116-25.doi:10.1093 / infdis / jit502.Epub 2013 Sep 16.PMID:24041791;PMCID:PMC3952665. 10.Odutola A,Ota MOC,Antonio M,Ogundare EO,Saidu Y,Foster-Nyarko E,Owiafe PK,Ceesay F,Worwui A,Idoko OT,Owolabi O,Bojang A,Jarju S,Drammeh I,Kampmann B,Greenwood BM,Alderson M,Traskine M,Devos N,Schoonbroodt S,Swinnen K,Verlant V,Dobbelaere K,Borys D.Efficacy of a novel,protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants:A phase 2,randomized,controlled,observer-blind study.Vaccine.2017 May 2;35(19):2531-2542.doi:10.1016 / j.vaccine.2017.03.071.Epub 2017 Apr 4.PMID:28389097. 11.Oloo EO,Yethon JA,Ochs MM,Carpick B,Oomen R.Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease.J Biol Chem.2011 Apr 8;286(14):12133-40.doi:10.1074 / jbc.M110.191148.Epub 2011 Feb 4.PMID:21296887;PMCID:PMC3069417. 12.Prymula R,Pazdiora P,Traskine M,Ruggeberg JU,Borys D.Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers:a phase II randomized clinical trial.Vaccine.2014 May 23;32(25):3025-34.doi:10.1016 / j.vaccine.2014.03.066.Epub 2014 Apr 1.PMID:24699466. 13.Thanawastien A,Joyce KE,Cartee RT,et al.Preclinical in vitro and in vivo profile of a highly attenuated,broadly efficacious pneumolysin genetic toxoid.Vaccine.2021;39(11):1652 60. 14.World Health Organization.Guidelines on the nonclinical evaluation of vaccines adjuvants and adjuvanted vaccines.WHO Expert Committee on Biological Standardization.Sixty-fourth report.WHO Technical Report Series No.987,2014. 15.World Health Organization.WHO guidelines of nonclinical evaluation of vaccines.Annex I of WHO Technical Report Series,No 927,2005. Bonten MJ,Huijts SM,Bolkenbaas M,et al.Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.N Engl J Med.2015;372(12):1114-25. Brandileone MC,Almeida SCG,Minamisava R,Andrade AL.Distribution of invasive Streptococcus pneumoniae serotypes before and 5years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.Vaccine.2018;36:2559-66. CDC,Centers for Disease Control and Prevention.Active Bacterial Core Surveillance Report,Emerging Infections Program Network,Streptococcus pneumoniae.2017.Available at:https: / / www.cdc.gov / abcs / reports-findings / survreports / spneu17.html. CDC,Centers for Disease Control and Prevention.Global pneumococcal disease and vaccine.Updated Nov 5,2018.Available at:https: / / www.cdc.gov / pneumococcal / global.html. Chen A,Mann B,Gao G,et al.Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes / Fragments of CbpA and / or PspA Elicit Strong and Broad Protection.Clin Vaccine Immunol.2015;22(10):1079-89. Daniels CC,Rogers PD,Shelton CM.A review of pneumococcal vaccines:current polysaccharide vaccine recommendations and future protein antigens.J Pediatr Pharmacol Ther.2016;21(1):27-35. ECDC,European Centre for Disease Prevention and Control.Invasive pneumococcal disease.In:ECDC.Annual epidemiological report for 2017.Stockholm:ECDC;2019. Farmaki PF,Chini MC,Mangafas NM,et al.Immunogenicity and immunological memory induced by the 13-valent pneumococcal conjugate followed by the 23-valent polysaccharide vaccine in HIV-infected adults.J Infect Dis.2018;218(1):26-34. Geno KA,et al.Pneumococcal capsules and their types:past,present,and future.Clin Microbiol Rev.2015;28:871-99. GBD,Global Burden of Disease 2016 Lower Respiratory Infections Collaborators.Estimates of the global,regional,and national morbidity,mortality,and aetiologies of lower respiratory infections in 195 countries,1990-2016:a systematic analysis for the Global Burden of Disease Study 2016.Lancet Infect Dis.2018;18(11):1191‐210. Goldblatt D,Assari T,Snapper C.The Immunology of Polysaccharide and Conjugate Vaccines.In:Siber G,et al(ed).Pneumococcal Vaccines;The Impact of Conjugate Vaccine.ASM Press,Washington,DC,2008. Kamtchoua T,Bologa M,Hopfer R,et al.Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.Vaccine.2013;31(2):327-33. Kim L,McGhee S,Tomczyk B,Beall B.Biological and epidemiological features of antibiotic-resistant streptococcus pneumoniae in pre- and post- conjugate vaccine eras;a United States perspective.Clin Microbiol Rev.2016;29:525-52. Klugman KP,Koornhof HJ,Kuhnle V.Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci.Am J Dis Child.1986;140:1186-90. Koornhof HJ,Wasa A,Klugman K.Antimicrobial resistance in Streptococcus pneumoniae:a South African perspective.Clin Infect Dis.1992;15:84-90. Ladhani SN,et al.Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales,2000-17:a prospective national observational cohort study.Lancet Infect Dis.2018;18:441-51. Lagousi T,Basdeki P,Routsias J,Spoulou V.Novel protein-based pneumococcal vaccines:assessing the use of distinct protein fragments instead of full-length proteins as vaccine Antigens.Vaccines(Basel).2019;7. Leroux-Roels G,Maes C,De Boever F,et al.Safety,reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults:a phase I / II randomized clinical study.Vaccine.2014;32(50):6838-46. Lewnard JA,Hanage WP.Making sense of differences in pneumococcal serotype replacement.Lancet Infect Dis.2019;19:e213-e220. Oloo EO,Yethon JA,Ochs MM,et al.Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal...

Claims

1. An immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:

43.

2. A polynucleotide encoding the immunogenic fusion protein of claim 1.

3. A host cell comprising the polynucleotide of claim 2.

4. A composition comprising the immunogenic fusion protein of claim 1 and a pharma- ceutically acceptable carrier.

5. The composition of claim 4 , wherein the immunogenic fusion protein is glycosylated.

6. The composition of claim 4 , wherein the immunogenic fusion protein is non-glycosylated.

7. The composition according to any one of claims 4 to 6, further comprising at least one adjuvant.

8. The composition of claim 7 , wherein the adjuvant comprises aluminum hydroxide, aluminum phosphate, or aluminum sulfate.

9. The composition of claim 8 , wherein the adjuvant comprises aluminum hydroxide.

10. 10. The composition of claim 9, wherein the aluminum hydroxide comprises Alhydrogel®.

11. 1. A composition comprising: i) a population of purified immunogenic fusion proteins, wherein at least about 90% of the purified immunogenic fusion proteins are full-length purified immunogenic fusion proteins comprising the amino acid sequence of SEQ ID NO:43; ii) less than 80,000 ng of host cell protein per mg of purified immunogenic fusion protein; and / or iii) A composition containing less than 17 EU endotoxin per mg of purified immunogenic fusion protein.

12. The composition, i) a population of purified immunogenic fusion proteins, wherein about 95%, about 96%, about 97%, about 98%, or about 99% of the purified immunogenic fusion proteins are full-length purified immunogenic fusion proteins comprising the amino acid sequence of SEQ ID NO:43; ii) less than 50 ng of host cell protein per mg of purified immunogenic fusion protein; and / or iii) The composition of claim 11, comprising less than 2 EU endotoxin per mg of purified immunogenic fusion protein.

13. 1. A method for producing an immunogenic fusion protein, comprising: a) culturing said population of host cells expressing an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43 under conditions suitable for said population of host cells to produce said immunogenic fusion protein; b) disrupting the cell membrane of the host cell; c) recovering a sample containing said immunogenic fusion protein and one or more impurities; d) contacting the sample containing the immunogenic fusion protein with a hydrophobic interaction chromatography resin and eluting the immunogenic fusion protein from the hydrophobic interaction chromatography resin under conditions that allow preferential desorption of the immunogenic fusion protein, thereby obtaining an eluate containing the immunogenic fusion protein; e) subjecting the eluate containing the immunogenic fusion protein of step d) to a flow-through anion exchange resin, thereby obtaining an eluate containing the immunogenic fusion protein; and f) contacting the eluate comprising the immunogenic fusion protein of step e) with a multimodal chromatography resin and eluting the immunogenic fusion protein from the multimodal chromatography resin under conditions allowing preferential desorption of the immunogenic fusion protein, thereby obtaining an eluate comprising the immunogenic fusion protein.

14. 14. The method of claim 13, further comprising the step of: g) contacting the eluate containing the immunogenic fusion protein of step f) with a flow-through anion exchange membrane, thereby obtaining an eluate containing the immunogenic fusion protein.

15. h) contacting the eluate containing the immunogenic fusion protein of step g) with an UF / DF membrane; and 15. The method of claim 14, further comprising the step of: i) washing said immunogenic fusion protein from said UF membrane under conditions allowing preferential detachment of said immunogenic fusion protein, thereby obtaining an eluate comprising said immunogenic fusion protein.

16. 16. The method of claim 15, further comprising the step of: j) contacting the eluate containing the immunogenic fusion protein of step i) with a 0.2 μm filter.

17. The method according to any one of claims 13 to 16, wherein the host cell is an E. coli cell.

18. A composition comprising a purified immunogenic fusion protein produced by the method of any one of claims 13 to 17.

19. 1. A formulation comprising: i) an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO: 43; ii) a surfactant; iii) a buffer; and iv) Formulations that include salts.

20. 20. The formulation of claim 19, wherein the surfactant is at a concentration of about 175 μg / mL to about 375 μg / mL.

21. i) the immunogenic fusion protein is at a concentration of about 0.5 mg / mL to about 1.5 mg / mL; ii) the surfactant is at a concentration of about 175 μg / mL to about 375 μg / mL; iii) the buffer has a concentration of about 5 mM to about 20 mM; iv) the salt is at a concentration of about 50 mM to about 200 mM; and 20. The formulation of claim 19, wherein the pH level of the formulation is between pH 6 and pH 9.

22. i) the immunogenic fusion protein is at a concentration of about 0.8 mg / mL to about 1.2 mg / mL; ii) the surfactant is at a concentration of about 275 μg / mL; iii) the buffer has a concentration of about 10 mM; iv) the salt is at a concentration of about 154 mM; 22. The formulation of claim 21, wherein the pH level of the formulation is about 7.

4.

23. 23. The formulation of any one of claims 19 to 22, wherein the buffer comprises sodium phosphate, the salt comprises sodium chloride (NaCl), and / or the surfactant comprises polysorbate 20.

24. The formulation of any one of claims 19 to 23, further comprising an adjuvant.

25. 25. The formulation of claim 24, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, and aluminum sulfate, and the adjuvant is at a concentration of about 0.5 mg / mL to about 2 mg / mL.

26. 26. The formulation of claim 25, wherein the adjuvant is at a concentration of about 1 mg / mL.

27. The formulation according to any one of claims 24 to 26, wherein the adjuvant is aluminium hydroxide.

28. 28. The formulation of claim 27, wherein the aluminum hydroxide is Alhydrogel®.

29. A formulation comprising:

1. A formulation comprising about 1.0 mg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 10 mM sodium phosphate, and about 154 mM sodium chloride, wherein the pH level of the formulation is about 7.

4.

30. 1. A formulation comprising:

1. A formulation comprising about 20 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.

4.

31. 1. A formulation comprising:

1. A formulation comprising about 60 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.

4.

32. 1. A formulation comprising:

1. A formulation comprising about 120 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.

4.

33. 1. A formulation comprising:

1. A formulation comprising about 180 μg / mL of an immunogenic fusion protein comprising the amino acid sequence of SEQ ID NO:43, about 275 μg / mL polysorbate 20, about 1 mg / mL aluminum hydroxide in 9 mM sodium phosphate, and about 139 mM sodium chloride, wherein the pH level of the formulation is about 7.

4.

34. A method of inducing a protective immune response in a subject comprising administering to the subject a composition according to any one of claims 4 to 12 or 18 or a formulation according to any one of claims 19 to 33.

35. A method of immunizing a subject against infection caused by Streptococcus pneumoniae, comprising administering to said subject a composition according to any one of claims 4 to 12 or 18 or a formulation according to any one of claims 19 to 33.

36. A method of treating, prophylactically preventing or reducing the occurrence of a condition, disease or infection caused by Streptococcus pneumoniae in a subject in need thereof, comprising administering to said subject a composition according to any one of claims 4 to 12 or 18 or a formulation according to any one of claims 19 to 33.

37. The method of any one of claims 34 to 36, wherein the subject is administered at least one dose of the immunogenic fusion protein.

38. 38. The method of claim 37, wherein the subject is administered no more than two doses of the immunogenic fusion protein.

39. 39. The method of any one of claims 37-38, wherein the dose further comprises about 1 mg / mL aluminum hydroxide.

40. 40. The method of any one of claims 37 to 39, wherein the dose comprises from about 1 μg to about 150 μg of the immunogenic fusion protein.

41. 41. The method of claim 40, wherein the dose comprises about 10 μg of the immunogenic fusion protein.

42. 41. The method of claim 40, wherein the dose comprises about 30 μg of the immunogenic fusion protein.

43. 41. The method of claim 40, wherein the dose comprises about 60 μg of the immunogenic fusion protein.

44. 41. The method of claim 40, wherein the dose comprises about 90 μg of the immunogenic fusion protein.

45. 45. The method of any one of claims 37-44, wherein the amount of time between each dose is from about four weeks to about a year.

46. 46. ​​The method of claim 45, wherein the amount of time between each dose is about one week, about two weeks, about three weeks, or about four weeks.

47. 47. The method of claim 46, wherein the amount of time between each dose is about four weeks.

48. The method of any one of claims 34 to 47, wherein the composition or formulation is administered by parenteral administration.

49. 49. The method of any one of claims 48, wherein the parenteral administration is by intramuscular injection.

50. 50. The method of any one of claims 34 to 49, wherein the subject is between 0 and 80 years old.

51. 51. The method of claim 50, wherein the subject is between 0 and 2 years old.

52. 51. The method of claim 50, wherein the subject is between 18 and 50 years old.

53. 51. The method of claim 50, wherein the subject is between 60 and 75 years old.